Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father^†

Abstract

Although it is widely considered, in many cases, to involve two separable stages (poor placentation followed by oxidative stress/inflammation), the precise originating causes of preeclampsia (PE) remain elusive. We have previously brought together some of the considerable evidence that a (dormant) microbial component is commonly a significant part of its etiology. However, apart from recognizing, consistent with this view, that the many inflammatory markers of PE are also increased in infection, we had little to say about immunity, whether innate or adaptive. In addition, we focused on the gut, oral and female urinary tract microbiomes as the main sources of the infection. We here marshall further evidence for an infectious component in PE, focusing on the immunological tolerance characteristic of pregnancy, and the well-established fact that increased exposure to the father’s semen assists this immunological tolerance. As well as these benefits, however, semen is not sterile, microbial tolerance mechanisms may exist, and we also review the evidence that semen may be responsible for inoculating the developing conceptus (and maybe the placenta) with microbes, not all of which are benign. It is suggested that when they are not, this may be a significant cause of PE. A variety of epidemiological and other evidence is entirely consistent with this, not least correlations between semen infection, infertility and PE. Our view also leads to a series of other, testable predictions. Overall, we argue for a significant paternal role in the development of PE through microbial infection of the mother via insemination.

Introduction

Preeclampsia (PE) is a multifactorial disease of pregnancy, in which the chief manifestations are hypertension and proteinuria (3–11). It is commonest in primigravidae, where it affects some 3–5% of such pregnancies worldwide (10, 12, 13), and is associated (if untreated) with high morbidity and mortality (14–18). The incidence can be even greater in some geographical locations (19, 20). There is much literature on accompanying features, and, notwithstanding possible disease subdivisions (21, 22), the development of PE is typically seen as a “two-stage” process [e.g., Ref. (23–29)], in which in a first stage incomplete remodeling of spiral arteries leads to poor placentation. In a second stage, the resulting stress, especially hypoxia-induced oxidative stress (30–36) (and possibly hypoxia-reperfusion injury), then leads to the symptoms typical of later-pregnancy PE. However, the various actual originating causes of either of these two stages remain obscure. Many theories have been proposed [albeit a unitary explanation is unlikely (21)], and indeed, PE has been referred to as a “disease of theories” (1, 37–39). The only effective “cure” is delivery (40, 41), which often occurs significantly preterm, with its attendant complications for both the neonate and in later life (42, 43). Consequently, it would be highly desirable to improve our understanding of the ultimate causes of PE, so that better prevention or treatments might be possible.

The “two-stage” theory is well established, and nothing we have to say changes it. However, none of this serves to explain what “initiating” or “external” factors are typically responsible for the poor placentation, inflammation, and other observable features of PE (44).

Microbes are ubiquitous in the environment, and one potential external or initiating factor is low-level microbial infection. In a recent review (44), we developed the idea (and summarized extensive evidence for it) that a significant contributor to PE might be a [largely dormant (45–48) and non-replicating] microbiome within the placenta and related tissues, also detectable in blood and urine. Others [e.g., Ref. (49–56)] have drawn similar conclusions. Interestingly, recent analyses (21, 57) of placental gene expression in PE implicate changes in the expression of triggering receptor on myeloid cells-1 and the metalloprotease INHA, and in one case (21) also lactotransferrin, that also occur during infection (58–61). Although we highlighted the role of antibiotics as potentially preventative of PE (44), and summarized the significant evidence for that, we had relatively little to say about immunology, and ignored another well-known antidote to infectious organisms in the form of vaccines. There is certainly also an immune component to PE [e.g., Ref. (26, 62–70) and below]. One of the main theories of (at least part of the explanation of) PE is that of “immune maladaptation” (62, 64, 66, 71). Thus, the main focus of the present analysis is to assess the extent to which there is any immunological evidence for a role of infectious agents (and the utility of immunotolerance to or immunosuppression of them) in PE. Figure 1 summarizes our review in the form of a “mind map” (72). We begin with the broad question of immunotolerance, before turning to an epidemiological analysis. A preprint has been lodged in bioRxiv (73).

Figure 1

Immune Tolerance in Pregnancy

Much of the original thinking on this dates back to Sir Peter Medawar (74–79), who recognized that the paternal origin of potentially half the antigens of the fetus (80) created an immunological conundrum: it should normally be expected that the fetus’s alloantigens would cause it to be attacked by the maternal immune system as “foreign.” There would therefore have to be an “immune tolerance” (79, 81–83). Historically it was believed that the fetus is largely “walled off” from the mother (84); however, we now appreciate (85–88) that significant trafficking of fetal material across the placenta into the maternal circulation and vice versa occurs throughout pregnancy. Indeed, this is the basis for the development of non-invasive prenatal testing. In line with this, grams of trophoblast alloantigens are secreted daily into the maternal circulation during the third trimester (Figure 2), and this is related to the prevalence of PE (89–95). Consequently, both the concept and the issue of immune tolerance are certainly both real and important. At all events, the immunobiology of the fetus has been treated in theory largely in the way that a transplanted graft is treated, and uteroplacental dysfunction [leading to PET and intrauterine growth restriction (IUGR)] has in some cases been regarded as a graft rejection [e.g., Ref. (70, 96–102)]. Clearly there are relationships between the immunogenicity of the foreign agent and the responsiveness of the host; to this end, Zelante et al. (103) recognize the interesting similarities between tolerance to paternal alloantigens (as in pregnancy) and the tolerance observed in chronic fungal infections. This said, the host–graft analogy is increasingly seen as somewhat naive (104–106).

Figure 2

The Clinical Course of Automimmune Disease during Pregnancy: An Inconsistent Effect

The seminal observation by Philip Hench that the symptoms of the rheumatoid arthritis (RA) were frequently and dramatically ameliorated by several conditions, including pregnancy (107), led to the discovery of cortisone (108) and gave unique insights into the complex interaction between the maternal immune system and the developing fetal/placental unit. Contemporary data suggests that the improvement in RA is not ubiquitous as first thought. Amongst all pregnant women about 25% of women have no improvement in their symptoms at any stage in pregnancy and in a small number of cases the disease may actually worsen (109). The process by which pregnancy affects disease activity in RA is not completely understood and several putative mechanisms have been proposed. Of interest, although plasma cortisol rises during pregnancy and was initially thought to be key in the amelioration of symptoms, there is actually no correlation between cortisol concentrations and disease state (110). It has also been reported that the degree of maternal and paternal MHC mismatch has been shown to correlate with the effect of the RA remission during pregnancy (111), leading to the hypothesis that the early immunological events in pregnancy that establish tolerance to the fetal allograft contribute to RA remission. Clearly, this may also account for the disparity in response to pregnancy. RA is not unique in being the only autoimmune disease to be profoundly altered by pregnancy. Although less well studied, non-infectious uveitis tends to improve during pregnancy from the second trimester onward, with the third trimester being associated with the lowest disease activity (112). Again, the mechanism underlying this phenomenon is not completely elucidated.

It is now generally accepted (113) that, notwithstanding the sweeping generalization, autoimmune diseases with a strong cellular (innate) pathophysiology (RA, multiple sclerosis) improve, whereas diseases characterized by autoantibody production such as systemic lupus erythematous and Grave’s disease tend toward increased severity in pregnancy.

We have previously reported an association between pregnancy and the risk of subsequent maternal autoimmune disease which was also related to the mode and gestation of delivery. There was an increased risk of autoimmune disease after cesarean section may be explained by amplified fetal cell traffic at delivery, while decreased risks after abortion may be due to the transfer of more primitive fetal stem cells (114).

Mechanisms of Immune Tolerance during Pregnancy

Following the recognition of maternal immunotolerance, a chief discovery was the choice of HLA-G, a gene with few alleles, for the antigens used at the placental interface. Thus, the idea that placental HLA-G proteins facilitate semiallogeneic pregnancy by inhibiting maternal immune responses to foreign (paternal) antigens via these actions on immune cells is now well established (115–120).

It is also well established that regulatory T cells (Tregs) play an indispensable role in maintaining immunological unresponsiveness to self-antigens and in suppressing excessive immune responses deleterious to the host (121). Consequently, much of present thinking seems to involve a crucial role for Tregs in maintaining immunological tolerance during pregnancy (70, 77, 122–132), with the result that effector T cells cannot accumulate within the decidua (the specialized stromal tissue encapsulating the fetus and placenta) (133).

In an excellent review, Williams et al. (134) remark “Regulatory T cells (Tregs) are a subset of inhibitory CD4+ helper T cells that function to curb the immune response to infection, inflammation, and autoimmunity.” “There are two developmental pathways of Tregs: thymic (tTreg) and extrathymic or peripheral (pTreg). tTregs appear to suppress autoimmunity, whereas pTregs may restrain immune responses to foreign antigens, such as those from diet, commensal bacteria, and allergens.” Their differential production is controlled by a transcription factor called Foxp3.

Further, “a Foxp3 enhancer, conserved noncoding sequence 1 (CNS1), essential for pTreg but dispensable for tTreg cell generation, is present only in placental mammals. It is suggested that during evolution, a CNS1-dependent mechanism of extrathymic differentiation of Treg cells emerged in placental animals to enforce maternal–fetal tolerance” (135).

Williams et al. conclude that “These findings indicate that maternal–fetal tolerance to paternal alloantigens is an active process in which pTregs specifically respond to paternal antigens to induce tolerance. Thus, therapies should aim not to suppress the maternal immune system but rather to enhance tolerance. These findings are consistent with an increase in the percentage of Tregs during pregnancy and with no such increase in women with recurrent pregnancy loss (136)” (134). Thus maternal tolerance is based on exposure to the paternal alloantigens, although mechanisms such as the haem oxygenase detoxification of haem from degrading erythrocytes (137) are also important. Note too that pregnancy loss is often caused by automimmune activity (138) (and see later).

Additionally, Treg cells have several important roles in the control of infection [e.g., Ref. (139–144)]. These include moderating the otherwise potentially dangerous response to infection and being exploited by certain parasites to induce immunotolerance.

Finally, here, it is also recognized that the placenta does allow maternal IgG antibodies to pass to the fetus to protect it against infections. Also, foreign fetal cells persist in the maternal circulation (145) [as does fetal DNA (146, 147), nowadays used in prenatal diagnosis]. One cause of PE is clearly an abnormal immune response toward the placenta. There is substantial evidence for exposure to partner’s semen as prevention for PE, largely due to the absorption of several immune modulating factors present in seminal fluid (148). We discuss this in detail below.

Innate and Adaptive Immunity

Although they are not entirely independent (149, 150), and both respond to infection, it is usual to discriminate (the faster) innate and (the more leisurely) adaptive immune responses [e.g., Ref. (151–155)]. As is well known [reviewed recently (156)], the innate immune system is responsible for the recognition of foreign organisms such as microbes. It would be particularly convenient if something in the immune response did actually indicate an infection rather than simply any alloantigen, but unfortunately—especially because of the lengthy timescale over which PE develops—innate responses tend to morph into adaptive ones. This means (i) that there may be specific signals from early innate events that may be more or less specific to innate responses and (ii) that it also does not exclude the use of particular patterns of immune responsive elements (157–159) to characterize disease states.

An alteration of the immune system is widely recognized as an accompaniment to normal pregnancy (77, 104–106, 127, 160–162), and especially in PE (63–65, 67, 69–71, 163–170), and it is worth looking at it a little more closely.

The innate immune system responds to microbial components such as lipopolysaccharide (LPS) via cell membrane receptors. Innate immune cells express a series of evolutionarily conserved receptors known as pattern-recognition receptors (PRRs). PRRs recognize and bind conserved sequences known as pathogen-associated molecular patterns (PAMPs). Bacterial LPS and peptidoglycan, and double stranded viral RNA are unique to microbes and act as canonical PAMPs, while the main family of PRRs is represented by the Toll-like receptors (TLRs) (171, 172). Downstream events, as with many others (173, 174) converge on the NF-κB system and/or interferon, leading to the release of a series of inflammatory cytokines such as IL-2, IL-6, IL-8, TNF-α, and especially IL-1β.

Matzinger’s “danger model” (175–180) [and see Ref. (79) and Figure 3] suggested that activation of the immune system could be evoked by danger signals from endogenous molecules expelled from injured/damaged tissues, rather than simply from the recognition of non-self (although of course in the case of pregnancy some of these antigens are paternal alloantigens). Such endogenous molecules are referred to as damage-associated molecular patterns (DAMPs), but are not our focus here, albeit they likely have a role in at least some elements of PE (181). We shall see later, however, that Matzinger’s theory is entirely consistent with the kinds of microbial (and disease) tolerance that do seem to be an important part of pregnancy and PE [and see Ref. (182)].

Figure 3

The maternal innate immune system plays an important role both in normal pregnancy and in particular in hypertensive disorders of pregnancy including preeclampsia (PE) (167, 183–189). One persuasive and widely accepted view is that normal pregnancy is characterized by a low-grade systemic inflammatory response and specific metabolic changes, and that virtually all of the features of normal pregnancy are simply exaggerated in PE (44, 183, 190, 191). Certainly it is long established that “Normal pregnancy and PE both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis” (183), and there are innate immune defenses in the uterus during pregnancy (160). Normal pregnancy has been considered to be a Th2 type immunological state that favors immune tolerance in order to prevent fetal rejection (137). However, normal pregnancy actually fluctuates between pro- (implantation and placentation; parturition) and anti-inflammatory (fetal growth) phases (105, 106). By contrast, PE has been classically described as a Th1/Th2 imbalance (125, 164, 192–194), but as mentioned above [and before (44)], recent studies have highlighted the role of Tregs as part of a Th1/Th2/Th17 paradigm (167, 168). This leads to the question of whether there is some kind of trade-off between the responses to paternal alloantigens and those of microbes.

A Trade-Off for Mating and Immune Defense against Infection

Certainly there is some evidence for a trade-off between mating and immune defense against infection (195–197). Consistent with this (albeit with much else) is the fact (198–200) that pregnancy is associated with an increased severity of at least some infectious diseases. There is evidence (201, 202) that “adaptive immune responses are weakened, potentially explaining reduced viral clearance. Evidence also suggests a boosted innate response, which may represent a compensatory immune mechanism to protect the pregnant mother and the fetus and which may imply decreased susceptibility to initial infection” (199).

The Role(S) of Complement in PE

Complement, or more accurately the complement cascade, is an important part of the innate immune system that responds to infection. Later (downstream) elements also respond to the adaptive immune system. Our previous review (44) listed many proteins whose concentrations are changed in both infection and PE. Since we regard low-level infection as a major cause of the inflammation observed in PE, one would predict that the complement system is activated in PE, and this observation is amply borne out (203–217). Some of the details are mentioned in Table 1.

The complement cascade may be activated in three main ways (Figure 4), known as classical, alternative or lectin pathways (150, 206, 208, 228, 229). Complement activation by the classical, alternative or lectin pathway results in the generation of split products C3a, C4a, and C5a with proinflammatory properties.

Figure 4

Because both innate and adaptive immunity can activate elements of the downstream complement system, it is hard to be definitive, but there is some evidence that elements such as Ba and Bb [the latter of known structure (230)] are selectively released during infection, very much upstream and in the alternative pathway (208, 228, 229, 231–233). Most importantly (Table 1), while probably not a specific serum marker, there is considerable evidence that Bb levels are increased in PE, arguably providing further evidence for a role of infectious agents in the etiology of PE.

We might also note that C1q^−/− mice shows features of PE (234), consistent with the view that lowering levels of anti-infection response elements of the complement system leads to PE, consistent again with an infectious component to PE.

Induction of Tolerance by Exposure to Antigens and Our Main Hypothesis: Roles of Semen and Seminal Plasma

A number of groups [e.g., Ref. (118, 148, 235–240)] have argued for a crucial role of semen in inducing maternal immunological protection, and this is an important part of our own hypothesis here. The second component, however, is a corollary of it. If it is accepted that semen can have beneficial effects, it may also be that in certain cases it can also have harmful effects. Specifically, we rehearse the fact that semen is not sterile, and that it can be a crucial source of the microbes that may, over time, be responsible for the development of PE (and indeed other disorders of pregnancy, some of which we rehearse).

Semen consists essentially of the sperm cells suspended in a fluid known as seminal plasma (241). Seminal plasma contains many components (242, 243), such as transforming growth factor β (TGF-β) (236, 244–248), and there is much evidence that a number of them are both protective and responsible for inducing the immune tolerance observed in pregnancy. Thus, in a key article on the issue, Robertson et al. state, “TGF-β has potent immune-deviating effects and is likely to be the key agent in skewing the immune response against a Type-1 bias. Prior exposure to semen in the context of TGF-β can be shown to be associated with enhanced fetal/placental development late in gestation. In this article, we review the experimental basis for these claims and propose the hypothesis that, in women, the partner-specific protective effect of insemination in PE might be explained by induction of immunological hyporesponsiveness conferring tolerance to histocompatibility antigens present in the ejaculate and shared by the conceptus” (148).

Transforming growth factor-β and prostaglandin E [also prevalent in seminal fluid (249)] are potent Treg cell-inducing agents, and coitus is one key factor involved in expanding the pool of inducible Treg cells that react with paternal alloantigens shared by conceptus tissues (250–253).

Both in humans and in agricultural practice, semen may be stored with or without the seminal fluid (in the latter cases, the sperm have been removed from it and they alone are used in the insemination). However, a number of articles have shown very clearly that it is the seminal fluid itself that contains many protective factors, not least in improving the likelihood of avoiding adverse pregnancy outcomes (148, 197, 254, 255). Thus semen is the preferred substrate for inducing immunotolerance and hence protection against PE.

Evidence from Epidemiology—Semen Can be Protective Against PE

We consider each in turn (Figure 5).

Figure 5

The First Pregnancy with Any Given Partner Means an Increased Susceptibility to PE

This is extremely well established [e.g., Ref. (5, 67, 163, 256, 258, 259, 280–288)]. Thus, Duckitt and Harrington (256) showed nulliparity to have a risk ratio (over pregnant women with previous pregnancies) of 2.91 (95% CI 1.28–6.61). Luo et al. (283) find an odds ratio (OR) of 2.42 (95% CI 2.16–2.71) for PE in primiparous vs. multiparous women, while Deis et al. found the OR to be 2.06 (CI 1.63–2.60), P = 0.0021. Dildy et al. (289) summarize several studies, including a very large one by Conde-Agudelo and Belizán (290) (RR 2.38; 95% CI 2.28–2.49), while the meta-analysis of English et al. (287) gives a risk ratio for nulliparity of 2.91 (CI 1.28–6.61). The consistency of each of these studies allows one to state with considerable confidence that there is a two- to threefold greater chance of PE with a first baby.

However, an additional and key clue here is not simply (and maybe even not mainly) that it is just being nulliparous (i.e., one’s first pregnancy) but that it is primipaternity—one’s first pregnancy with a given father—that leads to an increased susceptibility to PE (19, 204, 291–303) [cf. (304)]. Changing partners effectively “resets the clock” such that the risk with a new father is essentially as for first pregnancies. Thus, Lie et al. (305) noted that if a woman becomes pregnant by a man who has already fathered a pre-eclamptic pregnancy in a different woman her increased risk of developing pre-eclampsia is 1.8-fold (CI 1.2–2.6). This is far greater than the typical incidence of PE, even for nulliparous women. The equivalent figure in the study of Lynch et al. (204) was RR = 5.1, 95% CI 1.6–15. The strong implication of all of this is that the father can have bad effects but that some kind of “familiarity” with the partner is protective (301), the obvious version—and that more or less universally accepted—being an immunological familiarity (i.e., tolerance). Note, however, that this is when the pregnancy goes to term: a prior birth confers a strong protective effect against PE, whereas a prior abortion confers only a weaker protective effect (259).

Conception Early in a New Relationship Means an Increased Susceptibility to PE

The idea that conception early in a new relationship means an increased susceptibility to PE follows immediately from the above. The landmark studies here are those of Robillard et al. (19, 260, 296), of Einarsson et al. (261), and of Saftlas et al. (262).

Robillard et al. (260) studied 1,011 consecutive mothers in an obstetrics unit. The incidence of pregnancy-induced hypertension (PIH) was 11.9% among primigravidae, 4.7% among same-paternity multigravidae, and 24.0% among new-paternity multigravidae. For both primigravidae and multigravidae, the length of (sexual) cohabitation before conception was inversely related to the incidence of PIH (P < 0.0001).

Einarsson et al. (261) studied both the use of barrier methods and the extent of cohabitation prior to pregnancy. For those (allegedly, etc.) using barrier methods before insemination, the OR for PE when prior cohabitation was only 0–4 months versus the OR for PE: normotensive was 17.1 (CI 2.9–150.6) versus 1.2 (CI 0.1–11.5) when the period of cohabitation was 8–12 months, and 1.0 for periods of cohabitation exceeding 1 year.

Saftlas et al. (262) recognized that parous women who change partners before a subsequent pregnancy appear to lose the protective effect of a prior birth. In a large study (mainly based around calcium supplementation), they noted that women with a history of abortion who conceived again with the same partner had nearly half the risk of PE [adjusted odds ratio (aOR) = 0.54, 95% confidence interval: 0.31–0.97]. In contrast, women with an abortion history who conceived with a new partner had the same risk of PE as women without a history of abortion (aOR = 1.03, 95% confidence interval: 0.72–1.47). Thus, the protective effect of a prior abortion operated only among women who conceived again with the same partner.

Conception after Using Barrier Contraceptives Means an Increased Susceptibility to PE

A prediction that follows immediately from the idea that paternal antigens in semen (or seminal fluid) are protective is that the regular use of barrier methods will lower maternal exposure to them, and hence increase the likelihood of PE. This too is borne out (261, 263, 264). Thus Klonoff-Cohen et al. found a 2.37-fold (CI 1.01–5.58) increased risk of PE for users of contraceptives that prevent exposure to sperm. A dose-response gradient was observed, with increasing risk of PE for those with fewer episodes of sperm exposure. Similarly, Hernández-Valencia et al. (264) found that the OR for PE indicated a 2.52-fold (CI 1.17–5.44, P < 0.05), increased risk of PE for users of barrier contraceptives compared with women using nonbarrier contraceptive methods.

Conception after Using Non-Barrier Methods or after a Long Period of Cohabitation Means a Decreased Susceptibility to PE

This is the flip side of the studies given above [e.g., Ref. (260–262)]. It is clear that maternal–fetal HLA sharing is associated with the risk of PE, and the benefits of long-term exposure to the father’s semen, while complex (306), seem to be cumulative (307). Thus, short duration of sexual relationship was more common in women with PE compared with uncomplicated pregnancies [≤6 months 14.5 versus 6.9%, aOR 1.88, 95% CI 1.05–3.36; ≤ 3 months 6.9% versus 2.5%, aOR 2.32, 95% CI 1.03–5.25 (308)]. Oral contraceptives are somewhat confounding here, in that they may either be protective or a risk factor depending on the duration of their use and the mother’s physiological reaction to them (309).

Donor Egg Pregnancies Have a Hugely Inflated Chance of PE

If an immunological component is important to PE (as it evidently is), it is to be predicted that donor egg pregnancies are likely to be at much great risk of PE, and they are [e.g., Ref. (259, 265–267, 310–314)] [and also of preterm birth (PTB) (315)]. Thus, Letur et al. (265, 266) found that PE was some fourfold more prevalent using donated eggs (11.2 vs. 2.8%, P < 0.001), while Tandberg et al. (259) found that various “assisted reproductive technologies” had risk ratios of 1.3 (1.1–1.6) and 1.8 (1.2–2.8) in second and third pregnancies, respectively. Pecks et al. studied PIH (not just PE) and found that the calculated OR for PIH after oocyte donation, compared to conventional reproductive therapy, was 2.57 (CI 1.91–3.47), while the calculated OR for PIH after oocyte donation, compared to other women in the control group, was 6.60 (CI 4.55–9.57). Stoop et al. (316) found a Risk Ratio of 1.502 (CI 1.024–2.204) for PIH. In a study by Levron et al. (317), adjustment for maternal age, gravidity, parity, and chronic hypertension revealed that oocyte donation was independently associated with a higher rate of hypertensive diseases of pregnancy (P < 0.01). In a twins study, Fox et al. (318) found, on adjusted analysis, that the egg donation independently associated with PE (aOR 2.409, CI 1.051–5.524). The meta-anaysis of Thomopoulos et al. (319) gave a risk ratio for egg donation of 3.60 (CI 2.56–5.05) over controls, a value similar to that of Blázquez et al. (320). Finally, a recent meta-analysis by Masoudian et al. (313) found that that the risk of PE is considerably higher in oocyte-donation pregnancies compared to other methods of assisted reproductive technology (OR, 2.54; CI 1.98–3.24; P < 0.0001) or to natural conception (OR, 4.34; CI 3.10–6.06; P < 0.0001). The incidence of gestational hypertension and PE was significantly higher in ovum donor recipients compared with women undergoing autologous IVF [24.7% compared with 7.4%, P < 0.01, and 16.9% compared with 4.9%, P < 0.02 (321)]. All of these are entirely consistent with an immune component being a significant contributor to PE. Given our suggestion that many of these disorders of pregnancy have a microbial component, one obvious question pertains to whether the use of antibiotics assists the successful progression of IVF. Unfortunately this question has been little researched in humans (322).

PE in a First Pregnancy Increases Its Likelihood in Subsequent Pregnancies

This too is well established: a woman who has had PE has an increased risk of PE in subsequent pregnancies (288, 323), especially if suffering from hypertension (324). This may be seen as relatively unsurprising, and of course bears many explanations, and the increased risks can be very substantial (268). In the overall analysis of English et al. (287), the risk ratio was 7.19 (CI 5.85–8.83). Other examples give the recurrence risk, overall, as some 15–18% (288). The risk of recurrent PE is inversely related to gestational age at the first delivery, and in the study of Mostello et al. (325) was 38.6% for 28 weeks’ gestation or earlier, 29.1% for 29–32 weeks, 21.9% for 33–36 weeks, and 12.9% for 37 weeks or more. Low birthweight in the first pregnancy is an independent predictor of PE in the second: birth weight below the tenth percentile in the first delivery accounted for 10% of the total cases of PE in the second pregnancy and 30% of recurrent cases (326). From the perspective developed here, the suggestion is that whatever is responsible for PE in one pregnancy can “live on” in the mother and afflict subsequent ones. One thing that can “live on” is a dormant microbial community. We discussed at length in the previous review (44), and develop in more detail later (in the section “host tolerance to microbial pathogens”) the evidence that dormant microbes (such as Helicobacter pylori and Mycobacterium tuberculosis) can live within their host for decades.

Oral Sex with the Father Is Protective against PE in a Subsequent Pregnancy

Oral sex (with the father of one’s baby) protects against PE (269, 270) (P = 0.0003), arguably because exposure to the paternal antigens in the seminal fluid have a greater exposure to the blood stream via the buccal mucosa than they would via the vagina. This is a particularly interesting (and probably unexpected) finding, that is relatively easily understood from an immunological point of view, and it is hard to conceive of alternative explanations. [Note, however, that in the index study (269), the correlation or otherwise of oral and vaginal sex was not reported, so it is not entirely excluded that more oral sex also meant more vaginal sex.]

Age Is a Risk Factor for PE

Age is a well known risk factor for PE (271–275), and of course age is a risk factor for many other diseases, so we do not regard this as particularly strong evidence for our ideas. However, we have included it in order to note that age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction (327).

Donor Sperm Pregnancies (Artificial Insemination) Are Much More Likely to Lead to PE

Finally, here, turning again to the father, it has been recognized that certain fathers can simply be “dangerous” in terms of their ability to induce PE in those who they inseminate (302, 328). By contrast, if immunotolerance to a father builds up slowly as a result of cohabitation and unprotected sex, a crucial prediction is that donor sperm pregnancies will not have this property, and should lead to a much greater incidence of PE. This is precisely what is observed (270, 276–279, 310).

In an early study (276), Need et al. observed that the overall incidence of PE was high (9.3%) in pregnancies involving artificial insemination by donor (AID) compared with the expected incidence of 0.5–5.0%. The expected protective effect of a previous pregnancy was not seen, with a 47-fold increase in PE (observed versus expected) in AID pregnancies after a previous full-term pregnancy. That is a truly massive risk ratio.

Smith et al. (277) compared the frequency of PE when AI was via washed sperm from a partner or a donor, finding a relative risk for PE of 1.85 (95% CI 1.20–2.85) for the latter, and implying that the relevant factor was attached to (in or on) the sperm themselves.

In a similar kind of study, Hoy et al. found (278), after adjusting for maternal age, multiple birth, parity and presentation, that “donor sperm” pregnancies were more likely to develop PE (OR 1.4, 95% CI 1.2–1.8).

Salha et al. (310) found that the incidence of PE in pregnancies resulting from donated spermatozoa was 18.2% (6/33) compared with 0% in the age- and parity-matched partner insemination group (P < 0.05).

Wang et al. (329) found that the risk of PE tripled in those never exposed to their partner’s sperm, i.e., those treated with intracytoplasmatic sperm injection done with surgically obtained sperm.

In a study of older women, Le Ray et al. (330) noted that the PE rate differed significantly between various groups using assisted reproductive technology (3.8% after no IVF, 10.0% after IVF only, and 19.2% after IVF with oocyte donation, P < 0.001).

Davis and Gallup reviewed what was known in 2006 (279), particularly from an evolutionary point of view, concluding that one interpretation of PE was that it was the mother’s way of removing “unsuitable” fetuses. This does not sit easily with the considerable mortality and morbidity associated with PE predelivery, especially in the absence of treatment. However, Davis and Gallup (279) did recognize that “pregnancies and children that result from unfamiliar semen have a lower probability of receiving sufficient paternal investment than do pregnancies and children that result from familiar semen,” and that is fully consistent with our general thinking here. Bonney draws a similar view (182), based on the “danger” model (176, 178), that takes a different view from that of the “allograft” or “self-nonself discrimination” model. In the “danger model,” the decision to initiate an immune response is based not on discrimination between self and non-self, but instead is based on the recognition of “danger” (abnormal cell death, injury, or stress). One such recognition is the well-established recognition of microbes as something likely to be causative of undesirable outcomes.

In the study of González-Comadran et al. (331), conception using donor sperm was again associated with an increased risk of PE (OR 1.63, 95% CI 1.36–1.95).

Thomopoulos et al. carried out two detailed and systematic reviews (319, 332); the latter (319) covered 7,038,029 pregnancies (203,375 following any invasive ART) and determined that the risk of PE was increased by 75% (95% CI 50–103%).

Overall, these studies highlight very strongly indeed that the use of unfamiliar male sperm is highly conducive to PE relative to that of partner’s sperm, especially when exposure is over a long period. We next turn to the question of why, in spite of this, we also see PE even in partner-inseminated semen, as well as more generally.

Evidence from Epidemiology—Semen Can be Harmful and Can Contribute Strongly to PE

In our previous review (44), we rehearsed the evidence for a considerable placental and vaginal microbiome [see also (333–335)], but did not discuss the semen microbiome at all. To repeat, therefore, the particular, and essentially novel, part of our hypothesis here is that if it is accepted that semen (and seminal plasma) can have beneficial effects, it should also be recognized that in certain cases it can also have harmful effects. In particular, we shall be focusing on its microbial content [we ignore any epigenetic effects (336)]. We note that this idea would fit easily with the recognition that as well as inducing tolerance to paternal antigens, exposures to the father’s semen can build tolerance (immunity) to its microbes, thereby decreasing the risk of PE. However, microbes and their associated PAMPs are well known to be highly inflammatory, whether or not they are reproducing, and we consider that it is this that is likely the particular driver of the sequelae observable in PE.

Microbes Associated with PE

The female’s urogenital microbiome is important in a number of pregnancy disorders (56, 337–339). Specifically, we previously found many examples in which microbes are associated with PE, and we here update the CC-BY-licensed Table 2 thereof (44).

In addition, we recognize the considerable evidence for a role of viruses in various disorders of pregnancy (106, 382, 383).

Microbiology of Semen

Semen itself is very far from being sterile, even in normal individuals, with infection usually being defined as 10³ organisms/mL semen (384). Of course the mere existence of sexually transmitted diseases implies strongly that there is a seminal fluid (or semen) microbiome that can vary substantially between individuals, and that can contribute to infection [e.g., Ref. (385–387)], fertility (385) (and see below), and any other aspect of pregnancy (388), or even health in later life (389).

It is logical to start here with the observation that semen is a source of microbes from the fact that there are a great many sexually transmitted infectious diseases for which it is the vehicle. Table 3 summarizes some of these.

Notwithstanding the difficulties of measurement (405), there is, in particular, a considerable literature on fertility (406), since infertile males tend to donate sperm for assay in fertility clinics, and infection is a common cause of infertility [e.g., Ref. (384) and Table 4]. Note that “infertility” is not always an absolute term: pregnancies result in 27% of cases of treated “infertile” couples followed up after trying to conceive for 2 years, and with oligozoospermia as the primary cause of infertility (407). Most studies involve bacteria (bacteriospermia). Articles on this and other microbial properties of semen beyond STDs include those in Table 4.

We deliberately avoid discussing mechanisms in any real detail here, since our purpose is merely to show that semen is commonly infected with microbes, whose presence might well lead to PE. However, we were very struck by the ability of Escherichia coli and other organisms (440, 448, 471) actually to immobilize sperm [e.g., Ref. (472–475)]. As with amyloidogenic blood clotting (476, 477), bacterial LPS (156) may be a chief culprit (459). The Gram-positive equivalent, lipoteichoic acid (LTA), is just as potent in the fibrinogen-clotting amyloidogen assay (478), but while Gram-positives can also immobilize sperm (479, 480), the influence of purified LTA on sperm seems not to have been tested.

Another prediction from this analysis is that since infection is a significant cause of both infertility and PE [and it may account for 15% of infertile cases (384, 473)], we might expect to see some correlations between them. Although one might argue that anything seen as imperfect “background” health or subfecundity might impinge on the incidence of PE [such as endocrine disruption (481) or DNA damage of whatever cause (482)], the risk ratio for PE in couples whose infertility had an unknown basis was 5.61 (CI 3.3–9.3) in one study in Aberdeen (483) and 1.29 (CI 1.05–1.60) in another in Norway (484). Time to pregnancy in couples may be used (in part) as a surrogate for (in)fertility and is associated with a variety of poor pregnancy outcomes (485); in this case, the risk ratio for PE for TTP exceeding 6 months was 2.47 (CI 1.3–4.69) (486). Given the prevalence of infection in infertile sperm (Table 4), and the frequency of infertility [10% in the Danish study (485), which defined it as couples taking a year or more to conceive], it seems reasonable to suggest that microbiological testing of semen should be done on a more routine basis. It would also help to light up any relationships between the microbiological properties of sperm and the potentially causal consequence of increased PE risk.

We also note, as thoughtfully and importantly suggested by referee 1, that the microbes in the semen may already induce inflammation in the endometrium a few days before the conceptus implants. This may itself constitute a hostile “environment” that can contribute to the process of defective implantation, rather than working via the fetus itself.

More quantitatively, and importantly intellectually, if infection is seen as a major cause of PE, as we argue here, and it is known that infection is a cause of infertility, then one should suppose that infertility, and infertility caused by infection, should be at least as common, and probably more common than is PE, and this is the case, adding some considerable weight to the argument. Indeed, if PE was much more common than infertility or even infection, it would be much harder to argue that the latter was a major cause of the former. In European countries ~10–15% of couples are afflicted by infertility (384, 485), and in some 60% of cases infection or a male factor is implicated (384). In some countries, the frequency of male infertility is 13–15% http://bionumbers.hms.harvard.edu/bionumber.aspx?id=113483&ver=0 or higher (487), and the percentage of females with impaired fecundity has been given as 12.3% https://www.cdc.gov/nchs/fastats/infertility.htm. These kinds of numbers would imply that 6–9% of couples experience infection- or male-based infertility, and this exceeds the 3–5% incidence of PE.

In a similar vein, antibiotics, provided they can get through the relevant membranes (488–490), should also have benefits on sperm parameters or fertility if a lack of it is caused by infection, and this has indeed been observed [e.g., Ref. (436, 452, 491)].

Roles of the Prostate and Testes

In the previous review, we focused on the gut, periodontitis, and the urinary tract of the mother as the main source of organisms that might lead to PE. Here we focus on the male, specifically the prostate and the testes, given the evidence for how common infection is in semen. The main function of the prostate gland is to secrete prostate fluid, one of the components of semen. Thus, although it is unlikely that measurements have regularly been done to assess any relationship between this and any adverse effects of pregnancy, it was of interest to establish whether it too is likely to harbor microbes. Indeed, such “male accessory gland infection” is common (492–496). In some cases, the origin is probably periodontal (497). Recent studies have implicated microbial PRRs, especially TLRs, as well as inflammatory cytokines and their signaling pathways, in testicular function, implying an important link between infection/inflammation and testicular dysfunction (498). The testes are a common and important site of infection in the male (499, 500), and even bacterial LPS can cause testitis (501). Similarly, infection (especially urinary tract infection) is a common cause of prostatitis (502–512). Finally, prostatitis is also a major cause of infertility (492, 493, 495). Such data contribute strongly to the recognition that semen is not normally going to be sterile, consistent with the view that it is likely to be a major originating cause of the infections characteristic of PE.

Microbial Infections in Spontaneous Abortions, Miscarriages, and PTB

Our logic would also imply a role for (potentially male-derived) microbes in miscarriages and spontaneous abortions. A microbial component to these seems well established for both miscarriages (513–515) and spontaneous abortions (516–521). Of course the ability of Brucella abortus to induce abortions in domesticated livestock, especially cattle (and occasionally in humans), is well known (522–524); indeed, bacteriospermia is inimical to fertilization success (525), and nowadays it is well controlled in livestock by the use of vaccines (526) or antimicrobials (525). Indeed, stored semen is so widely used for the artificial insemination of livestock in modern agriculture that the recognition that semen is not sterile has led to the routine use of antibiotics in semen “extenders” [e.g., Ref. (527–530)].

The same general logic is true for infection as a common precursor to PTB in the absence of PE, where it is much better established [e.g., Ref. (531–565)]. It arguably has the same basic origins in semen.

Although recurrent pregnancy loss is usually treated separately from infertility (where the role of infection is reasonably well established) it is possible that in many cases it is, like PE, partly just a worsened form of an immune reaction, with both sharing similar causes (including the microbial infection of semen). There is in fact considerable evidence for this [e.g., Ref. (138, 443, 566–580)]. Of course it is not unreasonable that poor sperm quality, that may be just sufficient to initiate a pregnancy, may ultimately contribute to its premature termination or other disorders of pregnancy, so this association might really be expected. It does, however, add considerable weight to the view that a more common screening of the male than presently done might be of value (581) in assessing a range of pregnancy disorders besides PE. In particular, it seems that infection affects motility (see above), and that this in turn is well correlated (573) with sperm DNA fragmentation and ultimate loss of reproductive quality.

Amyloids in semen are known to enhance human immunodeficiency virus infectivity (582). According to our own recent experimental analyzes, they may be caused by bacterial LPS (476, 477) or LTA (478). We note too that the sperm metabolome also influences offspring, e.g., from obese parents (583), and that many other variables are related to sperm quality, including oxidative stress (584–591). Thus it is entirely reasonable to see semen as a cause of problems as well as benefits to an ensuing pregnancy.

Microbial Effects on Immunotolerance

If our thesis is sound, one may expect to find evidence for the effects of microbes on the loss of immunotolerance in other settings. One such is tolerance to dietary antigens, of which gluten, a cause of celiac disease, is preeminent. Recently, evidence has come forward that shows a substantial effect of a reovirus in lowering the immunotolerance to gluten in a mouse model of celiac disease, and thereby causing inflammation (592, 593). Interestingly, pregnancies in women with celiac disease were considerably more susceptible to PTB and other complications than were controls (594–601), especially when mothers were not on a gluten-free diet. Similarly, preeclamptic pregnancies led to a much (4-fold) higher likelihood of allergic sensitization in the offspring (602) The roles of hygiene, the microbiome and disease are a matter of considerable current interest [e.g., Ref. (603)].

It was consequently logical to see if intolerance to peanut antigen was also predictive of PE, but we could find no evidence for this. Again, however, in a study (604) in which PE had roughly its normal prevalence, mothers experiencing it were significantly more likely to give birth to children with increased risk of asthma, eczema, and aeroallergen and food allergy.

Effects of Vaccination on Pregnancy Outcomes, Including PE

We noted above (and again below) that the evidence for a role of microbes in PTB is overwhelming [also reviewed in Ref. (44)]. From an immunological point of view, there seems to be a hugely beneficial outcome of vaccination against influenza in terms of lowering PTB (605–610) [cf. (611)] or stillbirth (612). PE was not studied, save in Ref. (613) where the risk ratio of vaccination (0.484, CI 0.18–1.34) implied a marginal benefit. There do not seem to be any safety issues, either for influenza vaccine (612–633) or for other vaccines (625) such as those against pertussis (634–636) or human papillomavirus (637).

As well as miscarriage and PTB, other adverse pregnancy outcomes studied in relation to vaccine exposure (638) include IUGR. IUGR frequently presents as the fetal phenotype of PE, sharing a common etiology in terms of poor placentation in early pregnancy (639). These other adverse events have been scored more frequently than has been PE, and Table 5 summarizes the evidence for a protective effect of vaccines, though it is recognized that there is the potential for considerable confounding effects [e.g., Ref. (632, 640)]. While Table 5 does not have examples from PE this is because the tests have seemingly not been done; because the effects on related disorders of pregnancy are clear, we think these should be sufficient to encourage people to look at the effects on PE (indeed readers may already have unpublished data).

There are no apparent benefits of vaccine-based immunization vs. recurrent miscarriage (642, 643).

Unrelated to the present question, but very interesting, is the fact that the risk of RA for men was higher among men who fathered their first child at a young age (P for trend <0.001) (644). This is consistent with the fact that its prevalence in females is 3.5 times higher, and that it has a microbial origin (645–648).

General or Specific?

The fact that vaccination against organisms not usually associated with adverse pregnancy outcomes is protective can be interpreted in one (or both) of two ways, i.e., that the vaccine is unselective in terms of inhibiting the effects of its target organism, or the generally raised level of <some kind of> immune response is itself protective. Data to discriminate these are not yet to hand.

In a similar vein, the survival of the host in any “battle” between host and parasite (e.g., microbe) can be effected in one or both of two main ways: (i) the host invokes antimicrobial processes such as the immune systems described above, or produces antimicrobial compounds or (ii) the host modifies itself in ways that allow it to become tolerant to the presence of a certain standing crop of microbes. We consider each in turn.

Antimicrobial Components of Human Semen, a Part of Resistance in the Semen Microbiome

Antimicrobial peptides (AMPs) [http://aps.unmc.edu/AP/main.php (649)] are a well-known part of the defense systems of many animals [e.g., Ref. (650–659)] [and indeed plants (650, 660)], and are widely touted as potential anti-infectives [e.g., Ref. (661–663)]. Their presence in the cells and tissues of the uterus, fetus and the neonate indicates an important role in immunity during pregnancy and in early life (657, 664–668). Unsurprisingly, they have been proposed as agents for use in preventing the transmission of STDs (669, 670), and as antimicrobials for addition to stored semen for use in agriculture (671–675). Our interest here, however, is around whether there are natural AMPs in human (or animal) semen, and the answer is in the affirmative. They include secretory leukocyte protease inhibitor (659), semen-derived enhancer of viral infection (676), and in particular the semenogelins (677, 678). HE2 is another AMP that resides in the epididymis (679, 680), while the human cathelicidin hCAP-18 [cathelicidin AMP, 18 kDa)] is inactive in seminal plasma but is processed to the AMP LL-37 by the prostate-derived protease gastricsin (668, 681). Thus it is clear that at least some of the reason that the semen microbiome is not completely unchecked is down to AMPs. Stimulating their production, provided they are not also spermicidal, would seem like an excellent therapeutic option.

Host Tolerance to Microbial Pathogens

It is a commonplace that—for any number of systems biology reasons based on biochemical individuality (682)—even highly virulent diseases do not kill everyone who is exposed to them at the same level. As indicated above, this could be because the host is resistant and simply clears the infections; this is certainly the more traditional view. However, an additional or alternative contribution is because while hosts do not clear all of them they can develop “tolerance” to them. This latter view is gaining considerable ground, not least since the work of Schneider, Ayres et al. (683) showing that a variety of Drosophila mutants with known genetic defects could differentially tolerate infection by Listeria monocytogenes. This concept of tolerance (684–691) is very important to our considerations here, since it means that we do indeed have well-established methods of putting up with microbes more generally, without killing them. It is consistent with clearly established evolutionary theory (692–694), and the relative importance of resistance and tolerance within a population affects host–microbe coevolution (695). The concept of tolerance sits easily with the Matzinger model of danger/damage [e.g., Ref. (175, 177, 178, 180)], as well as the concept of a resident population of dormant microbes (45, 47, 48), and may indeed be seen in terms of a coevolution or mutualistic association (696, 697). Some specific mechanisms are becoming established, e.g., the variation by microbes of their danger signal to promote host defense (698). Others, such as the difference in the host metabolomes [that we reviewed (44)] as induced by resistance vs. tolerance responses (690) may allow one to infer the relative importance of each. At all events, it is clear from the concept of dormancy that we do not kill all the intracellular microbes that our bodies harbor, and that almost by definition we must then tolerate them. As well as the established maternal immunotolerance of pregnancy, tolerance of microbes seems to be another hallmark of pregnancy.

Sequelae of a Role of Infection in PE: Microbes, Molecules and Processes

The chief line taken in our previous review (44) and herein is that this should be detectable by various means. Those three chief means involve detecting the microbes themselves, detecting molecules whose concentration changes as a result of the microbes (and their inflammatory components) being present, and detecting host processes whose activities have been changed by the presence of the microbes.

Previously (44), updated here (Table 2), we provided considerable evidence for the presence of microbes within the mother as part of PE. Here we have adduced the equally considerable evidence that in many cases semen is very far from being sterile, and that the source of the originating infection may actually be the father. Equally, we showed (44) that a long list of proteins that were raised (or less commonly lowered) in PE were equally changed by known infections, consistent with the view that PE also involved such infections, albeit at a lower level at which their overt presence could be kept in check. One protein we did not discuss was Placental Protein 13 (PP13) or galectin 1, so we now discuss this briefly.

PP13 (Galectin 13)

Galectins are glycan-binding proteins that regulate innate and adaptive immune responses. Three of the five human cluster galectins are solely expressed in the placenta (699). One of these, encoded by the LGALS13 gene (700, 701), is known as galectin-13 or PP13 (702). Its β-sheet-rich “jelly-roll” structure places it strongly as a galectin homolog (701). It has a MW of ~16 kDa [32 kDa dimer (703)] and is expressed solely in the placenta (700, 704) (and see http://www.proteinatlas.org/ENSG00000105198-LGALS13/tissue). A decreased placental expression of PP13 and its low concentrations in first trimester maternal sera are associated with elevated risk of PE (699, 705–707), plausibly reflecting poor placentation. By contrast, and consistent with the usual oxidative stress, there is increased trophoblastic shedding of PP13-immunopositive microvesicles in PE, starting in the second trimester, which leads to high maternal blood PP13 concentrations (699, 708). Certain alleles such as promoter variant 98A-C predispose strongly to PE (709).

Galectin-1 is also highly overexpressed in PE (710). However, as with all the other proteomic biomarkers surveyed previously (44), galectins (including galectin-13 #http://amp.pharm.mssm.edu/Harmonizome/gene/LGALS13) are clear biomarkers of infection (711).

Toll-Like Receptors

Toll-like receptors are among the best known receptors for “DAMPs” such as LPS from Gram-negatives [TLR4 (156, 712–714)], LTAs from Gram-positives [TLR2 (715–726)] and viral DNA and its mimics (TLR3) (727). Note, however, that TLRs are not expressed solely at the cell surface, and that pathogens (and their DNA) may also be recognized intracellularly (728–733), often via a pathway involving an AIM2 (“absent in melanoma 2”) inflammasome and or STING (“stimulator of interferon genes”).

As expected, they are intimately involved in disorders of pregnancy such as PE (185, 727, 734–745). Indeed the animal model for PE developed by Faas et al. (746) actually involves injecting an ultralow dose of LPS into pregnant rat on day 14 of gestation. Overall, such data are fully consistent with the view that infection is a significant part of PE. In view of our suggestions surrounding the role of semen infection in PE it would be of interest to know if these markers were also raised in the semen of partners of women who later manifest PE. Sperm cells are well endowed with TLRs (498, 747–749). However, we can find only one study showing that increased semen expression of TLRs is indeed observed during inflammation and oxidative stress such as occurs during infection and infertility (750). A more wide-ranging assessment of TLR expression in sperm cells as a function of fertility seems warranted.

LPS Mimics

An interesting and striking feature of PE is the common appearance (2–7 weeks before the onset of clinical disease) of inositolphosphoglycan-P type (IPG-P) in the urine of patients destined to manifest PE (20, 751–762). These molecules are second messegers of insulin, and hence related to gestational diabetes. Robillard et al. (20) comment “These carbohydrate–lipid long-chain molecules mimic exactly endotoxins (such as E. coli or Plasmodium falciparum membranes). In theory, these compounds could circulate as endotoxins floating around in the bloodstream for weeks (before and during the appearance of clinical signs of PE). Would these greatly augment the systemic and more specific endothelial inflammation in the mother? This area needs urgent further research as anti-IPG-Pdrugs (or others, monoclonal antibodies, etc.) are intellectually conceivable.” In view of the arguments raised here about the role of other endotoxins such as LPS, we consider these observations as providing potentially significant clues. Surprisingly, little is known of changes in their levels that might accompany genuine infection.

Coagulopathies

Although we discussed this in the previous review (44), some further brief rehearsal is warranted, since coagulopathies are such a common feature of PE (44). Specifically, our finding that very low concentrations of cell wall products can induce amyloid formation during blood clotting (476, 478) has been further extended to recognize the ubiquity of the phenomenon in chronic, inflammatory diseases (477, 478, 648, 763–766). Often, an extreme example gives strong pointers, and the syndrome with the highest likelihood of developing PE is antiphospholipid syndrome (APS) (767–771), which is also caused by infection (772–777) and where the coagulopathies are also especially noteworthy (778–782). Consequently, the recognition of PE as an amyloidogenic coagulopathy (44, 783–785) is significant.

APS and Cardiolipin

Antiphospholipid syndrome is an autoimmune disorder defined in particular by the presence high circulating titers of what are referred to as antiphospholipid antibodies (aPL) [e.g., Ref. (786)]. Given that every human cell’s plasma membrane contains phospholipids, one might wonder how “antiphospholipid antibodies” do not simply attack every cell. The answer, most interestingly, is that, despite the name, anticardiolipin antibodies, anti-β2-glycoprotein-I, and lupus anticoagulant are the main autoantibodies found in APS (787).

In contrast to common phospholipids such as phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine, cardiolipins [1,3-bis(sn-3′-phosphatidyl)-sn-glycerol derivatives] (see Figure 6 for some structures) are synthesized in (Ref. (788–790)) and essentially confined to mitochondria, and in particular the inner mitochondrial membrane. While heart failure is a separate clinical condition, we note that such phospholipids can serve important functions in oxidative phosphorylation, apoptosis, and heart failure development (790–797).

Figure 6

Overall, there seems to be little doubt that APS and aPL are the result of infection (773–777, 798–800), and that, as with RA (645–648, 801), the autoimmune responses are essentially due to molecular mimicry.

Now, of course, from an evolutionary point of view, mitochondria are considered to have evolved from (α-proteo)bacteria (802–808) that were engulfed by a protoeukaryote (809), and bacteria might consequently be expected to possess cardiolipin. This is very much the case for both Gram-negative and Gram-positive strains (810–814), with Gram-positive organisms typically having the greater content. Particularly significant, from our point of view, is that the relative content of cardiolipin among phospholipids increases enormously as (at least Gram-positive) bacterial cells become dormant (815).

Thus, the cardiolipin can come from two main sources: (i) host cell death that liberates mitochondrial products or (ii) invading bacteria (especially those that lay dormant and awaken). Serum ferritin is a cell death marker (816), and some evidence for the former source (817) [and see Ref. (818)] is that hyperferritinemia was present in 9% vs. 0% of APS patients and controls, respectively (P < 0.001), and that hyperferritinemia was present in 71% of catastrophic APS (cAPS) patients, and ferritin levels among this subgroup were significantly higher compared with APS-non-cAPS patients (816–847 vs. 120–230 ng/ml, P < 0.001). One easy hypothesis is that both are due to invading bacteria, but cAPS patients also exhibit comparatively large amounts of host cell death (Figure 7).

Figure 7

Treatment Options Based on (Or Consistent with) the Ideas Presented Here

Although often unwritten or implicit, the purposes of much of fundamental biomedical science are to find better diagnostics and treatments for diseases (a combination sometimes referred to as theranostics). Consequently, our purposes here are to rehearse some of those areas where appropriate tests (in the form, ultimately, of randomized clinical trials) may be performed. Clearly, as before (44), and recognizing the issues of antimicrobial resistance, one avenue would exploit antibiotics much more commonly than now. We note that pharmaceutical drugs are prescribed or taken during 50% or more of pregnancies (819–828). Anti-infectives are the most common such drugs, and some 20–25% of women or more are prescribed one or more antibiotics during their pregnancies (820, 821, 824, 826, 828–832).

Given the role of male semen infection, we suggest that more common testing of semen for infection is warranted, especially using molecular tests. Our analyses suggest that antibiotics might also be of benefit to those males presenting with high microbial semen loads or poor fertility (833). Another strategy might involve stimulating the production of AMPs in semen.

Of the list of bacteria given in Table 2 as being associated with PE, H. pylori stands out as the most frequent. One may wonder why a vaccine against it has not been developed, but it seems to be less straightforward than for other infections (834, 835), probably because—consistent with its ability to persist within its hosts—it elicits only a poor immune response (836, 837). Our own experience (838) is that many small molecules can improve the ability of other agents to increase the primary mechanisms that are the target assay, while having no direct effects on them themselves. Although “combinatorial” strategies often lead to quite unexpected beneficial effects [e.g., Ref. (839, 840)], this “binary weapon” strategy is both novel and untried.

As also rehearsed in more detail previously [e.g., Ref. (841, 842)] many polyphenolic antioxidants act through their ability to chelate unliganded iron, and thereby keep it from doing damage or acting as a source of iron for microbial proliferation. Such molecules may also be expected to be beneficial. Other strategies may be useful for inhibiting the downstream sequelae of latent infections, such as targeting inflammation or coagulopathies.

Conclusion, Summary, and Open Questions

We consider that our previous review (44) made a very convincing case for the role of (mostly dormant) microbes in the etiology of PE. However, we there paid relatively scant attention to two elements, viz (i) the importance of the immune system (164), especially in maternal immunotolerance and (ii) the idea that possibly the commonest cause of the microbes providing the initial infection was actually infected semen from the father. We also recognize that epigenetic information (389, 843–845) can be provided by the father and this can be hard to discriminate from infection (if not measured), at least in the F₁ generation. This said, microbiological testing of semen seems to be a key discriminator if applied. The “danger model” (175, 177–180), in which it is recognized that immune activation owes more to the detection of specific damage signals than to “non-self,” thus seems to be highly relevant to PE (182).

References

• 1

  JeffcoateTNA. Pre-eclampsia and eclampsia: the disease of theories. Proc R Soc Med (1966) 59:397–404.

  • Google Scholar

• 2

  BaradDHKushnirVAGleicherN. Focus on recurrent miscarriage phenotypes. Fertil Steril (2017) 107:64–5.10.1016/j.fertnstert.2016.10.034

  • CrossRef
  • Google Scholar

• 3

  GrillSRusterholzCZanetti-DällenbachRTercanliSHolzgreveWHahnSet alPotential markers of preeclampsia – a review. Reprod Biol Endocrinol (2009) 7:70.10.1186/1477-7827-7-70

  • CrossRef
  • Google Scholar

• 4

  SteegersEAPVon DadelszenPDuvekotJJPijnenborgR. Pre-eclampsia. Lancet (2010) 376:631–44.10.1016/S0140-6736(10)60279-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5

  NorthRAMccowanLMDekkerGAPostonLChanEHStewartAWet alClinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ (2011) 342:d1875.10.1136/bmj.d1875

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6

  UzanJCarbonnelMPiconneOAsmarRAyoubiJM. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag (2011) 7:467–74.10.2147/VHRM.S20181

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7

  KennyL. Improving diagnosis and clinical management of pre-eclampsia. MLO Med Lab Obs (2012) 44(12):14.

  • Google Scholar

• 8

  DesaiP. Obstetric Vasculopathies. New Delhi: Jaypee (2013).

  • Google Scholar

• 9

  ChaiworapongsaTChaemsaithongPYeoLRomeroR. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol (2014) 10:466–80.10.1038/nrneph.2014.102

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10

  KennyLCBlackMAPostonLTaylorRMyersJEBakerPNet alEarly pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertension (2014) 64:644–52.10.1161/HYPERTENSIONAHA.114.03578

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11

  SircarMThadhaniRKarumanchiSA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens (2015) 24:131–8.10.1097/MNH.0000000000000105

  • CrossRef
  • Google Scholar

• 12

  AbalosECuestaCGrossoALChouDSayL. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol (2013) 170:1–7.10.1016/j.ejogrb.2013.05.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13

  VestARChoLS. Hypertension in pregnancy. Curr Atheroscler Rep (2014) 16:395.10.1007/s11883-013-0395-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14

  KhanKSWojdylaDSayLGulmezogluAMVan LookPF. WHO analysis of causes of maternal death: a systematic review. Lancet (2006) 367:1066–74.10.1016/S0140-6736(06)68397-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15

  DuleyL. The global impact of pre-eclampsia and eclampsia. Semin Perinatol (2009) 33:130–7.10.1053/j.semperi.2009.02.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16

  CantwellRClutton-BrockTCooperGDawsonADrifeJGarrodDet alSaving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG (2011) 118(Suppl 1):1–203.10.1111/j.1471-0528.2010.02847.x

  • CrossRef
  • Google Scholar

• 17

  GhulmiyyahLSibaiB. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol (2012) 36:56–9.10.1053/j.semperi.2011.09.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18

  AbalosECuestaCCarroliGQureshiZWidmerMVogelJPet alPre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization multicountry survey on maternal and newborn health. BJOG (2014) 121(Suppl 1):14–24.10.1111/1471-0528.12629

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19

  RobillardPYDekkerGChaouatGHulseyTCSaftlasA. Epidemiological studies on primipaternity and immunology in preeclampsia – a statement after twelve years of workshops. J Reprod Immunol (2011) 89:104–17.10.1016/j.jri.2011.02.003

  • CrossRef
  • Google Scholar

• 20

  RobillardPYDekkerGIacobelliSChaouatG. An essay of reflection: why does preeclampsia exist in humans, and why are there such huge geographical differences in epidemiology?J Reprod Immunol (2016) 114:44–7.10.1016/j.jri.2015.07.001

  • CrossRef
  • Google Scholar

• 21

  BrewOSullivanMHWoodmanA. Comparison of normal and pre-eclamptic placental gene expression: a systematic review with meta-analysis. PLoS One (2016) 11:e0161504.10.1371/journal.pone.0161504

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22

  LeaveyKBentonSJGrynspanDKingdomJCBainbridgeSACoxBJ. Unsupervised placental gene expression profiling identifies clinically relevant subclasses of human preeclampsia. Hypertension (2016) 68:137–47.10.1161/HYPERTENSIONAHA.116.07293

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23

  RedmanCWG. Current topic: pre-eclampsia and the placenta. Placenta (1991) 12:301–8.10.1016/0143-4004(91)90339-H

  • CrossRef
  • Google Scholar

• 24

  RobertsJMHubelCA. The two stage model of preeclampsia: variations on the theme. Placenta (2009) 30(Suppl A):S32–7.10.1016/j.placenta.2008.11.009

  • CrossRef
  • Google Scholar

• 25

  BakerPNKennyLC. Obstetrics by Ten Teachers. Boca Raton, FL: CRC Press (2011).

  • Google Scholar

• 26

  PenningtonKASchlittJMJacksonDLSchulzLCSchustDJ. Preeclampsia: multiple approaches for a multifactorial disease. Dis Model Mech (2012) 5:9–18.10.1242/dmm.008516

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27

  RedmanCWSargentILStaffAC. IFPA senior award lecture: making sense of pre-eclampsia – two placental causes of preeclampsia?Placenta (2014) 35(Suppl):S20–5.10.1016/j.placenta.2013.12.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28

  RedmanCWG. The six stages of pre-eclampsia. Pregnancy Hypertens (2014) 4:246.10.1016/j.preghy.2014.04.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29

  PerucciLOCorrêaMDDusseLMGomesKBSousaLP. Resolution of inflammation pathways in preeclampsia-a narrative review. Immunol Res (2017) 65:774–89.10.1007/s12026-017-8921-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  HungTHSkepperJNBurtonGJ. In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. Am J Pathol (2001) 159:1031–43.10.1016/S0002-9440(10)61778-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  BurtonGJJauniauxE. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig (2004) 11:342–52.10.1016/j.jsgi.2004.03.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  BurdonCMannCCindrova-DaviesTFerguson-SmithACBurtonGJ. Oxidative stress and the induction of cyclooxygenase enzymes and apoptosis in the murine placenta. Placenta (2007) 28:724–33.10.1016/j.placenta.2006.12.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33

  Cindrova-DaviesTSpasic-BoskovicOJauniauxECharnock-JonesDSBurtonGJ. Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. Am J Pathol (2007) 170:1511–20.10.2353/ajpath.2007.061035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  BurtonGJYungHWCindrova-DaviesTCharnock-JonesDS. Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia. Placenta (2009) 30(Suppl A):S43–8.10.1016/j.placenta.2008.11.003

  • CrossRef
  • Google Scholar

• 35

  BurtonGJJauniauxE. Oxidative stress. Best Pract Res Clin Endocrinol Metab (2011) 25:287–99.10.1016/j.bpobgyn.2010.10.016

  • CrossRef
  • Google Scholar

• 36

  Sánchez-ArangurenLCPradaCERiaño-MedinaCELopezM. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol (2014) 5:1.10.3389/fphys.2014.00372

  • CrossRef
  • Google Scholar

• 37

  Broughton PipkinFRubinPC. Pre-eclampsia – the ‘disease of theories’. Br Med Bull (1994) 50:381–96.10.1093/oxfordjournals.bmb.a072898

  • CrossRef
  • Google Scholar

• 38

  SchlembachD. Pre-eclampsia – still a disease of theories. Fukushima J Med Sci (2003) 49:69–115.10.5387/fms.49.69

  • CrossRef
  • Google Scholar

• 39

  GeorgeEM. The disease of theories: unravelling the mechanisms of pre-eclampsia. Biochemist (2017) 39:22–5.

  • Google Scholar

• 40

  HubelCA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med (1999) 222:222–35.10.1046/j.1525-1373.1999.d01-139.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41

  GeorgeEM. New approaches for managing preeclampsia: clues from clinical and basic research. Clin Ther (2014) 36:1873–81.10.1016/j.clinthera.2014.09.023

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42

  WuPKwokCSHaththotuwaRKotroniasRABabuAFryerAAet alPre-eclampsia is associated with a twofold increase in diabetes: a systematic review and meta-analysis. Diabetologia (2016) 59:2518–26.10.1007/s00125-016-4098-x

  • CrossRef
  • Google Scholar

• 43

  WuPHaththotuwaRKwokCSBabuAKotroniasRARushtonCet alPreeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes (2017) 10:e003497.10.1161/CIRCOUTCOMES.116.003497

  • CrossRef
  • Google Scholar

• 44

  KellDBKennyLC. A dormant microbial component in the development of pre-eclampsia. Front Med Obs Gynecol (2016) 3:60.10.3389/fmed.2016.00060

  • CrossRef
  • Google Scholar

• 45

  KaprelyantsASGottschalJCKellDB. Dormancy in non-sporulating bacteria. FEMS Microbiol Rev (1993) 10:271–86.10.1111/j.1574-6968.1993.tb05871.x

  • CrossRef
  • Google Scholar

• 46

  KellDBKaprelyantsASWeichartDHHarwoodCLBarerMR. Viability and activity in readily culturable bacteria: a review and discussion of the practical issues. Antonie Van Leeuwenhoek (1998) 73:169–87.10.1023/A:1000664013047

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47

  KellDBPotgieterMPretoriusE. Individuality, phenotypic differentiation, dormancy and ‘persistence’ in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology. F1000Research (2015) 4:179.10.12688/f1000research.6709.1

  • CrossRef
  • Google Scholar

• 48

  PotgieterMBesterJKellDBPretoriusE. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev (2015) 39:567–91.10.1093/femsre/fuv013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49

  HerreraJAChaudhuriGLópez-JaramilloP. Is infection a major risk factor for preeclampsia?Med Hypotheses (2001) 57:393–7.10.1054/mehy.2001.1378

  • CrossRef
  • Google Scholar

• 50

  TrogstadLISEskildABruuALJeanssonSJenumPA. Is preeclampsia an infectious disease?Acta Obstet Gynecol Scand (2001) 80:1036–8.10.1034/j.1600-0412.2001.801112.x

  • CrossRef
  • Google Scholar

• 51

  TodrosTVasarioECardaropoliS. Preeclampsia as an infectious disease. Exp Rev Obs Gynecol (2007) 2:735–41.10.1586/17474108.2.6.735

  • CrossRef
  • Google Scholar

• 52

  Conde-AgudeloAVillarJLindheimerM. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol (2008) 198:7–22.10.1016/j.ajog.2007.07.040

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53

  López-JaramilloPHerreraJAArenas-MantillaMJaureguiIEMendozaMA. Subclinical infection as a cause of inflammation in preeclampsia. Am J Ther (2008) 15:373–6.10.1097/MJT.0b013e318164c149

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54

  RustveldLOKelseySFSharmaR. Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies. Matern Child Health J (2008) 12:223–42.10.1007/s10995-007-0224-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55

  Di SimoneNTersigniCCardaropoliSFranceschiFDi NicuoloFCastellaniRet alHelicobacter pylori infection contributes to placental impairment in preeclampsia: basic and clinical evidences. Helicobacter (2017) 22:e12347.10.1111/hel.12347

  • CrossRef
  • Google Scholar

• 56

  Nourollahpour ShiadehMBehboodi MoghadamZAdamISaberVBagheriMRostamiA. Human infectious diseases and risk of preeclampsia: an updated review of the literature. Infection (2017) 45:589–600.10.1007/s15010-017-1031-2

  • CrossRef
  • Google Scholar

• 57

  KleinrouwelerCEVan UitertMMoerlandPDRis-StalpersCVan Der PostJAAfinkGB. Differentially expressed genes in the pre-eclamptic placenta: a systematic review and meta-analysis. PLoS One (2013) 8:e68991.10.1371/journal.pone.0068991

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58

  ChungMCJorgensenSCPopovaTGTonryJHBaileyCLPopovSG. Activation of plasminogen activator inhibitor implicates protease InhA in the acute-phase response to Bacillus anthracis infection. J Med Microbiol (2009) 58:737–44.10.1099/jmm.0.007427-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59

  UbagaiTTanshoSIekiROnoY. Evaluation of TREM1 gene expression in circulating polymorphonuclear leukocytes and its inverse correlation with the severity of pathophysiological conditions in patients with acute bacterial infections. Jpn J Infect Dis (2012) 65:376–82.10.7883/yoken.65.376

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60

  UbagaiTNakanoRKikuchiHOnoY. Gene expression analysis of TREM1 and GRK2 in polymorphonuclear leukocytes as the surrogate biomarkers of acute bacterial infections. Int J Med Sci (2014) 11:215–21.10.7150/ijms.7231

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61

  FillerovaRGalloJRadvanskyMKraiczovaVKudelkaMKriegovaE. Excellent diagnostic characteristics for ultrafast gene profiling of DEFA1-IL1B-LTF in detection of prosthetic joint infections. J Clin Microbiol (2017) 55:2686–97.10.1128/JCM.00558-17

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62

  DekkerGASibaiBM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol (1998) 179:1359–75.10.1016/S0002-9378(98)70160-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63

  SargentILBorzychowskiAMRedmanCW. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online (2006) 13:680–6.10.1016/S1472-6483(10)60659-1

  • CrossRef
  • Google Scholar

• 64

  DekkerGRobillardPY. Pre-eclampsia: is the immune maladaptation hypothesis still standing? An epidemiological update. J Reprod Immunol (2007) 76:8–16.10.1016/j.jri.2007.03.015

  • CrossRef
  • Google Scholar

• 65

  MoffettAHibySE. How does the maternal immune system contribute to the development of pre-eclampsia?Placenta (2007) 28(Suppl A):S51–6.10.1016/j.placenta.2006.11.008

  • CrossRef
  • Google Scholar

• 66

  CudihyDLeeRV. The pathophysiology of pre-eclampsia: current clinical concepts. J Obstet Gynaecol (2009) 29:576–82.10.1080/01443610903061751

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67

  JamesJLWhitleyGSCartwrightJE. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol (2010) 221:363–78.10.1002/path.2719

  • CrossRef
  • Google Scholar

• 68

  JianjunZYaliHZhiqunWMingmingZXiaZ. Imbalance of T-cell transcription factors contributes to the Th1 type immunity predominant in pre-eclampsia. Am J Reprod Immunol (2010) 63:38–45.10.1111/j.1600-0897.2009.00763.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69

  RedmanCWGSargentIL. Immunology of pre-eclampsia. Am J Reprod Immunol (2010) 63:534–43.10.1111/j.1600-0897.2010.00831.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70

  HsuPNananRK. Innate and adaptive immune interactions at the fetal-maternal interface in healthy human pregnancy and pre-eclampsia. Front Immunol (2014) 5:125.10.3389/fimmu.2014.00125

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71

  DekkerGARobillardPYHulseyTC. Immune maladaptation in the etiology of preeclampsia: a review of corroborative epidemiologic studies. Obstet Gynecol Surv (1998) 53:377–82.10.1097/00006254-199806000-00023

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72

  BuzanT. How to Mind Map. London: Thorsons (2002).

  • Google Scholar

• 73

  KennyLCKellDB. Immunological Tolerance, Pregnancy and Pre-Eclampsia: The Roles of Semen Microbes and the Father. bioRxiv Preprint. bioRxiv, 198796 (2017).10.1101/198796

  • CrossRef
  • Google Scholar

• 74

  MedawarPB. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symp Soc Exp Biol (1953) 7:320–38.

  • Google Scholar

• 75

  BillingtonWD. The immunological problem of pregnancy: 50 years with the hope of progress. A tribute to Peter Medawar. J Reprod Immunol (2003) 60:1–11.10.1016/S0165-0378(03)00083-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76

  TrowsdaleJBetzAG. Mother’s little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol (2006) 7:241–6.10.1038/ni1317

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77

  Munoz-SuanoAHamiltonABBetzAG. Gimme shelter: the immune system during pregnancy. Immunol Rev (2011) 241:20–38.10.1111/j.1600-065X.2011.01002.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78

  ColucciFMoffettATrowsdaleJ. Medawar and the immunological paradox of pregnancy: 60 years on. Eur J Immunol (2014) 44:1883–5.10.1002/eji.201470065

  • CrossRef
  • Google Scholar

• 79

  BonneyEA. Immune regulation in pregnancy: a matter of perspective?Obstet Gynecol Clin North Am (2016) 43:679–98.10.1016/j.ogc.2016.07.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80

  HaigD. Genetic conflicts in human pregnancy. Q Rev Biol (1993) 68:495–532.10.1086/418300

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81

  RobertsonSASharkeyDJ. The role of semen in induction of maternal immune tolerance to pregnancy. Semin Immunol (2001) 13:243–54.10.1006/smim.2000.0320

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82

  ClarkGFSchustDJ. Manifestations of immune tolerance in the human female reproductive tract. Front Immunol (2013) 4:26.10.3389/fimmu.2013.00026

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83

  GleicherNKushnirVABaradDH. Redirecting reproductive immunology research toward pregnancy as a period of temporary immune tolerance. J Assist Reprod Genet (2017) 34:425–30.10.1007/s10815-017-0874-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84

  MoffettALokeC. Immunology of placentation in eutherian mammals. Nat Rev Immunol (2006) 6:584–94.10.1038/nri1897

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85

  RusterholzCHahnSHolzgreveW. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol (2007) 29:151–62.10.1007/s00281-007-0071-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86

  DuttaPBurlinghamWJ. Microchimerism: tolerance vs. sensitization. Curr Opin Organ Transplant (2011) 16:359–65.10.1097/MOT.0b013e3283484b57

  • CrossRef
  • Google Scholar

• 87

  RusterholzCMesserliMHoesliIHahnS. Placental microparticles, DNA, and RNA in preeclampsia. Hypertens Pregnancy (2011) 30:364–75.10.3109/10641951003599571

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88

  KinderJMStelzerIAArckPCWaySS. Immunological implications of pregnancy-induced microchimerism. Nat Rev Immunol (2017) 17:483–94.10.1038/nri.2017.38

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  KnightMRedmanCWGLintonEASargentIL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol (1998) 105:632–40.10.1111/j.1471-0528.1998.tb10178.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90

  HuppertzBKingdomJCaniggiaIDesoyeGBlackSKorrHet alHypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta (2003) 24:181–90.10.1053/plac.2002.0903

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91

  SargentILGermainSJSacksGPKumarSRedmanCWG. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol (2003) 59:153–60.10.1016/S0165-0378(03)00044-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92

  GuptaAKHaslerPHolzgreveWGebhardtSHahnS. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum Immunol (2005) 66:1146–54.10.1016/j.humimm.2005.11.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93

  GoswamiDTannettaDSMageeLAFuchisawaARedmanCWGSargentILet alExcess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta (2006) 27:56–61.10.1016/j.placenta.2004.11.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94

  ReddyAZhongXYRusterholzCHahnSHolzgreveWRedmanCWGet alThe effect of labour and placental separation on the shedding of syncytiotrophoblast microparticles, cell-free DNA and mRNA in normal pregnancy and pre-eclampsia. Placenta (2008) 29:942–9.10.1016/j.placenta.2008.08.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95

  HartleyJDRFergusonBJMoffettA. The role of shed placental DNA in the systemic inflammatory syndrome of preeclampsia. Am J Obstet Gynecol (2015) 213:268–77.10.1016/j.ajog.2015.03.026

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  ClarkDAChaputATuttonD. Active suppression of host-vs-graft reaction in pregnant mice. VII. Spontaneous abortion of allogeneic CBA/J x DBA/2 fetuses in the uterus of CBA/J mice correlates with deficient non-T suppressor cell activity. J Immunol (1986) 136:1668–75.

  • Pubmed Abstract
  • Google Scholar

• 97

  MellorALSivakumarJChandlerPSmithKMolinaHMaoDet alPrevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol (2001) 2:64–8.10.1038/83183

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98

  WilczyńskiJR. Immunological analogy between allograft rejection, recurrent abortion and pre-eclampsia – the same basic mechanism?Hum Immunol (2006) 67:492–511.10.1016/j.humimm.2006.04.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  WarningJCMccrackenSAMorrisJM. A balancing act: mechanisms by which the fetus avoids rejection by the maternal immune system. Reproduction (2011) 141:715–24.10.1530/REP-10-0360

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100

  KimCJRomeroRChaemsaithongPKimJS. Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance. Am J Obstet Gynecol (2015) 213:S53–69.10.1016/j.ajog.2015.08.041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101

  RamanKWangHTronconeMJKhanWIPareGTerryJ. Overlap chronic placental inflammation is associated with a unique gene expression pattern. PLoS One (2015) 10:e0133738.10.1371/journal.pone.0133738

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102

  HydeKJSchustDJ. Immunologic challenges of human reproduction: an evolving story. Fertil Steril (2016) 106:499–510.10.1016/j.fertnstert.2016.07.1073

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103

  ZelanteTPieracciniGScaringiLAversaFRomaniL. Learning from other diseases: protection and pathology in chronic fungal infections. Semin Immunopathol (2016) 38:239–48.10.1007/s00281-015-0523-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104

  MorGCardenasIAbrahamsVGullerS. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci (2011) 1221:80–7.10.1111/j.1749-6632.2010.05938.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105

  RacicotKKwonJYAldoPSilasiMMorG. Understanding the complexity of the immune system during pregnancy. Am J Reprod Immunol (2014) 72:107–16.10.1111/aji.12289

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106

  MorGAldoPAlveroAB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol (2017) 17:469–82.10.1038/nri.2017.64

  • CrossRef
  • Google Scholar

• 107

  HenchPS. The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrositis and intermittent hydrarthritis. Mayo Clin Proc (1938) 13:161–7.

  • Google Scholar

• 108

  GlynJ. The discovery and early use of cortisone. J R Soc Med (1998) 91:513–7.10.1177/014107689809101004

  • CrossRef
  • Google Scholar

• 109

  de ManYADolhainRJVan De GeijnFEWillemsenSPHazesJM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum (2008) 59:1241–8.10.1002/art.24003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110

  Muñoz-ValleJFVazquez-Del MercadoMGarcía-IglesiasTOrozco-BarocioGBernard-MedinaGMartínez-BonillaGet alT(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol (2003) 131:377–84.10.1046/j.1365-2249.2003.02059.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111

  NelsonJLHughesKASmithAGNisperosBBBranchaudAMHansenJA. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med (1993) 329:466–71.10.1056/NEJM199308123290704

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112

  ChiamNPLimLL. Uveitis and gender: the course of uveitis in pregnancy. J Ophthalmol (2014) 2014:401915.10.1155/2014/401915

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113

  JamesDSteerPLWeinerCGonikBCrowtherCRobsonS, editors. High Risk Pregnancy. Amsterdam: Elsevier/Saunders (2010).

  • Google Scholar

• 114

  KhashanASKennyLCLaursenTMMahmoodUMortensenPBHenriksenTBet alPregnancy and the risk of autoimmune disease. PLoS One (2011) 6:e19658.10.1371/journal.pone.0019658

  • CrossRef
  • Google Scholar

• 115

  HuntJSPetroffMGMcintireRHOberC. HLA-G and immune tolerance in pregnancy. FASEB J (2005) 19:681–93.10.1096/fj.04-2078rev

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116

  HviidTV. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum Reprod Update (2006) 12:209–32.10.1093/humupd/dmi048

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117

  GuleriaISayeghMH. Maternal acceptance of the fetus: true human tolerance. J Immunol (2007) 178:3345–51.10.4049/jimmunol.178.6.3345

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118

  DahlMPerinTLDjurisicSRasmussenMOhlssonJBuusSet alSoluble human leukocyte antigen-G in seminal plasma is associated with HLA-G genotype: possible implications for fertility success. Am J Reprod Immunol (2014) 72:89–105.10.1111/aji.12251

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119

  Lynge NilssonLDjurisicSHviidTVF. Controlling the immunological crosstalk during conception and pregnancy: HLA-G in reproduction. Front Immunol (2014) 5:198.10.3389/fimmu.2014.00198

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120

  Martínez-VareaAPellicerBPerales-MarinAPellicerA. Relationship between maternal immunological response during pregnancy and onset of preeclampsia. J Immunol Res (2014) 2014:210241.10.1155/2014/210241

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121

  SakaguchiSYamaguchiTNomuraTOnoM. Regulatory T cells and immune tolerance. Cell (2008) 133:775–87.10.1016/j.cell.2008.05.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122

  AluvihareVRKallikourdisMBetzAG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol (2004) 5:266–71.10.1038/ni1037

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123

  GuerinLRPrinsJRRobertsonSA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?Hum Reprod Update (2009) 15:517–35.10.1093/humupd/dmp004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 124

  SaitoS. Th17 cells and regulatory T cells: new light on pathophysiology of preeclampsia. Immunol Cell Biol (2010) 88:615–7.10.1038/icb.2010.68

  • CrossRef
  • Google Scholar

• 125

  SaitoSNakashimaAShimaTItoM. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol (2010) 63:601–10.10.1111/j.1600-0897.2010.00852.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126

  ClarkDAChaouatG. Regulatory T cells and reproduction: how do they do it?J Reprod Immunol (2012) 96:1–7.10.1016/j.jri.2012.07.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127

  Alijotas-ReigJLlurbaEGrisJM. Potentiating maternal immune tolerance in pregnancy: a new challenging role for regulatory T cells. Placenta (2014) 35:241–8.10.1016/j.placenta.2014.02.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128

  JiangTTChaturvediVErteltJMKinderJMClarkDRValentAMet alRegulatory T cells: new keys for further unlocking the enigma of fetal tolerance and pregnancy complications. J Immunol (2014) 192:4949–56.10.4049/jimmunol.1400498

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 129

  La RoccaCCarboneFLongobardiSMatareseG. The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus. Immunol Lett (2014) 162:41–8.10.1016/j.imlet.2014.06.013

  • CrossRef
  • Google Scholar

• 130

  ClarkDA. The importance of being a regulatory T cell in pregnancy. J Reprod Immunol (2016) 116:60–9.10.1016/j.jri.2016.04.288

  • CrossRef
  • Google Scholar

• 131

  HarmonACCorneliusDCAmaralLMFaulknerJLCunninghamMWJrWallaceKet alThe role of inflammation in the pathology of preeclampsia. Clin Sci (Lond) (2016) 130:409–19.10.1042/CS20150702

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132

  LaMarcaBCorneliusDCHarmonACAmaralLMCunninghamMWFaulknerJLet alIdentifying immune mechanisms mediating the hypertension during preeclampsia. Am J Physiol Regul Integr Comp Physiol (2016) 311:R1–9.10.1152/ajpregu.00052.2016

  • CrossRef
  • Google Scholar

• 133

  NancyPTaglianiETayCSAspPLevyDEErlebacherA. Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface. Science (2012) 336:1317–21.10.1126/science.1220030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 134

  WilliamsZ. Inducing tolerance to pregnancy. N Engl J Med (2012) 367:1159–61.10.1056/NEJMcibr1207279

  • CrossRef
  • Google Scholar

• 135

  SamsteinRMJosefowiczSZArveyATreutingPMRudenskyAY. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell (2012) 150:29–38.10.1016/j.cell.2012.05.031

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136

  SomersetDAZhengYKilbyMDSansomDMDraysonMT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology (2004) 112:38–43.10.1111/j.1365-2567.2004.01869.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137

  SchumacherAZenclussenAC. Effects of heme oxygenase-1 on innate and adaptive immune responses promoting pregnancy success and allograft tolerance. Front Pharmacol (2014) 5:288.10.3389/fphar.2014.00288

  • CrossRef
  • Google Scholar

• 138

  CarpHJASelmiCShoenfeldY. The autoimmune bases of infertility and pregnancy loss. J Autoimmun (2012) 38:J266–74.10.1016/j.jaut.2011.11.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 139

  MittrückerH-WKaufmannSHE. Mini-review: regulatory T cells and infection: suppression revisited. Eur J Immunol (2004) 34:306–12.10.1002/eji.200324578

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 140

  BelkaidY. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol (2007) 7:875–88.10.1038/nri2189

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141

  BelkaidYTarbellK. Regulatory T cells in the control of host-microorganism interactions. Annu Rev Immunol (2009) 27:551–89.10.1146/annurev.immunol.021908.132723

  • CrossRef
  • Google Scholar

• 142

  MaizelsRMSmithKA. Regulatory T cells in infection. Adv Immunol (2011) 112:73–136.10.1016/B978-0-12-387827-4.00003-6

  • CrossRef
  • Google Scholar

• 143

  SanchezAMYangY. The role of natural regulatory T cells in infection. Immunol Res (2011) 49:124–34.10.1007/s12026-010-8176-8

  • CrossRef
  • Google Scholar

• 144

  BerodLPutturFHuehnJSparwasserT. Tregs in infection and vaccinology: heroes or traitors?Microb Biotechnol (2012) 5:260–9.10.1111/j.1751-7915.2011.00299.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145

  WilliamsZZepfDLongtineJAnchanRBroadmanBMissmerSAet alForeign fetal cells persist in the maternal circulation. Fertil Steril (2009) 91:2593–5.10.1016/j.fertnstert.2008.02.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146

  HahnSRusterholzCHösliILapaireO. Cell-free nucleic acids as potential markers for preeclampsia. Placenta (2011) 32(Suppl):S17–20.10.1016/j.placenta.2010.06.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147

  ViscaELapaireOHosliIHahnS. Cell-free fetal nucleic acids as prenatal biomarkers. Expert Opin Med Diagn (2011) 5:151–60.10.1517/17530059.2011.554821

  • CrossRef
  • Google Scholar

• 148

  RobertsonSABromfieldJJTremellenKP. Seminal ‘priming’ for protection from pre-eclampsia-a unifying hypothesis. J Reprod Immunol (2003) 59:253–65.10.1016/S0165-0378(03)00052-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149

  GetzGS. Thematic review series: the immune system and atherogenesis. Bridging the innate and adaptive immune systems. J Lipid Res (2005) 46:619–22.10.1194/jlr.E500002-JLR200

  • CrossRef
  • Google Scholar

• 150

  SarmaJVWardPA. The complement system. Cell Tissue Res (2011) 343:227–35.10.1007/s00441-010-1034-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151

  KennedyMA. A brief review of the basics of immunology: the innate and adaptive response. Vet Clin North Am Small Anim Pract (2010) 40:369–79.10.1016/j.cvsm.2010.01.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 152

  WarringtonRWatsonWKimHLAntonettiFR. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol (2011) 7(Suppl 1):S1.10.1186/1710-1492-7-S1-S1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 153

  AbbasAKLichtmanAHPillaiS. Basic Immunology: Functions and Disorders of the Immune System. 8th ed. St Louis, MO: Elsevier (2012).

  • Google Scholar

• 154

  AbbasAKLichtmanAHPillaiS. Basic Immunology: Functions and Disorders of the Immune System. 5th ed. St Louis, MO: Elsevier (2016).

  • Google Scholar

• 155

  MurphyKWeaverC, editors. Janeway’s Immunobiology. New York: Garland Science (2016).

  • Google Scholar

• 156

  KellDBPretoriusE. On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. Integr Biol (2015) 7:1339–77.10.1039/C5IB00158G

  • CrossRef
  • Google Scholar

• 157

  LegutkiJBMageeDMStaffordPJohnstonSA. A general method for characterization of humoral immunity induced by a vaccine or infection. Vaccine (2010) 28:4529–37.10.1016/j.vaccine.2010.04.061

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158

  StaffordPHalperinRLegutkiJBMageeDMGalgianiJJohnstonSA. Physical characterization of the “immunosignaturing effect”. Mol Cell Proteomics (2012) 11:M111011593.10.1074/mcp.M111.011593

  • CrossRef
  • Google Scholar

• 159

  SykesKFLegutkiJBStaffordP. Immunosignaturing: a critical review. Trends Biotechnol (2013) 31:45–51.10.1016/j.tibtech.2012.10.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160

  KingAEKellyRWSallenaveJ-MBockingADChallisJRG. Innate immune defences in the human uterus during pregnancy. Placenta (2007) 28:1099–106.10.1016/j.placenta.2007.06.002

  • CrossRef
  • Google Scholar

• 161

  SchminkeyDLGroerM. Imitating a stress response: a new hypothesis about the innate immune system’s role in pregnancy. Med Hypotheses (2014) 82:721–9.10.1016/j.mehy.2014.03.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162

  ZhangJDunkCCroyABLyeSJ. To serve and to protect: the role of decidual innate immune cells on human pregnancy. Cell Tissue Res (2016) 363:249–65.10.1007/s00441-015-2315-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 163

  RedmanCW. Immunological aspects of pre-eclampsia. Baillieres Clin Obstet Gynaecol (1992) 6:601–15.10.1016/S0950-3552(05)80012-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164

  SaitoSShiozakiANakashimaASakaiMSasakiY. The role of the immune system in preeclampsia. Mol Aspects Med (2007) 28:192–209.10.1016/j.mam.2007.02.006

  • CrossRef
  • Google Scholar

• 165

  VisserNVan RijnBBRijkersGTFranxABruinseHW. Inflammatory changes in preeclampsia: current understanding of the maternal innate and adaptive immune response. Obstet Gynecol Surv (2007) 62:191–201.10.1097/01.ogx.0000256779.06275.c4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166

  BrewsterJAOrsiNMGopichandranNMcshanePEkboteUVWalkerJJ. Gestational effects on host inflammatory response in normal and pre-eclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol (2008) 140:21–6.10.1016/j.ejogrb.2007.12.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 167

  Laresgoiti-ServitjeE. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol (2013) 94:247–57.10.1189/jlb.1112603

  • CrossRef
  • Google Scholar

• 168

  Perez-SepulvedaATorresMJKhouryMIllanesSE. Innate immune system and preeclampsia. Front Immunol (2014) 5:244.10.3389/fimmu.2014.00244

  • CrossRef
  • Google Scholar

• 169

  StaffACJohnsenGMDechendRRedmanCWG. Preeclampsia and uteroplacental acute atherosis: immune and inflammatory factors. J Reprod Immunol (2014) 10(1–102):120–6.10.1016/j.jri.2013.09.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170

  RedmanCWGSargentILTaylorRN. Immunology of normal pregnancy and preeclampsia. 4th ed. Chesley’s Hypertensive Disorders in Pregnancy. (2015). p. 161–79.10.1016/B978-0-12-407866-6.00008-0

  • CrossRef
  • Google Scholar

• 171

  ParkerLCPrinceLRSabroeI. Translational mini-review series on toll-like receptors: networks regulated by toll-like receptors mediate innate and adaptive immunity. Clin Exp Immunol (2007) 147:199–207.10.1111/j.1365-2249.2006.03203.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172

  TrinchieriGSherA. Cooperation of toll-like receptor signals in innate immune defence. Nat Rev Immunol (2007) 7:179–90.10.1038/nri2038

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173

  NelsonDEIhekwabaAECElliottMGibneyCAForemanBENelsonGet alOscillations in NF-κB signalling control the dynamics of gene expression. Science (2004) 306:704–8.10.1126/science.1099962

  • CrossRef
  • Google Scholar

• 174

  AshallLHortonCANelsonDEPaszekPRyanSSillitoeKet alPulsatile stimulation determines timing and specificity of NFkappa-B-dependent transcription. Science (2009) 324:242–6.10.1126/science.1164860

  • CrossRef
  • Google Scholar

• 175

  MatzingerP. Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 12:991–1045.10.1146/annurev.iy.12.040194.005015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176

  AndersonCCMatzingerP. Danger: the view from the bottom of the cliff. Semin Immunol (2000) 12:231–8; discussion 257–344.10.1006/smim.2000.0236

  • CrossRef
  • Google Scholar

• 177

  MatzingerP. Essay 1: the danger model in its historical context. Scand J Immunol (2001) 54:4–9.10.1046/j.1365-3083.2001.00974.x

  • CrossRef
  • Google Scholar

• 178

  MatzingerP. The danger model: a renewed sense of self. Science (2002) 296:301–5.10.1126/science.1071059

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179

  MatzingerPKamalaT. Tissue-based class control: the other side of tolerance. Nat Rev Immunol (2011) 11:221–30.10.1038/nri2940

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180

  MatzingerP. The evolution of the danger theory. Expert Rev Clin Immunol (2012) 8:311–7.10.1586/eci.12.21

  • CrossRef
  • Google Scholar

• 181

  McCarthyCMKennyLC. Immunostimulatory role of mitochondrial DAMPs: alarming for pre-eclampsia?Am J Reprod Immunol (2016) 76:341–7.10.1111/aji.12526

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182

  BonneyEA. Preeclampsia: a view through the danger model. J Reprod Immunol (2007) 76:68–74.10.1016/j.jri.2007.03.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183

  SacksGPStudenaKSargentKRedmanCWG. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol (1998) 179:80–6.10.1016/S0002-9378(98)70254-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184

  RedmanCWGSacksGPSargentIL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol (1999) 180:499–506.10.1016/S0002-9378(99)70239-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 185

  KimYMRomeroROhSYKimCJKilburnBAArmantDRet alToll-like receptor 4: a potential link between “danger signals,” the innate immune system and preeclampsia?Am J Obstet Gynecol (2005) 193:921–7.10.1016/j.ajog.2005.06.053

  • CrossRef
  • Google Scholar

• 186

  WangCCYimKWPoonTCWChoyKWChuCYLuiWTet alInnate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. Clin Chem (2007) 53:42–52.10.1373/clinchem.2007.074401

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187

  YehCCChaoKCHuangSJ. Innate immunity, decidual cells, and preeclampsia. Reprod Sci (2013) 20:339–53.10.1177/1933719112450330

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188

  BoundsKRNewell-RogersMKMitchellBM. Four pathways involving innate immunity in the pathogenesis of preeclampsia. Front Cardiovasc Med (2015) 2:20.10.3389/fcvm.2015.00020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189

  TriggianesePPerriconeCChimentiMSDe CarolisCPerriconeR. Innate immune system at the maternal-fetal interface: mechanisms of disease and targets of therapy in pregnancy syndromes. Am J Reprod Immunol (2016) 76:245–57.10.1111/aji.12509

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190

  RedmanCWGSargentIL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response – a review. Placenta (2003) 24(Suppl A):S21–7.10.1053/plac.2002.0930

  • CrossRef
  • Google Scholar

• 191

  HubelCA. Dyslipidemia and pre-eclampsia. In: BelfortMALydallF, editors. Pre-Eclampsia-Aetiology and Clinical Practice. Cambridge: Cambridge University Press (2006). p. 164–82.

  • Google Scholar

• 192

  ShurinMRLuLKalinskiPStewart-AkersAMLotzeMT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol (1999) 21:339–59.10.1007/BF00812261

  • CrossRef
  • Google Scholar

• 193

  SaitoSSakaiM. Th1/Th2 balance in preeclampsia. J Reprod Immunol (2003) 59:161–73.10.1016/S0165-0378(03)00045-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 194

  ChaouatG. The Th1/Th2 paradigm: still important in pregnancy?Semin Immunopathol (2007) 29:95–113.10.1007/s00281-007-0069-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195

  ShortSMWolfnerMFLazzaroBP. Female Drosophila melanogaster suffer reduced defense against infection due to seminal fluid components. J Insect Physiol (2012) 58:1192–201.10.1016/j.jinsphys.2012.06.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196

  ShortSMLazzaroBP. Reproductive status alters transcriptomic response to infection in female Drosophila melanogaster. G3 (Bethesda) (2013) 3:827–40.10.1534/g3.112.005306

  • CrossRef
  • Google Scholar

• 197

  SchjenkenJERobertsonSA. Seminal fluid signalling in the female reproductive tract: implications for reproductive success and offspring health. Adv Exp Med Biol (2015) 868:127–58.10.1007/978-3-319-18881-2_6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198

  Pejcic-KarapetrovicBGurnaniKRussellMSFinlayBBSadSKrishnanL. Pregnancy impairs the innate immune resistance to Salmonella typhimurium leading to rapid fatal infection. J Immunol (2007) 179:6088–96.10.4049/jimmunol.179.9.6088

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199

  SappenfieldEJamiesonDJKourtisAP. Pregnancy and susceptibility to infectious diseases. Infect Dis Obstet Gynecol (2013) 2013:752852.10.1155/2013/752852

  • CrossRef
  • Google Scholar

• 200

  KourtisAPReadJSJamiesonDJ. Pregnancy and infection. N Engl J Med (2014) 370:2211–8.10.1056/NEJMra1213566

  • CrossRef
  • Google Scholar

• 201

  KrausTAEngelSMSperlingRSKellermanLLoYWallensteinSet alCharacterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J Clin Immunol (2012) 32:300–11.10.1007/s10875-011-9627-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 202

  PazosMSperlingRSMoranTMKrausTA. The influence of pregnancy on systemic immunity. Immunol Res (2012) 54:254–61.10.1007/s12026-012-8303-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 203

  LynchAMGibbsRSMurphyJRByersTNevilleMCGiclasPCet alComplement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol (2008) 199(354):e351–8.10.1016/j.ajog.2008.07.044

  • CrossRef
  • Google Scholar

• 204

  LynchAMMurphyJRByersTGibbsRSNevilleMCGiclasPCet alAlternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol (2008) 198:385.e381–9.10.1016/j.ajog.2007.10.793

  • CrossRef
  • Google Scholar

• 205

  LynchAMMurphyJRGibbsRSLevineRJGiclasPCSalmonJEet alThe interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG (2010) 117:456–62.10.1111/j.1471-0528.2009.02473.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 206

  SotoERomeroRRichaniKEspinozaJChaiworapongsaTNienJKet alPreeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med (2010) 23:646–57.10.3109/14767050903301009

  • CrossRef
  • Google Scholar

• 207

  GirardiGProhaszkaZBullaRTedescoFScherjonS. Complement activation in animal and human pregnancies as a model for immunological recognition. Mol Immunol (2011) 48:1621–30.10.1016/j.molimm.2011.04.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 208

  LynchAMGibbsRSMurphyJRGiclasPCSalmonJEHolersVM. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obs Gynecol (2011) 117:75–83.10.1097/AOG.0b013e3181fc3afa

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 209

  QingXRedechaPBBurmeisterMATomlinsonSD’agatiVDDavissonRLet alTargeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int (2011) 79:331–9.10.1038/ki.2010.393

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 210

  BuurmaACohenDVeraarKSchonkerenDClaasFHBruijnJAet alPreeclampsia is characterized by placental complement dysregulation. Hypertension (2012) 60:1332–7.10.1161/HYPERTENSIONAHA.112.194324

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 211

  WangWIraniRAZhangYRaminSMBlackwellSCTaoLet alAutoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension (2012) 60:712–21.10.1161/HYPERTENSIONAHA.112.191817

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 212

  DennyKJCoulthardLGFinnellRHCallawayLKTaylorSMWoodruffTM. Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. J Reprod Immunol (2013) 97:211–6.10.1016/j.jri.2012.11.006

  • CrossRef
  • Google Scholar

• 213

  DennyKJWoodruffTMTaylorSMCallawayLK. Complement in pregnancy: a delicate balance. Am J Reprod Immunol (2013) 69:3–11.10.1111/aji.12000

  • CrossRef
  • Google Scholar

• 214

  HoffmanMCRumerKKKramerALynchAMWinnVD. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol (2014) 71:55–60.10.1111/aji.12162

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 215

  BanadakoppaMVidaeffACYallampalliURaminSMBelfortMAYallampalliC. Complement split products in amniotic fluid in pregnancies subsequently developing early-onset preeclampsia. Dis Markers (2015) 2015:263109.10.1155/2015/263109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 216

  HeYXuBSongDYuFChenQZhaoM. Expression of the complement system’s activation factors in plasma of patients with early/late-onset severe pre-eclampsia. Am J Reprod Immunol (2016) 76:205–11.10.1111/aji.12541

  • CrossRef
  • Google Scholar

• 217

  WuWYangHFengYZhangPLiSWangXet alPolymorphisms in complement genes and risk of preeclampsia in Taiyuan, China. Inflamm Res (2016) 65:837–45.10.1007/s00011-016-0968-4

  • CrossRef
  • Google Scholar

• 218

  VelickovicIDalloulMWongKABakareOSchweisFGaralaMet alComplement factor B activation in patients with preeclampsia. J Reprod Immunol (2015) 109:94–100.10.1016/j.jri.2014.12.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 219

  SotoERomeroRVaisbuchEErezOMazaki-ToviSKusanovicJPet alFragment Bb: evidence for activation of the alternative pathway of the complement system in pregnant women with acute pyelonephritis. J Matern Fetal Neonatal Med (2010) 23:1085–90.10.3109/14767051003649870

  • CrossRef
  • Google Scholar

• 220

  HeYXuBSongDYuFChenQZhaoM. Correlations between complement system’s activation factors and anti-angiogenesis factors in plasma of patients with early/late-onset severe preeclampsia. Hypertens Pregnancy (2016) 35:499–509.10.1080/10641955.2016.1190845

  • CrossRef
  • Google Scholar

• 221

  LynchAMEckelRHMurphyJRGibbsRSWestNAGiclasPCet alPrepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. Am J Obstet Gynecol (2012) 206:428.e421–28.10.1016/j.ajog.2012.02.035

  • CrossRef
  • Google Scholar

• 222

  HalmosARigoJJrSzijartoJFustGProhaszkaZMolvarecA. Circulating ficolin-2 and ficolin-3 in normal pregnancy and pre-eclampsia. Clin Exp Immunol (2012) 169:49–56.10.1111/j.1365-2249.2012.04590.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 223

  HaegerMBengtsonAKarlssonKHeidemanM. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid. Obstet Gynecol (1989) 73:551–6.

  • Pubmed Abstract
  • Google Scholar

• 224

  HaegerMUnanderMBengtssonA. Complement activation in relation to development of preeclampsia. Obstet Gynecol (1991) 78:46–9.

  • Pubmed Abstract
  • Google Scholar

• 225

  YeYKongYZhangY. Complement split products C3a/C5a and receptors: are they regulated by circulating angiotensin II type 1 receptor autoantibody in severe preeclampsia?Gynecol Obstet Invest (2016) 81:28–33.10.1159/000440651

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 226

  KestlerováAFeyereislJFrisováVMěchurováAŠůlaKZimaTet alImmunological and biochemical markers in preeclampsia. J Reprod Immunol (2012) 96:90–4.10.1016/j.jri.2012.10.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 227

  BurwickRMFichorovaRNDawoodHYYamamotoHSFeinbergBB. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension (2013) 62:1040–5.10.1161/HYPERTENSIONAHA.113.01420

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 228

  MerleNSChurchSEFremeaux-BacchiVRoumeninaLT. Complement system part I – molecular mechanisms of activation and regulation. Front Immunol (2015) 6:262.10.3389/fimmu.2015.00262

  • CrossRef
  • Google Scholar

• 229

  MerleNSNoeRHalbwachs-MecarelliLFremeaux-BacchiVRoumeninaLT. Complement system part II: role in immunity. Front Immunol (2015) 6:257.10.3389/fimmu.2015.00257

  • CrossRef
  • Google Scholar

• 230

  PonnurajKXuYMaconKMooreDVolanakisJENarayanaSVL. Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. Mol Cell (2004) 14:17–28.10.1016/S1097-2765(04)00160-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 231

  RooijakkersSHMWuJRuykenMVan DomselaarRPlankenKLTzekouAet alStructural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol (2009) 10:721–7.10.1038/ni.1756

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 232

  VaisbuchERomeroRErezOMazaki-ToviSKusanovicJPSotoEet alFragment Bb in amniotic fluid: evidence for complement activation by the alternative pathway in women with intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med (2009) 22:905–16.10.1080/14767050902994663

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 233

  LiQLiYXStahlGLThurmanJMHeYTongHH. Essential role of factor B of the alternative complement pathway in complement activation and opsonophagocytosis during acute pneumococcal otitis media in mice. Infect Immun (2011) 79:2578–85.10.1128/IAI.00168-11

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 234

  SinghJAhmedAGirardiG. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension (2011) 58:716–24.10.1161/HYPERTENSIONAHA.111.175919

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 235

  MartiJJHerrmannU. Immunogestosis: a new etiologic concept of “essential” EPH gestosis, with special consideration of the primigravid patient; preliminary report of a clinical study. Am J Obstet Gynecol (1977) 128:489–93.10.1016/0002-9378(77)90030-8

  • CrossRef
  • Google Scholar

• 236

  DekkerGSukcharoenN. Etiology of preeclampsia: an update. J Med Assoc Thai (2004) 87(Suppl 3):S96–103.

  • Pubmed Abstract
  • Google Scholar

• 237

  JohanssonMBromfieldJJJasperMJRobertsonSA. Semen activates the female immune response during early pregnancy in mice. Immunology (2004) 112:290–300.10.1111/j.1365-2567.2004.01876.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 238

  RobertsonSAGuerinLRBromfieldJJBransonKMAhlströmACCareAS. Seminal fluid drives expansion of the CD4+CD25+ T regulatory cell pool and induces tolerance to paternal alloantigens in mice. Biol Reprod (2009) 80:1036–45.10.1095/biolreprod.108.074658

  • CrossRef
  • Google Scholar

• 239

  LarsenMHBzorekMPassMBLarsenLGNielsenMWSvendsenSGet alHuman leukocyte antigen-G in the male reproductive system and in seminal plasma. Mol Hum Reprod (2011) 17:727–38.10.1093/molehr/gar052

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 240

  HviidTVF. Human leukocyte antigen-G within the male reproductive system: implications for reproduction. Adv Exp Med Biol (2015) 868:171–90.10.1007/978-3-319-18881-2_8

  • CrossRef
  • Google Scholar

• 241

  AndersonDJPolitchJA. Role of seminal plasma in human female reproductive failure: immunomodulation, inflammation, and infections. Adv Exp Med Biol (2015) 868:159–69.10.1007/978-3-319-18881-2_7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 242

  MilardiDGrandeGVincenzoniFCastagnolaMMaranaR. Proteomics of human seminal plasma: identification of biomarker candidates for fertility and infertility and the evolution of technology. Mol Reprod Dev (2013) 80:350–7.10.1002/mrd.22178

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 243

  DrabovichAPSaraonPJarviKDiamandisEP. Seminal plasma as a diagnostic fluid for male reproductive system disorders. Nat Rev Urol (2014) 11:278–88.10.1038/nrurol.2014.74

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 244

  RobertsonSA. Seminal plasma and male factor signalling in the female reproductive tract. Cell Tissue Res (2005) 322:43–52.10.1007/s00441-005-1127-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 245

  RobertsonSA. Seminal fluid signaling in the female reproductive tract: lessons from rodents and pigs. J Anim Sci (2007) 85:E36–44.10.2527/jas.2006-578

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 246

  BromfieldJJ. Seminal fluid and reproduction: much more than previously thought. J Assist Reprod Genet (2014) 31:627–36.10.1007/s10815-014-0243-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 247

  BromfieldJJSchjenkenJEChinPYCareASJasperMJRobertsonSA. Maternal tract factors contribute to paternal seminal fluid impact on metabolic phenotype in offspring. Proc Natl Acad Sci U S A (2014) 111:2200–5.10.1073/pnas.1305609111

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 248

  RobertsonSASharkeyDJ. Seminal fluid and fertility in women. Fertil Steril (2016) 106:511–9.10.1016/j.fertnstert.2016.07.1101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 249

  García-MontalvoIAMayoral AndradeGPerez-Campos MayoralLPina CansecoSMartinez CruzRMartinez-CruzMet alMolecules in seminal plasma related to platelets in preeclampsia. Med Hypotheses (2016) 93:27–9.10.1016/j.mehy.2016.05.009

  • CrossRef
  • Google Scholar

• 250

  RobertsonSAGuerinLRMoldenhauerLMHayballJD. Activating T regulatory cells for tolerance in early pregnancy – the contribution of seminal fluid. J Reprod Immunol (2009) 83:109–16.10.1016/j.jri.2009.08.003

  • CrossRef
  • Google Scholar

• 251

  RobertsonSAPrinsJRSharkeyDJMoldenhauerLM. Seminal fluid and the generation of regulatory T cells for embryo implantation. Am J Reprod Immunol (2013) 69:315–30.10.1111/aji.12107

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 252

  ShimaTInadaKNakashimaAUshijimaAItoMYoshinoOet alPaternal antigen-specific proliferating regulatory T cells are increased in uterine-draining lymph nodes just before implantation and in pregnant uterus just after implantation by seminal plasma-priming in allogeneic mouse pregnancy. J Reprod Immunol (2015) 108:72–82.10.1016/j.jri.2015.02.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 253

  SaitoSShimaTNakashimaAInadaKYoshinoO. Role of paternal antigen-specific treg cells in successful implantation. Am J Reprod Immunol (2016) 75:310–6.10.1111/aji.12469

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 254

  OkazakiTAkiyoshiTKanMMoriMTeshimaHShimadaM. Artificial insemination with seminal plasma improves the reproductive performance of frozen-thawed boar epididymal spermatozoa. J Androl (2012) 33:990–8.10.2164/jandrol.111.015115

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 255

  BromfieldJJ. A role for seminal plasma in modulating pregnancy outcomes in domestic species. Reproduction (2016) 152:R223–32.10.1530/REP-16-0313

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 256

  DuckittKHarringtonD. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Br Med J (2005) 330:565–7.10.1136/bmj.38380.674340.E0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 257

  BartschEMedcalfKEParkALRayJGHigh Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ (2016) 353:i1753.10.1136/bmj.i1753

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 258

  BdolahYElchalalUNatanson-YaronSYechiamHBdolah-AbramTGreenfieldCet alRelationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. Hypertens Pregnancy (2014) 33:250–9.10.3109/10641955.2013.858745

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 259

  TandbergAKlungsoyrKRomundstadLBSkjaervenR. Pre-eclampsia and assisted reproductive technologies: consequences of advanced maternal age, interbirth intervals, new partner and smoking habits. BJOG (2015) 122:915–22.10.1111/1471-0528.13051

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 260

  RobillardPYHulseyTCPerianinJJankyEMiriEHPapiernikE. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet (1994) 344:973–5.10.1016/S0140-6736(94)91638-1

  • CrossRef
  • Google Scholar

• 261

  EinarssonJISangi-HaghpeykarHGardnerMO. Sperm exposure and development of preeclampsia. Am J Obstet Gynecol (2003) 188:1241–3.10.1067/mob.2003.401

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 262

  SaftlasAFLevineRJKlebanoffMAMartzKLEwellMGMorrisCDet alAbortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol (2003) 157:1108–14.10.1093/aje/kwg101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 263

  Klonoff-CohenHSSavitzDACefaloRCMccannMF. An epidemiologic study of contraception and preeclampsia. JAMA (1989) 262:3143–7.10.1001/jama.262.22.3143

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 264

  Hernández-ValenciaMSaldaña QuezadaLAlvarez MuñozMValdez MartínezE. Barrier family planning methods as risk factor which predisposes to preeclampsia. Ginecol Obstet Mex (2000) 68:333–8.

  • Google Scholar

• 265

  Letur-KöenirschHPeignéMOhlJCédrinID’argentEMSchefflerFet alPregnancies issued from egg donation are associated to a higher risk of hypertensive pathologies then control ART pregnancies. Results of a large comparative cohort study. Hum Reprod (2014) 29:68–9.

  • Google Scholar

• 266

  LeturHPeignéMOhlJCédrin-DurnerinIMathieu-D’argentESchefflerFet alHypertensive pathologies and egg donation pregnancies: results of a large comparative cohort study. Fertil Steril (2016) 106:284–90.10.1016/j.fertnstert.2016.03.031

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 267

  TarlatziTBImbertRAlvaro MercadalBDemeestereIVenetisCAEnglertYet alDoes oocyte donation compared with autologous oocyte IVF pregnancies have a higher risk of preeclampsia?Reprod Biomed Online (2017) 34:11–8.10.1016/j.rbmo.2016.10.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 268

  GiannubiloSRLandiBCiavattiniA. Preeclampsia: what could happen in a subsequent pregnancy?Obstet Gynecol Surv (2014) 69:747–62.10.1097/OGX.0000000000000126

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 269

  KoelmanCACoumansABCNijmanHWDoxiadisIINDekkerGAClaasFHJ. Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid?J Reprod Immunol (2000) 46:155–66.10.1016/S0165-0378(99)00062-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 270

  MartinRD. A Biological Function for Oral Sex? Psychology Today (2016). Available from: https://www.psychologytoday.com/blog/how-we-do-it/201602/biological-function-oral-sex

  • Google Scholar

• 271

  SaftlasAFOlsonDRFranksALAtrashHKPokrasR. Epidemiology of preeclampsia and eclampsia in the United-States, 1979–1986. Am J Obstet Gynecol (1990) 163:460–5.10.1016/0002-9378(90)91176-D

  • CrossRef
  • Google Scholar

• 272

  ZhangJZeislerJHatchMCBerkowitzG. Epidemiology of pregnancy-induced hypertension. Epidemiol Rev (1997) 19:218–32.10.1093/oxfordjournals.epirev.a017954

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 273

  LamminpääRVehvilainen-JulkunenKGisslerMHeinonenS. Preeclampsia complicated by advanced maternal age: a registry-based study on primiparous women in Finland 1997–2008. BMC Pregnancy Childbirth (2012) 12:47.10.1186/1471-2393-12-47

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 274

  AnanthCVKeyesKMWapnerRJ. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ (2013) 347:f6564.10.1136/bmj.f6564

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 275

  CarolanM. Maternal age >= 45 years and maternal and perinatal outcomes: a review of the evidence. Midwifery (2013) 29:479–89.10.1016/j.midw.2012.04.001

  • CrossRef
  • Google Scholar

• 276

  NeedJABellBMeffinEJonesWR. Pre-eclampsia in pregnancies from donor inseminations. J Reprod Immunol (1983) 5:329–38.10.1016/0165-0378(83)90242-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 277

  SmithGNWalkerMTessierJLMillarKG. Increased incidence of preeclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility. Am J Obs Gynecol (1997) 177:455–8.10.1016/S0002-9378(97)70215-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 278

  HoyJVennAHallidayJKovacsGWaalwykK. Perinatal and obstetric outcomes of donor insemination using cryopreserved semen in Victoria, Australia. Hum Reprod (1999) 14:1760–4.10.1093/humrep/14.7.1760

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 279

  DavisJAGallupGG. Preeclampsia and other pregnancy complications as an adaptive response to unfamiliar semen. In: PlatekSMShackelfordTK, editors. Female Infidelity and Paternal Uncertainty: Evolutionary Perspectives on Male Anti-Cuckoldry Tactics. Cambridge: CUPpip (2006). p. 191–204.

  • Google Scholar

• 280

  GleicherNBolerLRJrNorusisMDel GranadoA. Hypertensive diseases of pregnancy and parity. Am J Obstet Gynecol (1986) 154:1044–9.10.1016/0002-9378(86)90747-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 281

  RobertsJMRedmanCW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet (1993) 341:1447–51.10.1016/0140-6736(93)90889-O

  • CrossRef
  • Google Scholar

• 282

  SibaiBDekkerGKupfermincM. Pre-eclampsia. Lancet (2005) 365:785–99.10.1016/S0140-6736(05)71003-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 283

  LuoZCAnNXuHRLaranteAAudibertFFraserWD. The effects and mechanisms of primiparity on the risk of pre-eclampsia: a systematic review. Paediatr Perinat Epidemiol (2007) 21(Suppl 1):36–45.10.1111/j.1365-3016.2007.00836.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 284

  Hernández-DíazSTohSCnattingiusS. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ (2009) 338:b2255.10.1136/bmj.b2255

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 285

  WuCSNohrEABechBHVestergaardMCatovJMOlsenJ. Health of children born to mothers who had preeclampsia: a population-based cohort study. Am J Obstet Gynecol (2009) 201:269.e261–269.e210.10.1016/j.ajog.2009.06.060

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 286

  WikströmAKGunnarsdóttirJCnattingiusS. The paternal role in pre-eclampsia and giving birth to a small for gestational age infant; a population-based cohort study. BMJ Open (2012) 2:e001178.10.1136/bmjopen-2012-001178

  • CrossRef
  • Google Scholar

• 287

  EnglishFAKennyLCMccarthyFP. Risk factors and effective management of preeclampsia. Integr Blood Press Control (2015) 8:7–12.10.2147/IBPC.S50641

  • CrossRef
  • Google Scholar

• 288

  Rich-EdwardsJWNessRBRobertsJM. Epidemiology of pregnancy-related hypertension. 4th ed. Chesley’s Hypertensive Disorders in Pregnancy. (2015). p. 37–55.10.1016/B978-0-12-407866-6.00003-1

  • CrossRef
  • Google Scholar

• 289

  DildyGAIIIBelfortMASmulianJC. Preeclampsia recurrence and prevention. Semin Perinatol (2007) 31:135–41.10.1053/j.semperi.2007.03.005

  • CrossRef
  • Google Scholar

• 290

  Conde-AgudeloABelizánJM. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. BJOG (2000) 107:75–83.10.1111/j.1471-0528.2000.tb11582.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 291

  FeeneyJGScottJS. Pre-eclampsia and changed paternity. Eur J Obstet Gynecol Reprod Biol (1980) 11:35–8.10.1016/0028-2243(80)90051-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 292

  IkedifeD. Eclampsia in multipara. Br Med J (1980) 280:985–6.10.1136/bmj.280.6219.985-a

  • CrossRef
  • Google Scholar

• 293

  ChngPK. Occurrence of pre-eclampsia in pregnancies to three husbands. Case report. Br J Obstet Gynaecol (1982) 89:862–3.10.1111/j.1471-0528.1982.tb05042.x

  • CrossRef
  • Google Scholar

• 294

  RobillardPYHulseyTCAlexanderGRKeenanADe CaunesFPapiernikE. Paternity patterns and risk of preeclampsia in the last pregnancy in multiparae. J Reprod Immunol (1993) 24:1–12.10.1016/0165-0378(93)90032-D

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 295

  TrupinLSSimonLPEskenaziB. Change in paternity: a risk factor for preeclampsia in multiparas. Epidemiology (1996) 7:240–4.10.1097/00001648-199605000-00004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 296

  RobillardPYDekkerGAHulseyTC. Revisiting the epidemiological standard of preeclampsia: primigravidity or primipaternity?Eur J Obstet Gynecol Reprod Biol (1999) 84:37–41.10.1016/S0301-2115(98)00250-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 297

  TubbergenPLachmeijerAMAAlthuisiusSMVlakMEJVan GeijnHPDekkerGA. Change in paternity: a risk factor for preeclampsia in multiparous women?J Reprod Immunol (1999) 45:81–8.10.1016/S0165-0378(99)00040-6

  • CrossRef
  • Google Scholar

• 298

  LiDKWiS. Changing paternity and the risk of preeclampsia/eclampsia in the subsequent pregnancy. Am J Epidemiol (2000) 151:57–62.10.1093/oxfordjournals.aje.a010122

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 299

  DekkerGARobillardPY. Preeclampsia: a couple’s disease with maternal and fetal manifestations. Curr Pharm Des (2005) 11:699–710.10.2174/1381612053381828

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 300

  DeenMERuurdaLGWangJDekkerGA. Risk factors for preeclampsia in multiparous women: primipaternity versus the birth interval hypothesis. J Matern Fetal Neonatal Med (2006) 19:79–84.10.1080/14767050500361653

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 301

  DekkerGRobillardPYRobertsC. The etiology of preeclampsia: the role of the father. J Reprod Immunol (2011) 89:126–32.10.1016/j.jri.2010.12.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 302

  NagayamaSOhkuchiAUsuiRMatsubaraSSuzukiM. The role of the father in the occurrence of preeclampsia. Med J Obs Gynecol (2014) 2:1029–32.

  • Google Scholar

• 303

  RobillardPYDekkerGChaouatGSciosciaMIacobelliSHulseyTC. Historical evolution of ideas on eclampsia/preeclampsia: a proposed optimistic view of preeclampsia. J Reprod Immunol (2017) 123:72–7.10.1016/j.jri.2017.09.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 304

  TrogstadLISEskildAMagnusPSamuelsenSONesheimBI. Changing paternity and time since last pregnancy; the impact on pre-eclampsia risk. A study of 547 238 women with and without previous pre-eclampsia. Int J Epidemiol (2001) 30:1317–22.10.1093/ije/30.6.1317

  • CrossRef
  • Google Scholar

• 305

  LieRTRasmussenSBrunborgHGjessingHKLie-NielsenEIrgensLM. Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ (1998) 316:1343–7.10.1136/bmj.316.7141.1343

  • CrossRef
  • Google Scholar

• 306

  TricheEWHarlandKKFieldEHRubensteinLMSaftlasAF. Maternal-fetal HLA sharing and preeclampsia: variation in effects by seminal fluid exposure in a case-control study of nulliparous women in Iowa. J Reprod Immunol (2014) 101-102:111–9.10.1016/j.jri.2013.06.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 307

  SaftlasAFRubensteinLPraterKHarlandKKFieldETricheEW. Cumulative exposure to paternal seminal fluid prior to conception and subsequent risk of preeclampsia. J Reprod Immunol (2014) 101-102:104–10.10.1016/j.jri.2013.07.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 308

  KhoEMMccowanLMNorthRARobertsCTChanEBlackMAet alDuration of sexual relationship and its effect on preeclampsia and small for gestational age perinatal outcome. J Reprod Immunol (2009) 82:66–73.10.1016/j.jri.2009.04.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 309

  BellamyLCasasJPHingoraniADWilliamsDJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ (2007) 335:974.10.1136/bmj.39335.385301.BE

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 310

  SalhaOSharmaVDadaTNugentDRutherfordAJTomlinsonAJet alThe influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Hum Reprod (1999) 14:2268–73.10.1093/humrep/14.9.2268

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 311

  GelbayaTA. Short and long-term risks to women who conceive through in vitro fertilization. Hum Fertil (Camb) (2010) 13:19–27.10.3109/14647270903437923

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 312

  van der HoornMLLashleyEEBianchiDWClaasFHSchonkerenCMScherjonSA. Clinical and immunologic aspects of egg donation pregnancies: a systematic review. Hum Reprod Update (2010) 16:704–12.10.1093/humupd/dmq017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 313

  MasoudianPNasrADe NanassyJFung-Kee-FungKBainbridgeSAEl DemellawyD. Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis. Am J Obstet Gynecol (2016) 214:328–39.10.1016/j.ajog.2015.11.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 314

  PorrecoRPHeyborneKD. Immunogenesis of preeclampsia: lessons from donor gametes. J Matern Fetal Neonatal Med (2017):1–7.10.1080/14767058.2017.1309385

  • CrossRef
  • Google Scholar

• 315

  DudeAMYehJSMuasherSJ. Donor oocytes are associated with preterm birth when compared to fresh autologous in vitro fertilization cycles in singleton pregnancies. Fertil Steril (2016) 106:660–5.10.1016/j.fertnstert.2016.05.029

  • CrossRef
  • Google Scholar

• 316

  StoopDBaumgartenMHaentjensPPolyzosNPDe VosMVerheyenGet alObstetric outcome in donor oocyte pregnancies: a matched-pair analysis. Reprod Biol Endocrinol (2012) 10:42.10.1186/1477-7827-10-42

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 317

  LevronYDviriMSegolIYerushalmiGMHourvitzAOrvietoRet alThe ’immunologic theory’ of preeclampsia revisited: a lesson from donor oocyte gestations. Am J Obstet Gynecol (2014) 211(383):e381–5.10.1016/j.ajog.2014.03.044

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 318

  FoxNSRomanASSaltzmanDHHourizadehTHastingsJRebarberA. Risk factors for preeclampsia in twin pregnancies. Am J Perinatol (2014) 31:163–6.10.1055/s-0033-1343775

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 319

  ThomopoulosCSalamalekisGKintisKAndrianopoulouIMichalopoulouHSkalisGet alRisk of hypertensive disorders in pregnancy following assisted reproductive technology: overview and meta-analysis. J Clin Hypertens (Greenwich) (2017) 19:173–83.10.1111/jch.12945

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 320

  BlázquezAGarcíaDRodríguezAVassenaRFiguerasFVernaeveV. Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis. J Assist Reprod Genet (2016) 33:855–63.10.1007/s10815-016-0701-9

  • CrossRef
  • Google Scholar

• 321

  KlatskyPCDelaneySSCaugheyABTranNDSchattmanGLRosenwaksZ. The role of embryonic origin in preeclampsia: a comparison of autologous in vitro fertilization and ovum donor pregnancies. Obstet Gynecol (2010) 116:1387–92.10.1097/AOG.0b013e3181fb8e59

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 322

  KroonBHartRJWongBMFordEYazdaniA. Antibiotics prior to embryo transfer in ART. Cochrane Database Syst Rev (2012) (3):CD008995.10.1002/14651858.CD008995.pub2

  • CrossRef
  • Google Scholar

• 323

  SibaiBMMercerBSarinogluC. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol (1991) 165:1408–12.10.1016/S0002-9378(12)90773-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 324

  van RijnBBHoeksLBBotsMLFranxABruinseHW. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol (2006) 195:723–8.10.1016/j.ajog.2006.06.044

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 325

  MostelloDKallogjeriDTungsiripatRLeetT. Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births. Am J Obstet Gynecol (2008) 199(55):e51–7.10.1016/j.ajog.2007.11.058

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 326

  RasmussenSIrgensLMAlbrechtsenSDalakerK. Predicting preeclampsia in the second pregnancy from low birth weight in the first pregnancy. Obstet Gynecol (2000) 96:696–700.10.1097/00006250-200011000-00010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 327

  ThevaranjanNPuchtaASchulzCNaidooASzamosiJCVerschoorCPet alAge-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction. Cell Host Microbe (2017) 21(455–466):e454.10.1016/j.chom.2017.03.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 328

  AstinMScottJRWorleyRJ. Pre-eclampsia/eclampsia: a fatal father factor. Lancet (1981) 2:533.10.1016/S0140-6736(81)90925-9

  • CrossRef
  • Google Scholar

• 329

  WangJXKnottnerusAMSchuitGNormanRJChanADekkerGA. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet (2002) 359:673–4.10.1016/S0140-6736(02)07804-2

  • CrossRef
  • Google Scholar

• 330

  Le RayCScherierSAnselemOMarszalekATsatsarisVCabrolDet alAssociation between oocyte donation and maternal and perinatal outcomes in women aged 43 years or older. Hum Reprod (2012) 27:896–901.10.1093/humrep/der469

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 331

  González-ComadranMAvilaJUTascónASJimenézRSolàIBrassescoMet alThe impact of donor insemination on the risk of preeclampsia: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol (2014) 182:160–6.10.1016/j.ejogrb.2014.09.022

  • CrossRef
  • Google Scholar

• 332

  ThomopoulosCTsioufisCMichalopoulouHMakrisTPapademetriouVStefanadisC. Assisted reproductive technology and pregnancy-related hypertensive complications: a systematic review. J Hum Hypertens (2013) 27:148–57.10.1038/jhh.2012.13

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 333

  BaudDGreubG. Intracellular bacteria and adverse pregnancy outcomes. Clin Microbiol Infect (2011) 17:1312–22.10.1111/j.1469-0691.2011.03604.x

  • CrossRef
  • Google Scholar

• 334

  ViglianiMBBakardjievAI. Intracellular organisms as placental invaders. Fetal Matern Med Rev (2014) 25:332–8.10.1017/S0965539515000066

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 335

  ParnellLABriggsCMCaoBDelannoy-BrunoOSchriefferAEMysorekarIU. Microbial communities in placentas from term normal pregnancy exhibit spatially variable profiles. Sci Rep (2017) 7:11200.10.1038/s41598-017-11514-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 336

  WuHEstillMSShershebnevASuvorovAKrawetzSAWhitcombBWet alPreconception urinary phthalate concentrations and sperm DNA methylation profiles among men undergoing IVF treatment: a cross-sectional study. Hum Reprod (2017) 32(11):2159–69.10.1093/humrep/dex283

  • CrossRef
  • Google Scholar

• 337

  VerstraelenHSenokAC. Vaginal lactobacilli, probiotics, and IVF. Reprod Biomed Online (2005) 11:674–5.10.1016/S1472-6483(10)61683-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 338

  SirotaIZarekSMSegarsJH. Potential influence of the microbiome on infertility and assisted reproductive technology. Semin Reprod Med (2014) 32:35–42.10.1055/s-0033-1361821

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 339

  ReidGBrigidiPBurtonJPContractorNDuncanSFargierEet alMicrobes central to human reproduction. Am J Reprod Immunol (2015) 73:1–11.10.1111/aji.12319

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 340

  XieFHuYMageeLAMoneyDMPatrickDMBrunhamRMet alChlamydia pneumoniae infection in preeclampsia. Hypertens Pregnancy (2010) 29:468–77.10.3109/10641950903242642

  • CrossRef
  • Google Scholar

• 341

  HeineRPNessRBRobertsJM. Seroprevalence of antibodies to Chlamydia pneumoniae in women with preeclampsia. Obstet Gynecol (2003) 101:221–6.10.1016/S0029-7844(02)02591-7

  • CrossRef
  • Google Scholar

• 342

  El-ShourbagyMAAEl-RefaieTASayedKKAWahbaKAHEl-DinASSFathyMM. Impact of seroconversion and antichlamydial treatment on the rate of pre-eclampsia among Egyptian primigravidae. Int J Gynaecol Obstet (2011) 113:137–40.10.1016/j.ijgo.2010.11.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 343

  MosbahANabielY. Helicobacter pylori, Chlamydiae pneumoniae and trachomatis as probable etiological agents of preeclampsia. J Matern Fetal Neonat Med (2016) 29:1607–12.10.3109/14767058.2015.1056146

  • CrossRef
  • Google Scholar

• 344

  GomezLMParryS. Trophoblast infection with Chlamydia pneumoniae and adverse pregnancy outcomes associated with placental dysfunction. Am J Obstet Gynecol (2009) 200(526):e521–7.10.1016/j.ajog.2009.03.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 345

  HaggertyCLKlebanoffMAPanumIUldumSABassDCOlsenJet alPrenatal Chlamydia trachomatis infection increases the risk of preeclampsia. Pregnancy Hypertens (2013) 3:151–4.10.1016/j.preghy.2013.03.002

  • CrossRef
  • Google Scholar

• 346

  HaggertyCLPanumIUldumSABassDCOlsenJDarvilleTet alChlamydia trachomatis infection may increase the risk of preeclampsia. Pregnancy Hypertens (2013) 3:28–33.10.1016/j.preghy.2012.09.002

  • CrossRef
  • Google Scholar

• 347

  XieFHuYMageeLAMoneyDMPatrickDMKrajdenMet alAn association between cytomegalovirus infection and pre-eclampsia: a case-control study and data synthesis. Acta Obstet Gynecol Scand (2010) 89:1162–7.10.3109/00016349.2010.499449

  • CrossRef
  • Google Scholar

• 348

  XieFVon DadelszenPNadeauJ. CMV infection, TLR-2 and -4 expression, and cytokine profiles in early-onset preeclampsia with HELLP syndrome. Am J Reprod Immunol (2014) 71:379–86.10.1111/aji.12199

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 349

  PonzettoACardaropoliSPiccoliERolfoAGenneroLKanducDet alPre-eclampsia is associated with Helicobacter pylori seropositivity in Italy. J Hypertens (2006) 24:2445–9.10.1097/HJH.0b013e3280109e8c

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 350

  PanarelliMSattarN. Pre-eclampsia associated with Helicobacter pylori seropositivity. J Hypertens (2006) 24:2353–4.10.1097/HJH.0b013e3280113638

  • CrossRef
  • Google Scholar

• 351

  TersigniCFranceschiFTodrosTCardaropoliSScambiaGDi SimoneN. Insights into the role of Helicobacter pylori infection in preeclampsia: from the bench to the bedside. Front Immunol (2014) 5:484.10.3389/fimmu.2014.00484

  • CrossRef
  • Google Scholar

• 352

  ÜstünYEngin-ÜstünYOzkaplanEOtluBSait TekerekoğluM. Association of Helicobacter pylori infection with systemic inflammation in preeclampsia. J Matern Fetal Neonatal Med (2010) 23:311–4.10.3109/14767050903121456

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 353

  AksoyHOzkanAAktasFBorekciB. Helicobacter pylori seropositivity and its relationship with serum malondialdehyde and lipid profile in preeclampsia. J Clin Lab Anal (2009) 23:219–22.10.1002/jcla.20330

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 354

  CardaropoliSRolfoATodrosT. Helicobacter pylori and pregnancy-related disorders. World J Gastroenterol (2014) 20:654–64.10.3748/wjg.v20.i3.654

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 355

  PuglieseABeltramoTTodrosTCardaropoliSPonzettoA. Interleukin-18 and gestosis: correlation with Helicobacter pylori seropositivity. Cell Biochem Funct (2008) 26:817–9.10.1002/cbf.1503

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 356

  CardaropoliSGiuffridaDPiazzeseATodrosT. Helicobacter pylori seropositivity and pregnancy-related diseases: a prospective cohort study. J Reprod Immunol (2015) 109:41–7.10.1016/j.jri.2015.02.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 357

  CardaropoliSRolfoAPiazzeseAPonzettoATodrosT. Helicobacter pylori’s virulence and infection persistence define pre-eclampsia complicated by fetal growth retardation. World J Gastroenterol (2011) 17:5156–65.10.3748/wjg.v17.i47.5156

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 358

  den HollanderWJSchalekamp-TimmermansSHolsterILJaddoeVWHofmanAMollHAet alHelicobacter pylori colonization and pregnancies complicated by preeclampsia, spontaneous prematurity, and small for gestational age birth. Helicobacter (2017) 22:e12364.10.1111/hel.12364

  • CrossRef
  • Google Scholar

• 359

  SansoneMSarnoLSacconeGBerghellaVMaruottiGMMigliucciAet alRisk of preeclampsia in human immunodeficiency virus-infected pregnant women. Obstet Gynecol (2016) 127:1027–32.10.1097/AOG.0000000000001424

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 360

  McDonnoldMDunnHHesterAPachecoLDHankinsGDSaadeGRet alHigh risk human papillomavirus at entry to prenatal care and risk of preeclampsia. Am J Obstet Gynecol (2014) 210(138):e131–5.10.1016/j.ajog.2013.09.040

  • CrossRef
  • Google Scholar

• 361

  HillJADevoeLDBryansCIJr. Frequency of asymptomatic bacteriuria in preeclampsia. Obstet Gynecol (1986) 67:529–32.

  • Pubmed Abstract
  • Google Scholar

• 362

  HsuCDWitterFR. Urogenital infection in preeclampsia. Int J Gynaecol Obstet (1995) 49:271–5.10.1016/0020-7292(95)02373-K

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 363

  MittendorfRLainKYWilliamsMAWalkerCK. Preeclampsia. A nested, case-control study of risk factors and their interactions. J Reprod Med (1996) 41:491–6.

  • Google Scholar

• 364

  EasterSRCantonwineDEZeraCALimKHParrySIMcelrathTF. Urinary tract infection during pregnancy, angiogenic factor profiles, and risk of preeclampsia. Am J Obs Gynecol (2016) 214:387.e1–7.10.1016/j.ajog.2015.09.101

  • CrossRef
  • Google Scholar

• 365

  Mazor-DrayELevyASchlaefferFSheinerE. Maternal urinary tract infection: is it independently associated with adverse pregnancy outcome?J Matern Fetal Neonatal Med (2009) 22:124–8.10.1080/14767050802488246

  • CrossRef
  • Google Scholar

• 366

  MinassianCThomasSLWilliamsDJCampbellOSmeethL. Acute maternal infection and risk of pre-eclampsia: a population-based case-control study. PLoS One (2013) 8:e73047.10.1371/journal.pone.0073047

  • CrossRef
  • Google Scholar

• 367

  RezavandNVeisiFZanganeMAminiRAlmasiA. Association between asymptomatic bacteriuria and pre-eclampsia. Glob J Health Sci (2016) 8:235–9.10.5539/gjhs.v8n7p235

  • CrossRef
  • Google Scholar

• 368

  KarmonASheinerE. The relationship between urinary tract infection during pregnancy and preeclampsia: causal, confounded or spurious?Arch Gynecol Obstet (2008) 277:479–81.10.1007/s00404-008-0643-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 369

  VillarJCarroliGWojdylaDAbalosEGiordanoDBa’aqeelHet alPreeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?Am J Obstet Gynecol (2006) 194:921–31.10.1016/j.ajog.2005.10.813

  • CrossRef
  • Google Scholar

• 370

  BánhidyFÁcsNPuhóEHCzeizelAE. Pregnancy complications and birth outcomes of pregnant women with urinary tract infections and related drug treatments. Scand J Infect Dis (2007) 39:390–7.10.1080/00365540601087566

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 371

  IdeMPapapanouPN. Epidemiology of association between maternal periodontal disease and adverse pregnancy outcomes – systematic review. J Periodontol (2013) 84:S181–94.10.1902/jop.2013.134009

  • CrossRef
  • Google Scholar

• 372

  DunlopALMulleJGFerrantiEPEdwardsSDunnABCorwinEJ. Maternal microbiome and pregnancy outcomes that impact infant health: a review. Adv Neonatal Care (2015) 15:377–85.10.1097/ANC.0000000000000218

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 373

  DoronMWMakhloufRAKatzVLLawsonEEStilesAD. Increased incidence of sepsis at birth in neutropenic infants of mothers with preeclampsia. J Pediatr (1994) 125:452–8.10.1016/S0022-3476(05)83294-9

  • CrossRef
  • Google Scholar

• 374

  WeiB-JChenY-JYuLWuB. Periodontal disease and risk of preeclampsia: a meta-analysis of observational studies. PLoS One (2013) 8:e70901.10.1371/journal.pone.0070901

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 375

  ShettyMShettyPKRameshAThomasBPrabhuSRaoA. Periodontal disease in pregnancy is a risk factor for preeclampsia. Acta Obstet Gynecol Scand (2010) 89:718–21.10.3109/00016341003623738

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 376

  KumarABasraMBegumNRaniVPrasadSLambaAKet alAssociation of maternal periodontal health with adverse pregnancy outcome. J Obstet Gynaecol Res (2013) 39:40–5.10.1111/j.1447-0756.2012.01957.x

  • CrossRef
  • Google Scholar

• 377

  AmarasekaraRJayasekaraRWSenanayakeHDissanayakeVHW. Microbiome of the placenta in pre-eclampsia supports the role of bacteria in the multifactorial cause of pre-eclampsia. J Obstet Gynaecol Res (2015) 41:662–9.10.1111/jog.12619

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 378

  HlimiT. Association of anemia, pre-eclampsia and eclampsia with seasonality: a realist systematic review. Health Place (2015) 31:180–92.10.1016/j.healthplace.2014.12.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 379

  BrabinBJJohnsonPM. Placental malaria and pre-eclampsia through the looking glass backwards?J Reprod Immunol (2005) 65:1–15.10.1016/j.jri.2004.09.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 380

  AnyaSE. Seasonal variation in the risk and causes of maternal death in the Gambia: malaria appears to be an important factor. Am J Trop Med Hyg (2004) 70:510–3.

  • Pubmed Abstract
  • Google Scholar

• 381

  SarteletHRogierCMilko-SarteletIAngelGMichelG. Malaria associated pre-eclampsia in Senegal. Lancet (1996) 347:1121.10.1016/S0140-6736(96)90321-9

  • CrossRef
  • Google Scholar

• 382

  SilasiMCardenasIKwonJYRacicotKAldoPMorG. Viral infections during pregnancy. Am J Reprod Immunol (2015) 73:199–213.10.1111/aji.12355

  • CrossRef
  • Google Scholar

• 383

  RacicotKMorG. Risks associated with viral infections during pregnancy. J Clin Invest (2017) 127:1591–9.10.1172/JCI87490

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 384

  KeckCGerber-SchaferCCladAWilhelmCBreckwoldtM. Seminal tract infections: impact on male fertility and treatment options. Hum Reprod Update (1998) 4:891–903.10.1093/humupd/4.6.891

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 385

  OchsendorfFR. Sexually transmitted infections: impact on male fertility. Andrologia (2008) 40:72–5.10.1111/j.1439-0272.2007.00825.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 386

  SwidsinskiADörffelYLoening-BauckeVMendlingWVerstraelenHDieterleSet alDesquamated epithelial cells covered with a polymicrobial biofilm typical for bacterial vaginosis are present in randomly selected cryopreserved donor semen. FEMS Immunol Med Microbiol (2010) 59:399–404.10.1111/j.1574-695X.2010.00688.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 387

  GalloMFWarnerLKingCCSobelJDKleinRSCu-UvinSet alAssociation between semen exposure and incident bacterial vaginosis. Infect Dis Obstet Gynecol (2011) 2011:842652.10.1155/2011/842652

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 388

  PaavonenJEggert-KruseW. Chlamydia trachomatis: impact on human reproduction. Hum Reprod Update (1999) 5:433–47.10.1093/humupd/5.5.433

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 389

  RandoOJSimmonsRA. I’m eating for two: parental dietary effects on offspring metabolism. Cell (2015) 161:93–105.10.1016/j.cell.2015.02.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 390

  Dehghan MarvastLAflatoonianATalebiARGhasemzadehJPaceyAA. Semen inflammatory markers and Chlamydia trachomatis infection in male partners of infertile couples. Andrologia (2016) 48:729–36.10.1111/and.12501

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 391

  López-HurtadoMVelazco-FernándezMPedraza-SánchezMJEFlores-SalazarVRVillagrana ZesatiRGuerra-InfanteFM. Molecular detection of Chlamydia trachomatis and semen quality of sexual partners of infertile women. Andrologia (2017) e12812.10.1111/and.12812

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 392

  DelwartELMullinsJIGuptaPLearnGHJrHolodniyMKatzensteinDet alHuman immunodeficiency virus type 1 populations in blood and semen. J Virol (1998) 72:617–23.

  • Pubmed Abstract
  • Google Scholar

• 393

  WinterAJTaylorSWorkmanJWhiteDRossJDSwanAVet alAsymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect (1999) 75:261–3.10.1136/sti.75.4.261

  • CrossRef
  • Google Scholar

• 394

  PilcherCDJoakiGHoffmanIFMartinsonFEMapanjeCStewartPWet alAmplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 21:1723–30.10.1097/QAD.0b013e3281532c82

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 395

  HladikFMcElrathMJ. Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 8:447–57.10.1038/nri2302

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 396

  LiuCMOsborneBJWHungateBAShahabiKHuibnerSLesterRet alThe semen microbiome and its relationship with local immunology and viral load in HIV infection. PloS Path (2014) 10:e1004262.10.1371/journal.ppat.1004262

  • CrossRef
  • Google Scholar

• 397

  RametseCLOlivierAJMassonLBarnabasSMckinnonLRNgcapuSet alRole of semen in altering the balance between inflammation and tolerance in the female genital tract: does it contribute to HIV risk?Viral Immunol (2014) 27:200–6.10.1089/vim.2013.0136

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 398

  GruberFLipozencicJKehlerT. History of venereal diseases from antiquity to the renaissance. Acta Dermatovenerol Croat (2015) 23:1–11.

  • Pubmed Abstract
  • Google Scholar

• 399

  ShermanJKRosenfeldJ. Importance of frozen-stored human semen in the spread of gonorrhea. Fertil Steril (1975) 26:1043–7.10.1016/S0015-0282(16)41468-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 400

  ZhengH. Analysis of the antigen-antibody specificity in the semen of patients with Neisseria gonorrhoeae. Chin Med Sci J (1997) 12:47–9.

  • Pubmed Abstract
  • Google Scholar

• 401

  IsbeySFAlcornTMDavisRHHaizlipJLeonePACohenMS. Characterisation of Neisseria gonorrhoeae in semen during urethral infection in men. Genitourin Med (1997) 73:378–82.

  • Pubmed Abstract
  • Google Scholar

• 402

  KertsézG. A new method of inoculation to prove the infectivity of the semen in latent syphilis. Br J Dermatol Syph (1931) 43:588–92.10.1111/j.1365-2133.1931.tb09454.x

  • CrossRef
  • Google Scholar

• 403

  AdeobaA. Interpretation of positive serological tests for syphilis in pregnancy. Br J Vener Dis (1967) 43:249–58.

  • Google Scholar

• 404

  BurchellANAllenVGGardnerSLMoravanVTanDHSGrewalRet alHigh incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada. BMC Infect Dis (2015) 15:356.10.1186/s12879-015-1098-2

  • CrossRef
  • Google Scholar

• 405

  PunjabiUWynsCMahmoudAVernelenKChinaBVerheyenG. Fifteen years of Belgian experience with external quality assessment of semen analysis. Andrology (2016) 4:1084–93.10.1111/andr.12230

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 406

  TrompoukisCKalaitzisCGiannakopoulosSSofikitisNTouloupidisS. Semen and the diagnosis of infertility in Aristotle. Andrologia (2007) 39:33–7.10.1111/j.1439-0272.2006.00757.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 407

  JungwirthADiemerTDohleGRGiwercmanAKopaZKrauszCet alGuidelines on Male Infertility. Eur Assoc Urol (2015).

  • Google Scholar

• 408

  MändarRPunabMBorovkovaNLappEKiikerRKorrovitsPet alComplementary seminovaginal microbiome in couples. Res Microbiol (2015) 166:440–7.10.1016/j.resmic.2015.03.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 409

  FowlkesDMDooherGBO’LearyWM. Evidence by scanning electron microscopy for an association between spermatozoa and T-mycoplasmas in men of infertile marriage. Fertil Steril (1975) 26:1203–11.10.1016/S0015-0282(16)41536-0

  • CrossRef
  • Google Scholar

• 410

  FowlkesDMMacleodJO’LearyWM. T-mycoplasmas and human infertility: correlation of infection with alterations in seminal parameters. Fertil Steril (1975) 26:1212–8.10.1016/S0015-0282(16)41537-2

  • CrossRef
  • Google Scholar

• 411

  RehewyMSHafezESThomasABrownWJ. Aerobic and anaerobic bacterial flora in semen from fertile and infertile groups of men. Arch Androl (1979) 2:263–8.10.3109/01485017908987323

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 412

  SwensonCETothATothCWolfgruberLO’LearyWM. Asymptomatic bacteriospermia in infertile men. Andrologia (1980) 12:7–11.10.1111/j.1439-0272.1980.tb00567.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 413

  MograNDhruvaAKothariLK. Non-specific seminal tract infection and male infertility: a bacteriological study. J Postgrad Med (1981) 27:99–104.

  • Pubmed Abstract
  • Google Scholar

• 414

  BusoloFZanchettaRLanzoneECusinatoR. Microbial flora in semen of asymptomatic infertile men. Andrologia (1984) 16:269–75.10.1111/j.1439-0272.1984.tb00282.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 415

  NaessensAFoulonWDebruckerPDevroeyPLauwersS. Recovery of microorganisms in semen and relationship to semen evaluation. Fertil Steril (1986) 45:101–5.10.1016/S0015-0282(16)49105-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 416

  Eggert-KruseWRohrGStrockWPohlSSchwalbachBRunnebaumB. Anaerobes in ejaculates of subfertile men. Hum Reprod Update (1995) 1:462–78.10.1093/humupd/1.5.462

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 417

  MerinoGCarranza-LiraSMurrietaSRodriguezLCuevasEMoranC. Bacterial infection and semen characteristics in infertile men. Arch Androl (1995) 35:43–7.10.3109/01485019508987852

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 418

  JarviKLacroixJMJainADumitruIHeritzDMittelmanMW. Polymerase chain reaction-based detection of bacteria in semen. Fertil Steril (1996) 66:463–7.10.1016/S0015-0282(16)58520-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 419

  LacroixJMJarviKBatraSDHeritzDMMittelmanMW. PCR-based technique for the detection of bacteria in semen and urine. J Microbiol Meth (1996) 26:61–71.10.1016/0167-7012(96)00844-5

  • CrossRef
  • Google Scholar

• 420

  ByrnRAKiesslingAA. Analysis of human immunodeficiency virus in semen: indications of a genetically distinct virus reservoir. J Reprod Immunol (1998) 41:161–76.10.1016/S0165-0378(98)00056-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 421

  CardosoEMSantoianniJEDe PaulisANAndradaJAPredariSCArreggerAL. Improvement of semen quality in infected asymptomatic infertile male after bacteriological cure. Medicina (B Aires) (1998) 58:160–4.

  • Pubmed Abstract
  • Google Scholar

• 422

  KöhnFMErdmannIOedaTEl MullaKFSchieferHGSchillWB. Influence of urogenital infections on sperm functions. Andrologia (1998) 30(Suppl 1):73–80.10.1111/j.1439-0272.1998.tb02829.x

  • CrossRef
  • Google Scholar

• 423

  OnemuSOIbehIN. Studies on the significance of positive bacterial semen cultures in male fertility in Nigeria. Int J Fertil Womens Med (2001) 46:210–4.

  • Pubmed Abstract
  • Google Scholar

• 424

  EsfandiariNSalehRAAbdoosMRouzrokhANazemianZ. Positive bacterial culture of semen from infertile men with asymptomatic leukocytospermia. Int J Fertil Womens Med (2002) 47:265–70.

  • Pubmed Abstract
  • Google Scholar

• 425

  SanockaDFraczekMJedrzejczakPSzumala-KakolAKurpiszM. Male genital tract infection: an influence of leukocytes and bacteria on semen. J Reprod Immunol (2004) 62:111–24.10.1016/j.jri.2003.10.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 426

  Sanocka-MaciejewskaDCiupińskaMKurpiszM. Bacterial infection and semen quality. J Reprod Immunol (2005) 67:51–6.10.1016/j.jri.2005.06.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 427

  GdouraRKchaouWChaariCZnazenAKeskesLRebaiTet alUreaplasma urealyticum, Ureaplasma parvum, Mycoplasma hominis and Mycoplasma genitalium infections and semen quality of infertile men. BMC Infect Dis (2007) 7:129.10.1186/1471-2334-7-129

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 428

  IkechukwuOGeorgeESabinusAEFlorenceO. Role of enriched media in bacterial isolation from semen and effect of microbial infection on semen quality: a study on 100 infertile men. Pak J Med Sci (2007) 23:885–8.

  • Google Scholar

• 429

  KiesslingAADesmaraisBMYinHZLoverdeJEyreRC. Detection and identification of bacterial DNA in semen. Fertil Steril (2008) 90:1744–56.10.1016/j.fertnstert.2007.08.083

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 430

  PellatiDMylonakisIBertoloniGFioreCAndrisaniAAmbrosiniGet alGenital tract infections and infertility. Eur J Obstet Gynecol Reprod Biol (2008) 140:3–11.10.1016/j.ejogrb.2008.03.009

  • CrossRef
  • Google Scholar

• 431

  MorettiECapitaniSFiguraNPammolliAFedericoMGGianneriniVet alThe presence of bacteria species in semen and sperm quality. J Assist Reprod Genet (2009) 26:47–56.10.1007/s10815-008-9283-5

  • CrossRef
  • Google Scholar

• 432

  KokabAAkhondiMMSadeghiMRModarresiMHAarabiMJenningsRet alRaised inflammatory markers in semen from men with asymptomatic chlamydial infection. J Androl (2010) 31:114–20.10.2164/jandrol.109.008300

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 433

  OnemuSOOgbimiAOOphoriEA. Microbiology and semen indices of sexually-active males in Benin City, Edo State, Nigeria. J Bacteriol Res (2010) 2:55–9.

  • Google Scholar

• 434

  UnekeCJUgwuoruCD. Antibiotic susceptibility of urogenital microbial profile of infertile men in South-eastern Nigeria. Andrologia (2010) 42:268–73.10.1111/j.1439-0272.2009.00988.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 435

  De FrancescoMANegriniRRavizzolaGGalliPMancaN. Bacterial species present in the lower male genital tract: a five-year retrospective study. Eur J Contracept Reprod Health Care (2011) 16:47–53.10.3109/13625187.2010.533219

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 436

  HamadaAAgarwalASharmaRFrenchDBRaghebASabaneghESJr. Empirical treatment of low-level leukocytospermia with doxycycline in male infertility patients. Urology (2011) 78:1320–5.10.1016/j.urology.2011.08.062

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 437

  IsaiahINNcheBTNwaguIGNnannaII. Current studies on bacterospermia the leading cause of male infertility: a protégé and potential threat towards mans extinction. N Am J Med Sci (2011) 3:562–4.10.4297/najms.2011.3559

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 438

  La VigneraSVicariECondorelliRAD’agataRCalogeroAE. Male accessory gland infection and sperm parameters (review). Int J Androl (2011) 34:e330–47.10.1111/j.1365-2605.2011.01200.x

  • CrossRef
  • Google Scholar

• 439

  MomohARMIdonijeBONwokeEOOsifoUCOkhaiOOmoroguiwaAet alPathogenic bacteria-a probable cause of primary infertility among couples in Ekpoma. J Microbiol Biotechnol Res (2011) 1:66–71.

  • Google Scholar

• 440

  KaurSPrabhaV. Infertility as a consequence of spermagglutinating Staphylococcus aureus colonization in genital tract of female mice. PLoS One (2012) 7:e52325.10.1371/journal.pone.0052325

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 441

  RuszAPilatzAWagenlehnerFLinnTDiemerTSchuppeHCet alInfluence of urogenital infections and inflammation on semen quality and male fertility. World J Urol (2012) 30:23–30.10.1007/s00345-011-0726-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 442

  SalmeriMValentiDLa VigneraSBellancaSMorelloAToscanoMAet alPrevalence of Ureaplasma urealyticum and Mycoplasma hominis infection in unselected infertile men. J Chemother (2012) 24:81–6.10.1179/1120009X12Z.00000000021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 443

  NabiAKhaliliMAHalvaeiIGhasemzadehJZareE. Seminal bacterial contaminations: probable factor in unexplained recurrent pregnancy loss. Iran J Reprod Med (2013) 11:925–32.

  • Pubmed Abstract
  • Google Scholar

• 444

  SlehaRBoštíkováVSalavecMMosioPKusákováEKuklaRet alBacterial infection as a cause of infertility in humans(paper in Czech). Epidemiol Mikrobiol Imunol (2013) 62:26–32.

  • Google Scholar

• 445

  La VigneraSCondorelliRAVicariESalmeriMMorgiaGFavillaVet alMicrobiological investigation in male infertility: a practical overview. J Med Microbiol (2014) 63:1–14.10.1099/jmm.0.062968-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 446

  WengSLChiuCMLinFMHuangWCLiangCYangTet alBacterial communities in semen from men of infertile couples: metagenomic sequencing reveals relationships of seminal microbiota to semen quality. PLoS One (2014) 9:e110152.10.1371/journal.pone.0110152

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 447

  FraczekMKurpiszM. Mechanisms of the harmful effects of bacterial semen infection on ejaculated human spermatozoa: potential inflammatory markers in semen. Folia Histochem Cytobiol (2015) 53:201–17.10.5603/fhc.a2015.0019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 448

  VanderHPrabhaV. Evaluation of fertility outcome as a consequence of intravaginal inoculation with sperm-impairing micro-organisms in a mouse model. J Med Microbiol (2015) 64:344–7.10.1099/jmm.0.000036

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 449

  FraczekMHryhorowiczMGillKZarzyckaMGaczarzewiczDJedrzejczakPet alThe effect of bacteriospermia and leukocytospermia on conventional and nonconventional semen parameters in healthy young normozoospermic males. J Reprod Immunol (2016) 118:18–27.10.1016/j.jri.2016.08.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 450

  RuggeriMCannasSCubedduMMolicottiPPirasGLDessoleSet alBacterial agents as a cause of infertility in humans. New Microbiol (2016) 39:206–9.

  • Pubmed Abstract
  • Google Scholar

• 451

  ShiadehMNNiyyatiMFallahiSRostamiA. Human parasitic protozoan infection to infertility: a systematic review. Parasitol Res (2016) 115:469–77.10.1007/s00436-015-4827-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 452

  VicariLOCastiglioneRSalemiMVicariBOMazzarinoMCVicariE. Effect of levofloxacin treatment on semen hyperviscosity in chronic bacterial prostatitis patients. Andrologia (2016) 48:380–8.10.1111/and.12456

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 453

  AhmadiMHMirsalehianASadighi GilaniMABahadorATalebiM. Asymptomatic infection with Mycoplasma hominis negatively affects semen parameters and leads to male infertility as confirmed by improved semen parameters after antibiotic treatment. Urology (2017) 100:97–102.10.1016/j.urology.2016.11.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 454

  KjaergaardNKristensenBHansenESFarholtSSchønheyderHCUldbjergNet alMicrobiology of semen specimens from males attending a fertility clinic. APMIS (1997) 105:566–70.10.1111/j.1699-0463.1997.tb05054.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 455

  HillierSLRabeLKMullerCHZarutskiePKuzanFBStencheverMA. Relationship of bacteriologic characteristics to semen indices in men attending an infertility clinic. Obstet Gynecol (1990) 75:800–4.

  • Pubmed Abstract
  • Google Scholar

• 456

  DieterleS. Urogenital infections in reproductive medicine. Andrologia (2008) 40:117–9.10.1111/j.1439-0272.2008.00833.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 457

  VilvanathanSKandasamyBJayachandranALSathiyanarayananSTanjore SingaraveluVKrishnamurthyVet alBacteriospermia and its impact on basic semen parameters among infertile men. Interdiscip Perspect Infect Dis (2016) 2016:2614692.10.1155/2016/2614692

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 458

  LiversedgeNHJenkinsJMKeaySDMclaughlinEAAl-SufyanHMaileLAet alAntibiotic treatment based on seminal cultures from asymptomatic male partners in in-vitro fertilization is unnecessary and may be detrimental. Hum Reprod (1996) 11:1227–31.10.1093/oxfordjournals.humrep.a019361

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 459

  BhandariPRishiPPrabhaV. Positive effect of probiotic Lactobacillus plantarum in reversing the LPS induced infertility in mouse model. J Med Microbiol (2016) 65:345–50.10.1099/jmm.0.000230

  • CrossRef
  • Google Scholar

• 460

  HouDZhouXZhongXSettlesMLHerringJWangLet alMicrobiota of the seminal fluid from healthy and infertile men. Fertil Steril (2013) 100:1261–9.10.1016/j.fertnstert.2013.07.1991

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 461

  JavurekABSpollenWGAliAMMJohnsonSALubahnDBBivensNJet alDiscovery of a novel seminal fluid microbiome and influence of estrogen receptor alpha genetic status. Sci Rep (2016) 6.10.1038/srep23027

  • CrossRef
  • Google Scholar

• 462

  CraigLBPeckJDXuJSankaranarayananKWarinnerCHansenKRet alCharacterizing the semen microbiome and associations with semen parameters: the Chasm study. Fertil Steril (2015) 104:E66.10.1016/j.fertnstert.2015.07.202

  • CrossRef
  • Google Scholar

• 463

  DeenGFKnustBBroutetNSesayFRFormentyPRossCet alEbola RNA persistence in semen of ebola virus disease survivors – preliminary report. N Engl J Med (2015).10.1056/NEJMoa1511410

  • CrossRef
  • Google Scholar

• 464

  SokaMJChoiMJBallerAWhiteSRogersEPurpuraLJet alPrevention of sexual transmission of ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of ebola virus RNA results and behavioural data. Lancet Glob Health (2016) 4:e736–43.10.1016/S2214-109X(16)30175-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 465

  ThorsonAFormentyPLofthouseCBroutetN. Systematic review of the literature on viral persistence and sexual transmission from recovered ebola survivors: evidence and recommendations. BMJ Open (2016) 6:e008859.10.1136/bmjopen-2015-008859

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 466

  SissokoDDuraffourSKerberRKolieJSBeavoguiAHCamaraAMet alPersistence and clearance of ebola virus RNA from seminal fluid of ebola virus disease survivors: a longitudinal analysis and modelling study. Lancet Glob Health (2017) 5:e80–8.10.1016/S2214-109X(16)30243-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 467

  KlattNRCheuRBirseKZevinASPernerMNoël-RomasLet alVaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science (2017) 356:938–45.10.1126/science.aai9383

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 468

  MaWLiSMaSJiaLZhangFZhangYet alZika virus causes testis damage and leads to male infertility in mice. Cell (2016) 167:1511–24.e1510.10.1016/j.cell.2016.11.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 469

  BaudDMussoDVougaMAlvesMPVulliemozN. Zika virus: a new threat to human reproduction. Am J Reprod Immunol (2017) 77:e12614.10.1111/aji.12614

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 470

  HamerDHWilsonMEJeanJChenLH. Epidemiology, prevention, and potential future treatments of sexually transmitted zika virus infection. Curr Infect Dis Rep (2017) 19:16.10.1007/s11908-017-0571-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 471

  OhriMPrabhaV. Isolation of a sperm-agglutinating factor from Staphylococcus aureus isolated from a woman with unexplained infertility. Fertil Steril (2005) 84:1539–41.10.1016/j.fertnstert.2005.05.030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 472

  DiemerTHuwePLudwigMHauckEWWeidnerW. Urogenital infection and sperm motility. Andrologia (2003) 35:283–7.10.1111/j.1439-0272.2003.tb00858.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 473

  PrabhaVSandhuRKaurSKaurKSarwalAMavuduruRSet alMechanism of sperm immobilization by Escherichia coli. Adv Urol (2010) 2010:240268.10.1155/2010/240268

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 474

  FraczekMWilandEPiaseckaMBoksaMGaczarzewiczDSzumala-KakolAet alFertilizing potential of ejaculated human spermatozoa during in vitro semen bacterial infection. Fertil Steril (2014) 102(711–719):e711.10.1016/j.fertnstert.2014.06.002

  • CrossRef
  • Google Scholar

• 475

  KaurKPrabhaV. Spermagglutinating Escherichia coli and its role in infertility: in vivo study. Microb Pathog (2014) 6(9–70):33–8.10.1016/j.micpath.2014.03.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 476

  PretoriusEMbotweSBesterJRobinsonCJKellDB. Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. J R Soc Interface (2016) 123:20160539.10.1098/rsif.2016.0539

  • CrossRef
  • Google Scholar

• 477

  KellDBPretoriusE. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progr Biophys Mol Biol (2017) 123:16–41.10.1016/j.pbiomolbio.2016.08.006

  • CrossRef
  • Google Scholar

• 478

  PretoriusEPageMJHendricksLNkosiNBBensonSRKellDB. Both Lipopolysaccharide and Lipoteichoic Acids Potently Induce Anomalous Fibrin Amyloid Formation: Assessment with Novel Amytracker™ Stains. bioRxiv preprint. bioRxiv, 143867 (2017).10.1101/143867

  • CrossRef
  • Google Scholar

• 479

  GuptaSPrabhaV. Human sperm interaction with Staphylococcus aureus: a molecular approach. J Pathog (2012) 2012:816536.10.1155/2012/816536

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 480

  EnwuruCAIwalokunBEnwuruVNEzechiOOluwadunA. The effect of presence of facultative bacteria species on semen and sperm quality of men seeking fertility care. Afr J Urol (2016) 22:213–22.10.1016/j.afju.2016.03.010

  • CrossRef
  • Google Scholar

• 481

  AnwayMDCuppASUzumcuMSkinnerMK. Epigenetic transgenerational actions of endocrine disruptors and mate fertility. Science (2005) 308:1466–9.10.1126/science.1108190

  • CrossRef
  • Google Scholar

• 482

  FenechM. Micronuclei and their association with sperm abnormalities, infertility, pregnancy loss, pre-eclampsia and intra-uterine growth restriction in humans. Mutagenesis (2011) 26:63–7.10.1093/mutage/geq084

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 483

  PandianZBhattacharyaSTempletonA. Review of unexplained infertility and obstetric outcome: a 10 year review. Hum Reprod (2001) 16:2593–7.10.1093/humrep/16.12.2593

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 484

  TrogstadLMagnusPMoffettAStoltenbergC. The effect of recurrent miscarriage and infertility on the risk of pre-eclampsia. BJOG (2009) 116:108–13.10.1111/j.1471-0528.2008.01978.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 485

  BassoOBairdDD. Infertility and preterm delivery, birthweight, and Caesarean section: a study within the Danish National Birth Cohort. Hum Reprod (2003) 18:2478–84.10.1093/humrep/deg444

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 486

  BassoOWeinbergCRBairdDDWilcoxAJOlsenJ. Subfecundity as a correlate of preeclampsia: a study within the Danish National Birth Cohort. Am J Epidemiol (2003) 157:195–202.10.1093/aje/kwf194

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 487

  SohrabvandFJafariMShariatMHaghollahiFLotfiM. Frequency and epidemiologic aspects of male infertility. Acta Med Iran (2015) 53:231–5.

  • Pubmed Abstract
  • Google Scholar

• 488

  DobsonPDKellDB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?Nat Rev Drug Disc (2008) 7:205–20.10.1038/nrd2438

  • CrossRef
  • Google Scholar

• 489

  KellDBDobsonPDBilslandEOliverSG. The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Disc Today (2013) 18:218–39.10.1016/j.drudis.2012.11.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 490

  KellDBOliverSG. How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol (2014) 5:231.10.3389/fphar.2014.00231

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 491

  PajovicBRadojevicNVukovicMStjepcevicA. Semen analysis before and after antibiotic treatment of asymptomatic Chlamydia- and Ureaplasma-related pyospermia. Andrologia (2013) 45:266–71.10.1111/and.12004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 492

  SchoorRA. Prostatitis and male infertility: evidence and links. Curr Urol Rep (2002) 3:324–9.10.1007/s11934-002-0058-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 493

  EveraertKMahmoudADepuydtCMaeyaertMComhaireF. Chronic prostatitis and male accessory gland infection – is there an impact on male infertility (diagnosis and therapy)?Andrologia (2003) 35:325–30.10.1111/j.1439-0272.2003.tb00867.x

  • CrossRef
  • Google Scholar

• 494

  La VigneraSCondorelliRVicariED’agataRCalogeroAE. High frequency of sexual dysfunction in patients with male accessory gland infections. Andrologia (2012) 44(Suppl 1):438–46.10.1111/j.1439-0272.2011.01202.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 495

  AlshahraniSMcgillJAgarwalA. Prostatitis and male infertility. J Reprod Immunol (2013) 100:30–6.10.1016/j.jri.2013.05.004

  • CrossRef
  • Google Scholar

• 496

  La VigneraSVicariECondorelliRAFranchinaCScaliaGMorgiaGet alPrevalence of human papilloma virus infection in patients with male accessory gland infection. Reprod Biomed Online (2015) 30:385–91.10.1016/j.rbmo.2014.12.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 497

  EstemalikJDemkoCBissadaNFJoshiNBodnerDShankarEet alSimultaneous detection of oral pathogens in subgingival plaque and prostatic fluid of men with periodontal and prostatic diseases. J Periodontol (2017) 88:823–29.10.1902/jop.2017.160477

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 498

  HedgerMP. Toll-like receptors and signalling in spermatogenesis and testicular responses to inflammation – a perspective. J Reprod Immunol (2011) 88:130–41.10.1016/j.jri.2011.01.010

  • CrossRef
  • Google Scholar

• 499

  BhushanSSchuppeHCFijakMMeinhardtA. Testicular infection: microorganisms, clinical implications and host-pathogen interaction. J Reprod Immunol (2009) 83:164–7.10.1016/j.jri.2009.07.007

  • CrossRef
  • Google Scholar

• 500

  BhushanSSchuppeHCTchatalbachevSFijakMWeidnerWChakrabortyTet alTesticular innate immune defense against bacteria. Mol Cell Endocrinol (2009) 306:37–44.10.1016/j.mce.2008.10.017

  • CrossRef
  • Google Scholar

• 501

  ChenBYuLWangJLiCZhaoKZhangH. Involvement of prokineticin 2 and prokineticin receptor 1 in lipopolysaccharide-induced testitis in rats. Inflammation (2016) 39:534–42.10.1007/s10753-015-0277-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 502

  LipskyBA. Prostatitis and urinary tract infection in men: what’s new; what’s true?Am J Med (1999) 106:327–34.10.1016/S0002-9343(99)00017-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 503

  LipskyBAByrenIHoeyCT. Treatment of bacterial prostatitis. Clin Infect Dis (2010) 50:1641–52.10.1086/652861

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 504

  VicariECalogeroAECondorelliRAVicariLOLa VigneraS. Male accessory gland infection frequency in infertile patients with chronic microbial prostatitis and irritable bowel syndrome. Int J Androl (2012) 35:183–9.10.1111/j.1365-2605.2011.01216.x

  • CrossRef
  • Google Scholar

• 505

  WagenlehnerFMEPilatzABschleipferTDiemerTLinnTMeinhardtAet alBacterial prostatitis. World J Urol (2013) 31:711–6.10.1007/s00345-013-1055-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 506

  KrebsJBartelPPannekJ. Bacterial persistence in the prostate after antibiotic treatment of chronic bacterial prostatitis in men with spinal cord injury. Urology (2014) 83:515–20.10.1016/j.urology.2013.11.023

  • CrossRef
  • Google Scholar

• 507

  KrebsJBartelPPannekJ. Chronic bacterial prostatitis in men with spinal cord injury. World J Urol (2014) 32:1579–85.10.1007/s00345-013-1235-8

  • CrossRef
  • Google Scholar

• 508

  WagenlehnerFMEWeidnerWPilatzANaberKG. Urinary tract infections and bacterial prostatitis in men. Curr Opin Infect Dis (2014) 27:97–101.10.1097/QCO.0000000000000024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 509

  Videčnik ZormanJMatičičMJevericaSSmrkoljT. Diagnosis and treatment of bacterial prostatitis. Acta Dermatovenereol (2015) 24:25–9.

  • Google Scholar

• 510

  CondorelliRAVicariEMongioiLMRussoGIMorgiaGLa VigneraSet alHuman papilloma virus infection in patients with male accessory gland infection: usefulness of the ultrasound evaluation. Int J Endocrinol (2016) 2016:9174609.10.1155/2016/9174609

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 511

  GillBCShoskesDA. Bacterial prostatitis. Curr Opin Infect Dis (2016) 29:86–91.10.1097/QCO.0000000000000222

  • CrossRef
  • Google Scholar

• 512

  KriegerJNThumbikatP. Bacterial prostatitis: bacterial virulence, clinical outcomes, and new directions. Microbiol Spectr (2016) 4(1):UTI-0004-2012.10.1128/microbiolspec.UTI-0004-2012

  • CrossRef
  • Google Scholar

• 513

  Alvarado-EsquivelCPacheco-VegaSJHernández-TinocoJCenteno-TinocoMMBeristain-GarciaISánchez-AnguianoLFet alMiscarriage history and Toxoplasma gondii infection: a cross-sectional study in women in Durango City, Mexico. Eur J Microbiol Immunol (Bp) (2014) 4:117–22.10.1556/EuJMI.4.2014.2.4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 514

  GiakoumelouSWheelhouseNCuschieriKEntricanGHowieSEMHorneAW. The role of infection in miscarriage. Hum Reprod Update (2015).10.1093/humupd/dmv041

  • CrossRef
  • Google Scholar

• 515

  van der EijkAAVan GenderenPJVerdijkRMReuskenCBMoglingRVan KampenJJet alMiscarriage associated with zika virus infection. N Engl J Med (2016) 375:1002–4.10.1056/NEJMc1605898

  • CrossRef
  • Google Scholar

• 516

  McDonaldHMChambersHM. Intrauterine infection and spontaneous midgestation abortion: is the spectrum of microorganisms similar to that in preterm labor?Infect Dis Obstet Gynecol (2000) 8:220–7.10.1155/S1064744900000314

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 517

  RomeroREspinozaJMazorM. Can endometrial infection/inflammation explain implantation failure, spontaneous abortion, and preterm birth after in vitro fertilization?Fertil Steril (2004) 82:799–804.10.1016/j.fertnstert.2004.05.076

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 518

  Conde-FerráezLChan MayADACarrillo-MartínezJRAyora-TalaveraGGonzález-LosaMDR. Human papillomavirus infection and spontaneous abortion: a case-control study performed in Mexico. Eur J Obstet Gynecol Reprod Biol (2013) 170:468–73.10.1016/j.ejogrb.2013.07.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 519

  WangHCaoQGeJLiuCMaYMengYet alLncRNA-regulated infection and inflammation pathways associated with pregnancy loss: genome wide differential expression of lncRNAs in early spontaneous abortion. Am J Reprod Immunol (2014) 72:359–75.10.1111/aji.12275

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 520

  AhmadiAKhodabandehlooMRamazanzadehRFarhadifarFRoshaniDGhaderiEet alThe relationship between Chlamydia trachomatis genital infection and spontaneous abortion. J Reprod Infertil (2016) 17:110–6.

  • Pubmed Abstract
  • Google Scholar

• 521

  AmbühlLMMBaandrupUDybkaerKBlaakaerJUldbjergNSørensenS. Human papillomavirus infection as a possible cause of spontaneous abortion and spontaneous preterm delivery. Infect Dis Obstet Gynecol (2016) 2016:3086036.10.1155/2016/3086036

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 522

  GoldingBScottDEScharfOHuangLYZaitsevaMLaphamCet alImmunity and protection against Brucella abortus. Microbes Infect (2001) 3:43–8.10.1016/S1286-4579(00)01350-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 523

  CorbelMJElbergSSCosiviO. Brucellosis in Humans and Animals. Geneva: World Health Organization (2006).

  • Google Scholar

• 524

  OliveiraSCDe OliveiraFSMacedoGCDe AlmeidaLACarvalhoNB. The role of innate immune receptors in the control of Brucella abortus infection: toll-like receptors and beyond. Microbes Infect (2008) 10:1005–9.10.1016/j.micinf.2008.07.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 525

  KusterCEAlthouseGC. The impact of bacteriospermia on boar sperm storage and reproductive performance. Theriogenology (2016) 85:21–6.10.1016/j.theriogenology.2015.09.049

  • CrossRef
  • Google Scholar

• 526

  DornelesEMSSriranganathanNLageAP. Recent advances in Brucella abortus vaccines. Vet Res (2015) 46:76.10.1186/s13567-015-0199-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 527

  BrownVGSchollumLMJarvisBDW. Microbiology of bovine semen and artificial breeding practices under New-Zealand conditions. NZ J Agric Res (1974) 17:431–2.10.1080/00288233.1974.10421030

  • CrossRef
  • Google Scholar

• 528

  SchollumLM. The Microbiology of Bovine Serum and the Antimicrobial Activity of Bovine Seminal Plasma [PhD thesis]. Palmerston North: Massey University (1977).

  • Google Scholar

• 529

  YánizJLMarco-AguadoMAMateosJASantolariaP. Bacterial contamination of ram semen, antibiotic sensitivities, and effects on sperm quality during storage at 15 degrees C. Anim Reprod Sci (2010) 122:142–9.10.1016/j.anireprosci.2010.08.006

  • CrossRef
  • Google Scholar

• 530

  GaczarzewiczDUdałaJPiaseckaMBłaszczykBStankiewiczT. Bacterial contamination of boar semen and its relationship to sperm quality preserved in commercial extender containing gentamicin sulfate. Pol J Vet Sci (2016) 19:451–9.10.1515/pjvs-2016-0057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 531

  RomeroRMazorMWuYKSirtoriMOyarzunEMitchellMDet alInfection in the pathogenesis of preterm labor. Semin Perinatol (1988) 12:262–79.

  • Google Scholar

• 532

  TothMWitkinSSLedgerWThalerH. The role of infection in the etiology of preterm birth. Obstet Gynecol (1988) 71:723–6.

  • Pubmed Abstract
  • Google Scholar

• 533

  CassellGHWaitesKBWatsonHLCrouseDTHarasawaR. Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns. Clin Microbiol Rev (1993) 6:69–87.10.1128/CMR.6.1.69

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 534

  McGregorJAFrenchJIJonesWMilliganKMckinneyPJPattersonEet alBacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol (1994) 170:1048–59; discussion 1059–60.10.1016/S0002-9378(94)70098-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 535

  GoldenbergRLHauthJCAndrewsWW. Intrauterine infection and preterm delivery. N Engl J Med (2000) 342:1500–7.10.1056/NEJM200005183422007

  • CrossRef
  • Google Scholar

• 536

  GonçalvesLFChaiworapongsaTRomeroR. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev (2002) 8:3–13.10.1002/mrdd.10008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 537

  GerberSVialYHohlfeldPWitkinSS. Detection of Ureaplasma urealyticum in second-trimester amniotic fluid by polymerase chain reaction correlates with subsequent preterm labor and delivery. J Infect Dis (2003) 187:518–21.10.1086/368205

  • CrossRef
  • Google Scholar

• 538

  GardellaCRileyDEHittiJAgnewKKriegerJNEschenbachD. Identification and sequencing of bacterial rDNAs in culture-negative amniotic fluid from women in premature labor. Am J Perinatol (2004) 21:319–23.10.1055/s-2004-831884

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 539

  EspinozaJErezORomeroR. Preconceptional antibiotic treatment to prevent preterm birth in women with a previous preterm delivery. Am J Obstet Gynecol (2006) 194:630–7.10.1016/j.ajog.2005.11.050

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 540

  LeeSERomeroRKimCJShimSSYoonBH. Funisitis in term pregnancy is associated with microbial invasion of the amniotic cavity and intra-amniotic inflammation. J Matern Fetal Neonatal Med (2006) 19:693–7.10.1080/14767050600927353

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 541

  GoldenbergRLCulhaneJFIamsJDRomeroR. Epidemiology and causes of preterm birth. Lancet (2008) 371:75–84.10.1016/S0140-6736(08)60074-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 542

  CheckJH. A practical approach to the prevention of miscarriage part 4-role of infection. Clin Exp Obstet Gyn (2010) 37:252–5.

  • Google Scholar

• 543

  BastekJAGómezLMElovitzMA. The role of inflammation and infection in preterm birth. Clin Perinatol (2011) 38:385–406.10.1016/j.clp.2011.06.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 544

  JohnsonHLGhanemKGZenilmanJMErbeldingEJ. Sexually transmitted infections and adverse pregnancy outcomes among women attending inner city public sexually transmitted diseases clinics. Sex Transm Dis (2011) 38:167–71.10.1097/OLQ.0b013e3181f2e85f

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 545

  ManzoniPRizzolloSDecembrinoLRuffinazziGRossi RicciAGalloEet alRecent advances in prevention of sepsis in the premature neonates in NICU. Early Hum Dev (2011) 87(Suppl 1):S31–3.10.1016/j.earlhumdev.2011.01.008

  • CrossRef
  • Google Scholar

• 546

  RoursGIJGDuijtsLMollHAArendsLRDe GrootRJaddoeVWet alChlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. Eur J Epidemiol (2011) 26:493–502.10.1007/s10654-011-9586-1

  • CrossRef
  • Google Scholar

• 547

  JeffersonKK. The bacterial etiology of preterm birth. Adv Appl Microbiol (2012) 80:1–22.10.1016/B978-0-12-394381-1.00001-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 548

  LeeSYRLeungCW. Histological chorioamnionitis – implication for bacterial colonization, laboratory markers of infection, and early onset sepsis in very-low-birth-weight neonates. J Matern Fetal Neonatal Med (2012) 25:364–8.10.3109/14767058.2011.579208

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 549

  ShinarSSkornick-RapaportARimonE. Placental abruption remote from term associated with Q fever infection. Obstet Gynecol (2012) 120:503–5.10.1097/AOG.0b013e318260590f

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 550

  SubramaniamAAbramoviciAAndrewsWWTitaAT. Antimicrobials for preterm birth prevention: an overview. Infect Dis Obs Gynecol (2012).10.1155/2012/157159

  • CrossRef
  • Google Scholar

• 551

  AagaardKMaJAntonyKMGanuRPetrosinoJVersalovicJ. The placenta harbors a unique microbiome. Sci Transl Med (2014) 6:237ra265.10.1126/scitranslmed.3008599

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 552

  JoergensenJSKjaer WeileLKLamontRF. The early use of appropriate prophylactic antibiotics in susceptible women for the prevention of preterm birth of infectious etiology. Expert Opin Pharmacother (2014) 15:2173–91.10.1517/14656566.2014.950225

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 553

  Allen-DanielsMJSerranoMGPflugnerLPFettweisJMPrestosaMAKopardeVNet alIdentification of a gene in Mycoplasma hominis associated with preterm birth and microbial burden in intraamniotic infection. Am J Obstet Gynecol (2015) 212:779.e1–779.e13.10.1016/j.ajog.2015.01.032

  • CrossRef
  • Google Scholar

• 554

  de Andrade RamosBKanninenTTSistiGWitkinSS. Microorganisms in the female genital tract during pregnancy: tolerance versus pathogenesis. Am J Reprod Immunol (2015) 73:383–9.10.1111/aji.12326

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 555

  KacerovskyMVrbackyFKutovaRPliskovaLAndrysCMusilovaIet alCervical microbiota in women with preterm prelabor rupture of membranes. PLoS One (2015) 10:e0126884.10.1371/journal.pone.0126884

  • CrossRef
  • Google Scholar

• 556

  LamontRF. Advances in the prevention of infection-related preterm birth. Front Immunol (2015) 6:566.10.3389/fimmu.2015.00566

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 557

  LisRRowhani-RahbarAManhartLE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis (2015) 61:418–26.10.1093/cid/civ312

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 558

  PammiMWeismanLE. Late-onset sepsis in preterm infants: update on strategies for therapy and prevention. Expert Rev Anti Infect Ther (2015) 13:487–504.10.1586/14787210.2015.1008450

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 559

  UenoTNiimiHYonedaNYonedaSMoriMTabataHet alEukaryote-made thermostable DNA polymerase enables rapid PCR-based detection of mycoplasma, ureaplasma and other bacteria in the amniotic fluid of preterm labor cases. PLoS One (2015) 10:e0129032.10.1371/journal.pone.0129032

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 560

  FreyHAKlebanoffMA. The epidemiology, etiology, and costs of preterm birth. Semin Fetal Neonatal Med (2016) 21:68–73.10.1016/j.siny.2015.12.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 561

  NadeauHCGSubramaniamAAndrewsWW. Infection and preterm birth. Semin Fetal Neonatal Med (2016) 21:100–5.10.1016/j.siny.2015.12.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 562

  VinturacheAEGyamfi-BannermanCHwangJMysorekarIUJacobssonBPreterm Birth International Collaborative (Prebic). Maternal microbiome – a pathway to preterm birth. Semin Fetal Neonatal Med (2016) 21:94–9.10.1016/j.siny.2016.02.004

  • CrossRef
  • Google Scholar

• 563

  YonedaSShiozakiAYonedaNItoMShimaTFukudaKet alAntibiotic therapy increases the risk of preterm birth in preterm labor without intra-amniotic microbes, but may prolong the gestation period in preterm labor with microbes, evaluated by rapid and high-sensitive PCR system. Am J Reprod Immunol (2016) 75:440–50.10.1111/aji.12484

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 564

  García-VelascoJAMenabritoMCatalánIB. What fertility specialists should know about the vaginal microbiome: a review. Reprod Biomed Online (2017) 35:103–12.10.1016/j.rbmo.2017.04.005

  • CrossRef
  • Google Scholar

• 565

  van WellGTJDaalderopLAWolfsTKramerBW. Human perinatal immunity in physiological conditions and during infection. Mol Cell Pediatr (2017) 4:4.10.1186/s40348-017-0070-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 566

  ZiniABomanJMBelzileECiampiA. Sperm DNA damage is associated with an increased risk of pregnancy loss after IVF and ICSI: systematic review and meta-analysis. Hum Reprod (2008) 23:2663–8.10.1093/humrep/den321

  • CrossRef
  • Google Scholar

• 567

  Gil-VillaAMCardona-MayaWAgarwalASharmaRCadavidÁ. Assessment of sperm factors possibly involved in early recurrent pregnancy loss. Fertil Steril (2010) 94:1465–72.10.1016/j.fertnstert.2009.05.042

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 568

  BrahemSMehdiMLandolsiHMougouSElghezalHSaadA. Semen parameters and sperm DNA fragmentation as causes of recurrent pregnancy loss. Urology (2011) 78:792–6.10.1016/j.urology.2011.05.049

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 569

  ShinaACarpHJA. Recurrent pregnancy loss – beyond evidence based medicine. Gynecol Endocrinol (2012) 28:991–2.10.3109/09513590.2012.683083

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 570

  LewisSEMJohn AitkenRConnerSJIuliisGDEvensonDPHenkelRet alThe impact of sperm DNA damage in assisted conception and beyond: recent advances in diagnosis and treatment. Reprod Biomed Online (2013) 27:325–37.10.1016/j.rbmo.2013.06.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 571

  SimonLProutskiIStevensonMJenningsDMcmanusJLuttonDet alSperm DNA damage has a negative association with live-birth rates after IVF. Reprod Biomed Online (2013) 26:68–78.10.1016/j.rbmo.2012.09.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 572

  WangRZhouHZhangZDaiRGengDLiuR. The impact of semen quality, occupational exposure to environmental factors and lifestyle on recurrent pregnancy loss. J Assist Reprod Genet (2013) 30:1513–8.10.1007/s10815-013-0091-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 573

  BellocSBenkhalifaMCohen-BacrieMDalleacAChahineHAmarEet alWhich isolated sperm abnormality is most related to sperm DNA damage in men presenting for infertility evaluation. J Assist Reprod Genet (2014) 31:527–32.10.1007/s10815-014-0194-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 574

  BonneyEABrownSA. To drive or be driven: the path of a mouse model of recurrent pregnancy loss. Reproduction (2014) 147:R153–67.10.1530/REP-13-0583

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 575

  KavithaPMaliniSS. Positive association of sperm dysfunction in the pathogenesis of recurrent pregnancy loss. J Clin Diagn Res (2014) 8:OC07–10.10.7860/JCDR/2014/9109.5172

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 576

  ZhaoJZhangQWangYLiY. Whether sperm deoxyribonucleic acid fragmentation has an effect on pregnancy and miscarriage after in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. Fertil Steril (2014) 102:998–1005.e1008.10.1016/j.fertnstert.2014.06.033

  • CrossRef
  • Google Scholar

• 577

  BronsonR, editor. The Male Role in Pregnancy Loss and Embryo Implantation Failure. Berlin: Springer (2015).

  • Google Scholar

• 578

  EstevesSCSánchez-MartinFSánchez-MartinPSchneiderDTGosálvezJ. Comparison of reproductive outcome in oligozoospermic men with high sperm DNA fragmentation undergoing intracytoplasmic sperm injection with ejaculated and testicular sperm. Fertil Steril (2015) 104:1398–405.10.1016/j.fertnstert.2015.08.028

  • CrossRef
  • Google Scholar

• 579

  Zidi-JrahIHajlaouiAMougou-ZerelliSKammounMMeniaouiISallemAet alRelationship between sperm aneuploidy, sperm DNA integrity, chromatin packaging, traditional semen parameters, and recurrent pregnancy loss. Fertil Steril (2016) 105:58–64.10.1016/j.fertnstert.2015.09.041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 580

  SimonLZiniADyachenkoACiampiACarrellDT. A systematic review and meta-analysis to determine the effect of sperm DNA damage on in vitro fertilization and intracytoplasmic sperm injection outcome. Asian J Androl (2017) 19:80–90.10.4103/1008-682X.182822

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 581

  AgarwalAMajzoubAEstevesSCKoERamasamyRZiniA. Clinical utility of sperm DNA fragmentation testing: practice recommendations based on clinical scenarios. Transl Androl Urol (2016) 5:935–50.10.21037/tau.2016.10.03

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 582

  UsmaniSLiuHCPilcherCDWitkowskaHEKirchhoffFGreeneWCet alHIV-enhancing amyloids are prevalent in fresh semen and are a determinant for semen’s ability to enhance HIV infection: relevance for HIV transmission. AIDS Res Hum Retroviruses (2014) 30:A183–4.10.1089/aid.2014.5392.abstract

  • CrossRef
  • Google Scholar

• 583

  BinderNKSheedyJRHannanNJGardnerDK. Male obesity is associated with changed spermatozoa Cox4i1 mRNA level and altered seminal vesicle fluid composition in a mouse model. Mol Hum Reprod (2015) 21:424–34.10.1093/molehr/gav010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 584

  Gil-VillaAMCardona-MayaWAgarwalASharmaRCadavidÁ. Role of male factor in early recurrent embryo loss: do antioxidants have any effect?Fertil Steril (2009) 92:565–71.10.1016/j.fertnstert.2008.07.1715

  • CrossRef
  • Google Scholar

• 585

  ShivaMGautamAKVermaYShivgotraVDoshiHKumarS. Association between sperm quality, oxidative stress, and seminal antioxidant activity. Clin Biochem (2011) 44:319–24.10.1016/j.clinbiochem.2010.11.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 586

  AgarwalADurairajanayagamDHalabiJPengJVazquez-LevinM. Proteomics, oxidative stress and male infertility. Reprod Biomed Online (2014) 29:32–58.10.1016/j.rbmo.2014.02.013

  • CrossRef
  • Google Scholar

• 587

  DurairajanayagamDAgarwalAOngCPrashastP. Lycopene and male infertility. Asian J Androl (2014) 16:420–5.10.4103/1008-682X.126384

  • CrossRef
  • Google Scholar

• 588

  KoEYSabaneghESJrAgarwalA. Male infertility testing: reactive oxygen species and antioxidant capacity. Fertil Steril (2014) 102:1518–27.10.1016/j.fertnstert.2014.10.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 589

  CruzDFLumeCSilvaJVNunesACastroISilvaRet alOxidative stress markers: can they be used to evaluate human sperm quality?Turk J Urol (2015) 41:198–207.10.5152/tud.2015.06887

  • CrossRef
  • Google Scholar

• 590

  AgarwalARoychoudhurySSharmaRGuptaSMajzoubASabaneghE. Diagnostic application of oxidation-reduction potential assay for measurement of oxidative stress: clinical utility in male factor infertility. Reprod Biomed Online (2017) 34:48–57.10.1016/j.rbmo.2016.10.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 591

  AgarwalAWangSM. Clinical relevance of oxidation-reduction potential in the evaluation of male infertility. Urology (2017) 104:84–9.10.1016/j.urology.2017.02.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 592

  BouziatRHinterleitnerRBrownJJStencel-BaerenwaldJEIkizlerMMayassiTet alReovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science (2017) 356:44–50.10.1126/science.aah5298

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 593

  VerduEFCamineroA. How infection can incite sensitivity to food. Science (2017) 356:29–30.10.1126/science.aan1500

  • CrossRef
  • Google Scholar

• 594

  LudvigssonJFMontgomerySMEkbomA. Celiac disease and risk of adverse fetal outcome: a population-based cohort study. Gastroenterology (2005) 129:454–63.10.1016/j.gastro.2005.05.065

  • CrossRef
  • Google Scholar

• 595

  WolfHIlsenAVan PampusMGSahebdienSPenaSVon BlombergME. Celiac serology in women with severe pre-eclampsia or delivery of a small for gestational age neonate. Int J Gynaecol Obstet (2008) 103:175–7.10.1016/j.ijgo.2008.05.024

  • CrossRef
  • Google Scholar

• 596

  BastAO’BryanTBastE. Celiac disease and reproductive health. Practical Gastroenterol (2009):10–21.

  • Google Scholar

• 597

  ÖzgörBSelimoğluMA. Coeliac disease and reproductive disorders. Scand J Gastroenterol (2010) 45:395–402.10.3109/00365520903508902

  • CrossRef
  • Google Scholar

• 598

  SoniSBadawySZ. Celiac disease and its effect on human reproduction: a review. J Reprod Med (2010) 55:3–8.

  • Google Scholar

• 599

  TersigniCCastellaniRDe WaureCFattorossiADe SpiritoMGasbarriniAet alCeliac disease and reproductive disorders: meta-analysis of epidemiologic associations and potential pathogenic mechanisms. Hum Reprod Update (2014) 20:582–93.10.1093/humupd/dmu007

  • CrossRef
  • Google Scholar

• 600

  MoleskiSMLindenmeyerCCVeloskiJJMillerRSMillerCLKastenbergDet alIncreased rates of pregnancy complications in women with celiac disease. Ann Gastroenterol (2015) 28:236–40.

  • Pubmed Abstract
  • Google Scholar

• 601

  SacconeGBerghellaVSarnoLMaruottiGMCetinIGrecoLet alCeliac disease and obstetric complications: a systematic review and metaanalysis. Am J Obstet Gynecol (2016) 214:225–34.10.1016/j.ajog.2015.09.080

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 602

  BybergKKOglandBEideGEØymarK. Birth after preeclamptic pregnancies: association with allergic sensitization and allergic rhinoconjunctivitis in late childhood; a historically matched cohort study. BMC Pediatr (2014) 14:101.10.1186/1471-2431-14-101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 603

  LiuAH. Revisiting the hygiene hypothesis for allergy and asthma. J Allergy Clin Immunol (2015) 136:860–5.10.1016/j.jaci.2015.08.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 604

  StokholmJSevelstedAAndersonUDBisgaardH. Preeclampsia associates with asthma, allergy, and eczema in childhood. Am J Respir Crit Care Med (2017) 195:614–21.10.1164/rccm.201604-0806OC

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 605

  OmerSBGoodmanDSteinhoffMCRochatRKlugmanKPStollBJet alMaternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med (2011) 8:e1000441.10.1371/journal.pmed.1000441

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 606

  AdedinsewoDANooryLBednarczykRASteinhoffMCDavisROgbuanuCet alImpact of maternal characteristics on the effect of maternal influenza vaccination on fetal outcomes. Vaccine (2013) 31:5827–33.10.1016/j.vaccine.2013.09.071

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 607

  RichardsJLHansenCBredfeldtCBednarczykRASteinhoffMCAdjaye-GbewonyoDet alNeonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. Clin Infect Dis (2013) 56:1216–22.10.1093/cid/cit045

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 608

  OlsenSJMirzaSAVonglokhamPKhanthamalyVChitryBPholsenaVet alThe effect of influenza vaccination on birth outcomes in a cohort of pregnant women in Lao PDR, 2014–2015. Clin Infect Dis (2016) 63:487–94.10.1093/cid/ciw290

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 609

  PhadkeVKSteinhoffMCOmerSBMacdonaldNE. Maternal influenza immunization and adverse birth outcomes: using data and practice to inform theory and research design. Am J Epidemiol (2016) 184:789–92.10.1093/aje/kww110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 610

  LeslieM. Can flu shots help women get pregnant?Science (2017) 355:1247–8.10.1126/science.355.6331.1247

  • CrossRef
  • Google Scholar

• 611

  NordinJDKharbandaEOVazquez BenitezGLipkindHVellozziCDestefanoFet alMaternal influenza vaccine and risks for preterm or small for gestational age birth. J Pediatr (2014) 164:1051–7.e1052.10.1016/j.jpeds.2014.01.037

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 612

  BrattonKNWardleMTOrensteinWAOmerSB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis (2015) 60:e11–9.10.1093/cid/ciu915

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 613

  CoendersAKoopmansNKBroekhuijsenKGroenHKarstenberg-KramerJMAVan GoorKet alAdjuvanted vaccines in pregnancy: no evidence for effect of the adjuvanted H1N1/09 vaccination on occurrence of preeclampsia or intra-uterine growth restriction. Eur J Obstet Gynecol Reprod Biol (2015) 187:14–9.10.1016/j.ejogrb.2015.01.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 614

  MunozFMGreisingerAJWehmanenOAMouzoonMEHoyleJCSmithFAet alSafety of influenza vaccination during pregnancy. Am J Obstet Gynecol (2005) 192:1098–106.10.1016/j.ajog.2004.12.019

  • CrossRef
  • Google Scholar

• 615

  MakTKMangtaniPLeeseJWatsonJMPfeiferD. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis (2008) 8:44–52.10.1016/S1473-3099(07)70311-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 616

  TammaPDAultKADel RioCSteinhoffMCHalseyNAOmerSB. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol (2009) 201:547–52.10.1016/j.ajog.2009.09.034

  • CrossRef
  • Google Scholar

• 617

  YamaguchiKHisanoMIsojimaSIrieSArataNWatanabeNet alRelationship of Th1/Th2 cell balance with the immune response to influenza vaccine during pregnancy. J Med Virol (2009) 81:1923–8.10.1002/jmv.21620

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 618

  BednarczykRAAdjaye-GbewonyoDOmerSB. Safety of influenza immunization during pregnancy for the fetus and the neonate. Am J Obstet Gynecol (2012) 207:S38–46.10.1016/j.ajog.2012.07.002

  • CrossRef
  • Google Scholar

• 619

  JamiesonDJKissinDMBridgesCBRasmussenSA. Benefits of influenza vaccination during pregnancy for pregnant women. Am J Obstet Gynecol (2012) 207:S17–20.10.1016/j.ajog.2012.06.070

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 620

  KharbandaEOVazquez-BenitezGShiWXLipkindHNalewayAMolitorBet alAssessing the safety of influenza immunization during pregnancy: the Vaccine Safety Datalink. Am J Obstet Gynecol (2012) 207:S47–51.10.1016/j.ajog.2012.06.073

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 621

  MoroPLTepperNKGrohskopfLAVellozziCBroderK. Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy. Expert Rev Vaccines (2012) 11:911–21.10.1586/erv.12.72

  • CrossRef
  • Google Scholar

• 622

  PasternakBSvanströmHMølgaard-NielsenDKrauseTGEmborgHDMelbyeMet alRisk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA (2012) 308:165–74.10.1001/jama.2012.6131

  • CrossRef
  • Google Scholar

• 623

  PasternakBSvanströmHMølgaard-NielsenDKrauseTGEmborgHDMelbyeMet alVaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ (2012) 344:e2794.10.1136/bmj.e2794

  • CrossRef
  • Google Scholar

• 624

  BeauABHurault-DelarueCVidalSGuitardCVayssièreCPetiotDet alPandemic A/H1N1 influenza vaccination during pregnancy: a comparative study using the EFEMERIS database. Vaccine (2014) 32:1254–8.10.1016/j.vaccine.2014.01.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 625

  Keller-StanislawskiBEnglundJAKangGMangtaniPNeuzilKNohynekHet alSafety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine (2014) 32:7057–64.10.1016/j.vaccine.2014.09.052

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 626

  NalewayALIrvingSAHenningerMLLiDKShifflettPBallSet alSafety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. Vaccine (2014) 32:3122–7.10.1016/j.vaccine.2014.04.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 627

  VaughnDWSeifertHHepburnADeweWLiPDrameMet alSafety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials. Hum Vaccin Immunother (2014) 10:2942–57.10.4161/21645515.2014.972149

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 628

  BaumULeinoTGisslerMKilpiTJokinenJ. Perinatal survival and health after maternal influenza A(H1N1)pdm09 vaccination: a cohort study of pregnancies stratified by trimester of vaccination. Vaccine (2015) 33:4850–7.10.1016/j.vaccine.2015.07.061

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 629

  FabianiMBellaARotaMCClagnanEGalloTD’amatoMet alA/H1N1 pandemic influenza vaccination: a retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy. Vaccine (2015) 33:2240–7.10.1016/j.vaccine.2015.03.041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 630

  FellDBPlattRWLanesAWilsonKKaufmanJSBassoOet alFetal death and preterm birth associated with maternal influenza vaccination: systematic review. BJOG (2015) 122:17–26.10.1111/1471-0528.12977

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 631

  LudvigssonJFStrömPLundholmCCnattingiusSEkbomAÖrtqvistÅet alMaternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. BMJ (2015) 351:h5585.10.1136/bmj.h5585

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 632

  SavitzDAFellDBOrtizJRBhatN. Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs. Vaccine (2015) 33:6430–5.10.1016/j.vaccine.2015.08.041

  • CrossRef
  • Google Scholar

• 633

  WallsTGrahamPPetousis-HarrisHHillLAustinN. Infant outcomes after exposure to Tdap vaccine in pregnancy: an observational study. BMJ Open (2016) 6:e009536.10.1136/bmjopen-2015-009536

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 634

  DoneganKKingBBryanP. Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ (2014) 349:g4219.10.1136/bmj.g4219

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 635

  KharbandaEOVazquez-BenitezGLipkindHSKleinNPCheethamTCNalewayALet alMaternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007–2013. Vaccine (2016) 34:968–73.10.1016/j.vaccine.2015.12.046

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 636

  Petousis-HarrisHWallsTWatsonDPaynterJGrahamPTurnerN. Safety of Tdap vaccine in pregnant women: an observational study. BMJ Open (2016) 6:e010911.10.1136/bmjopen-2015-010911

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 637

  WheelerCMSkinnerSRDel Rosario-RaymundoMRGarlandSMChatterjeeALazcano-PonceEet alEfficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis (2016) 16:1154–68.10.1016/S1473-3099(16)30120-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 638

  RajRSBonneyEAPhillippeM. Influenza, immune system, and pregnancy. Reprod Sci (2014) 21:1434–51.10.1177/1933719114537720

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 639

  StaffACBentonSJVon DadelszenPRobertsJMTaylorRNPowersRWet alRedefining preeclampsia using placenta-derived biomarkers. Hypertension (2013) 61:932–42.10.1161/HYPERTENSIONAHA.111.00250

  • CrossRef
  • Google Scholar

• 640

  ScheminskeMHenningerMIrvingSAThompsonMWilliamsJShifflettPet alThe association between influenza vaccination and other preventative health behaviors in a cohort of pregnant women. Health Educ Behav (2015) 42:402–8.10.1177/1090198114560021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 641

  SteinhoffMCOmerSBRoyEEl ArifeenSRaqibRDoddCet alNeonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. CMAJ (2012) 184:645–53.10.1503/cmaj.110754

  • CrossRef
  • Google Scholar

• 642

  PorterTFLacoursiereYScottJR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev (2006):CD000112.10.1002/14651858.CD000112.pub2

  • CrossRef
  • Google Scholar

• 643

  WongLFPorterTFScottJR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev (2014):CD000112.10.1002/14651858.CD000112.pub3

  • CrossRef
  • Google Scholar

• 644

  JørgensenKTPedersenBVJacobsenSBiggarRJFrischM. National cohort study of reproductive risk factors for rheumatoid arthritis in Denmark: a role for hyperemesis, gestational hypertension and pre-eclampsia?Ann Rheum Dis (2010) 69:358–63.10.1136/ard.2008.099945

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 645

  EbringerARashidTWilsonC. Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper. Autoimmun Rev (2010) 9:216–23.10.1016/j.autrev.2009.10.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 646

  EbringerA. Rheumatoid Arthritis and Proteus. London: Springer (2012).

  • Google Scholar

• 647

  EbringerARashidT. Rheumatoid arthritis is caused by a Proteus urinary tract infection. APMIS (2014) 122:363–8.10.1111/apm.12154

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 648

  PretoriusEAkeredoluO-OSomaPKellDB. Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability. Exp Biol Med (2017) 242:355–73.10.1177/1535370216681549

  • CrossRef
  • Google Scholar

• 649

  WangGLiXWangZ. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res (2016) 44:D1087–93.10.1093/nar/gkv1278

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 650

  ZasloffM. Antimicrobial peptides of multicellular organisms. Nature (2002) 415:389–95.10.1038/415389a

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 651

  AuvynetCRosensteinY. Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS J (2009) 276:6497–508.10.1111/j.1742-4658.2009.07360.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 652

  GustafssonAOlinAILjunggrenL. LPS interactions with immobilized and soluble antimicrobial peptides. Scand J Clin Lab Invest (2010) 70:194–200.10.3109/00365511003663622

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 653

  LeeSHJunHKLeeHRChungCPChoiBK. Antibacterial and lipopolysaccharide (LPS)-neutralising activity of human cationic antimicrobial peptides against periodontopathogens. Int J Antimicrob Agents (2010) 35:138–45.10.1016/j.ijantimicag.2009.09.024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 654

  KościuczukEMLisowskiPJarczakJStrzałkowskaNJóźwikAHorbańczukJet alCathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep (2012) 39:10957–70.10.1007/s11033-012-1997-x

  • CrossRef
  • Google Scholar

• 655

  SeoMDWonHSKimJHMishig-OchirTLeeBJ. Antimicrobial peptides for therapeutic applications: a review. Molecules (2012) 17:12276–86.10.3390/molecules171012276

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 656

  ZhaoJZhaoCLiangGZhangMZhengJ. Engineering antimicrobial peptides with improved antimicrobial and hemolytic activities. J Chem Inf Model (2013) 53:3280–96.10.1021/ci400477e

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 657

  AshbyMPetkovaAHilpertK. Cationic antimicrobial peptides as potential new therapeutic agents in neonates and children: a review. Curr Opin Infect Dis (2014) 27:258–67.10.1097/QCO.0000000000000057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 658

  WaghuFHGopiLBaraiRSRamtekePNizamiBIdicula-ThomasS. CAMP: collection of sequences and structures of antimicrobial peptides. Nucleic Acids Res (2014) 42:D1154–8.10.1093/nar/gkt1157

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 659

  WangG. Human antimicrobial peptides and proteins. Pharmaceuticals (Basel) (2014) 7:545–94.10.3390/ph7050545

  • CrossRef
  • Google Scholar

• 660

  KidoEAPandolfiVHoullou-KidoLMAndradePPMarcelinoFCNepomucenoALet alPlant antimicrobial peptides: an overview of SuperSAGE transcriptional profile and a functional review. Curr Protein Pept Sci (2010) 11:220–30.10.2174/138920310791112110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 661

  LiWTailhadesJO’brien-SimpsonNMSeparovicFOtvosLJrHossainMAet alProline-rich antimicrobial peptides: potential therapeutics against antibiotic-resistant bacteria. Amino Acids (2014) 46:2287–94.10.1007/s00726-014-1820-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 662

  KosikowskaPLesnerA. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015). Expert Opin Ther Pat (2016) 26:689–702.10.1080/13543776.2016.1176149

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 663

  KangHKKimCSeoCHParkY. The therapeutic applications of antimicrobial peptides (AMPs): a patent review. J Microbiol (2017) 55:1–12.10.1007/s12275-017-6452-1

  • CrossRef
  • Google Scholar

• 664

  YoshioHTollinMGudmundssonGHLagercrantzHJornvallHMarchiniGet alAntimicrobial polypeptides of human vernix caseosa and amniotic fluid: implications for newborn innate defense. Pediatr Res (2003) 53:211–6.10.1203/01.PDR.0000047471.47777.B0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 665

  FrewLStockSJ. Antimicrobial peptides and pregnancy. Reproduction (2011) 141:725–35.10.1530/REP-10-0537

  • CrossRef
  • Google Scholar

• 666

  Kai-LarsenYGudmundssonGHAgerberthB. A review of the innate immune defence of the human foetus and newborn, with the emphasis on antimicrobial peptides. Acta Paediatr (2014) 103:1000–8.10.1111/apa.12700

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 667

  TribeRM. Small peptides with a big role: antimicrobial peptides in the pregnant female reproductive tract. Am J Reprod Immunol (2015) 74:123–5.10.1111/aji.12379

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 668

  YarbroughVLWinkleSHerbst-KralovetzMM. Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications. Hum Reprod Update (2015) 21:353–77.10.1093/humupd/dmu065

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 669

  YederyRDReddyKVR. Antimicrobial peptides as microbicidal contraceptives: prophecies for prophylactics – a mini review. Eur J Contracept Reprod Health Care (2005) 10:32–42.10.1080/13625180500035124

  • CrossRef
  • Google Scholar

• 670

  ZairiATangyFBouassidaKHaniK. Dermaseptins and magainins: antimicrobial peptides from frogs’ skin-new sources for a promising spermicides microbicides-a mini review. J Biomed Biotechnol (2009) 2009:452567.10.1155/2009/452567

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 671

  SchulzeMJunkesCMuellerPSpeckSRuedigerKDatheMet alEffects of cationic antimicrobial peptides on liquid-preserved boar spermatozoa. PLoS One (2014) 9:e100490.10.1371/journal.pone.0100490

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 672

  SpeckSCourtiolAJunkesCDatheMMüllerKSchulzeM. Cationic synthetic peptides: assessment of their antimicrobial potency in liquid preserved boar semen. PLoS One (2014) 9:e105949.10.1371/journal.pone.0105949

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 673

  SchulzeMGrobbelMMüllerKJunkesCDatheMRüdigerKet alChallenges and limits using antimicrobial peptides in boar semen preservation. Reprod Domest Anim (2015) 50(Suppl 2):5–10.10.1111/rda.12553

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 674

  SchulzeMDatheMWaberskiDMüllerK. Liquid storage of boar semen: current and future perspectives on the use of cationic antimicrobial peptides to replace antibiotics in semen extenders. Theriogenology (2016) 85:39–46.10.1016/j.theriogenology.2015.07.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 675

  BussalleuESanchoSBrizMDYesteMBonetS. Do antimicrobial peptides PR-39, PMAP-36 and PMAP-37 have any effect on bacterial growth and quality of liquid-stored boar semen?Theriogenology (2017) 89:235–43.10.1016/j.theriogenology.2016.11.017

  • CrossRef
  • Google Scholar

• 676

  EasterhoffDOntiverosFBrooksLRKimYRossBSilvaJNet alSemen-derived enhancer of viral infection (SEVI) binds bacteria, enhances bacterial phagocytosis by macrophages, and can protect against vaginal infection by a sexually transmitted bacterial pathogen. Antimicrob Agents Chemother (2013) 57:2443–50.10.1128/AAC.02464-12

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 677

  EdströmAMLMalmJFrohmBMartelliniJAGiwercmanAMörgelinMet alThe major bactericidal activity of human seminal plasma is zinc-dependent and derived from fragmentation of the semenogelins. J Immunol (2008) 181:3413–21.10.4049/jimmunol.181.5.3413

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 678

  ZhaoHLeeWHShenJHLiHZhangY. Identification of novel semenogelin I-derived antimicrobial peptide from liquefied human seminal plasma. Peptides (2008) 29:505–11.10.1016/j.peptides.2008.01.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 679

  YenuguSHamilKGBirseCERubenSMFrenchFSHallSH. Antibacterial properties of the sperm-binding proteins and peptides of human epididymis 2 (HE2) family; salt sensitivity, structural dependence and their interaction with outer and cytoplasmic membranes of Escherichia coli. Biochem J (2003) 372:473–83.10.1042/BJ20030225

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 680

  AvellarMCWHondaLHamilKGYenuguSGrossmanGPetruszPet alDifferential expression and antibacterial activity of epididymis protein 2 isoforms in the male reproductive tract of human and rhesus monkey (Macaca mulatta). Biol Reprod (2004) 71:1453–60.10.1095/biolreprod.104.031740

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 681

  SørensenOEGramLJohnsenAHAnderssonEBangsbøllSTjabringaGSet alProcessing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J Biol Chem (2003) 278:28540–6.10.1074/jbc.M301608200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 682

  WilliamsRJ. Biochemical Individuality. New York: John Wiley (1956).

  • Google Scholar

• 683

  AyresJSFreitagNSchneiderDS. Identification of Drosophila mutants altering defense of and endurance to Listeria monocytogenes infection. Genetics (2008) 178:1807–15.10.1534/genetics.107.083782

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 684

  SchneiderDSAyresJS. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat Rev Immunol (2008) 8:889–95.10.1038/nri2432

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 685

  RåbergLGrahamALReadAF. Decomposing health: tolerance and resistance to parasites in animals. Philos Trans R Soc Lond B Biol Sci (2009) 364:37–49.10.1098/rstb.2008.0184

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 686

  AyresJSSchneiderDS. Tolerance of infections. Annu Rev Immunol (2012) 30:271–94.10.1146/annurev-immunol-020711-075030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 687

  MedzhitovRSchneiderDSSoaresMP. Disease tolerance as a defense strategy. Science (2012) 335:936–41.10.1126/science.1214935

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 688

  RåbergL. How to live with the enemy: understanding tolerance to parasites. PLoS Biol (2014) 12:e1001989.10.1371/journal.pbio.1001989

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 689

  Palaferri SchieberAMLeeYMChangMWLeblancMCollinsBDownesMet alDisease tolerance mediated by microbiome E. coli involves inflammasome and IGF-1 signaling. Science (2015) 350:558–63.10.1126/science.aac6468

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 690

  KogutMHArsenaultRJ. Immunometabolic phenotype alterations associated with the induction of disease tolerance and persistent asymptomatic infection of Salmonella in the chicken intestine. Front Immunol (2017) 8:372.10.3389/fimmu.2017.00372

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 691

  MeunierIKaufmannEDowneyJDivangahiM. Unravelling the networks dictating host resistance versus tolerance during pulmonary infections. Cell Tissue Res (2017) 367:525–36.10.1007/s00441-017-2572-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 692

  LongoVDFinchCE. Evolutionary medicine: from dwarf model systems to healthy centenarians?Science (2003) 299:1342–6.10.1126/science.1077991

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 693

  GluckmanPBeedleAHansonM. Principles of Evolutionary Medicine. Oxford: Oxford University Press (2009).

  • Google Scholar

• 694

  RühliFJHennebergM. New perspectives on evolutionary medicine: the relevance of microevolution for human health and disease. BMC Med (2013) 11:115.10.1186/1741-7015-11-115

  • CrossRef
  • Google Scholar

• 695

  SvenssonEIRåbergL. Resistance and tolerance in animal enemy-victim coevolution. Trends Ecol Evol (2010) 25:267–74.10.1016/j.tree.2009.12.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 696

  AyresJS. Cooperative microbial tolerance behaviors in host-microbiota mutualism. Cell (2016) 165:1323–31.10.1016/j.cell.2016.05.049

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 697

  AyresJS. Microbes dress for success: tolerance or resistance?Trends Microbiol (2017) 25:1–3.10.1016/j.tim.2016.11.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 698

  RanganKJPedicordVAWangYCKimBLuYShahamSet alA secreted bacterial peptidoglycan hydrolase enhances tolerance to enteric pathogens. Science (2016) 353:1434–7.10.1126/science.aaf3552

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 699

  ThanNGBaloghARomeroRKárpátiÉErezOSzilágyiAet alPlacental protein 13 (PP13) – a placental immunoregulatory galectin protecting pregnancy. Front Immunol (2014) 5:348.10.3389/fimmu.2014.00348

  • CrossRef
  • Google Scholar

• 700

  ThanNGSumegiBThanGNBerenteZBohnH. Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein. Placenta (1999) 20:703–10.10.1053/plac.1999.0436

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 701

  VisegrádyBThanNGKilárFSümegiBThanGNBohnH. Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin-13). Protein Eng (2001) 14:875–80.10.1093/protein/14.11.875

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 702

  BohnHKrausWWincklerW. Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17). Oncodev Biol Med (1983) 4:343–50.

  • Pubmed Abstract
  • Google Scholar

• 703

  ThanNGPickEBellyeiSSzigetiABurgerOBerenteZet alFunctional analyses of placental protein 13/galectin-13. Eur J Biochem (2004) 271:1065–78.10.1111/j.1432-1033.2004.04004.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 704

  ThanNGRomeroRGoodmanMWeckleAXingJDongZet alA primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci U S A (2009) 106:9731–6.10.1073/pnas.0903568106

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 705

  RomeroRKusanovicJPThanNGErezOGotschFEspinozaJet alFirst-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol (2008) 199:122.e121–122.e111.10.1016/j.ajog.2008.01.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 706

  CowansNJStamatopoulouAKhalilASpencerK. PP13 as a marker of pre-eclampsia: a two platform comparison study. Placenta (2011) 32(Suppl):S37–41.10.1016/j.placenta.2010.08.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 707

  De MuroPCapobiancoGLepeddaAJNiedduGFormatoMTramNHQet alPlasma PP13 and urinary GAGs/PGs as early markers of pre-eclampsia. Arch Gynecol Obstet (2016) 294:959–65.10.1007/s00404-016-4111-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 708

  ThanNGAbdul RahmanOMagenheimRNagyBFuleTHargitaiBet alPlacental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. Virchows Arch (2008) 453:387–400.10.1007/s00428-008-0658-x

  • CrossRef
  • Google Scholar

• 709

  BruinersNBosmanMPostmaAGebhardtSRebelloGSammarMet alPromoter variant-98A-C of the LGALS13 gene and pre-eclampsia. Proceedings of the 8th World Congress of Perinatal Medicine. Florence (2007). p. 371–4.

  • Google Scholar

• 710

  ThanNGErezOWildmanDETarcaALEdwinSSAbbasAet alSevere preeclampsia is characterized by increased placental expression of galectin-1. J Matern Fetal Neonatal Med (2008) 21:429–42.10.1080/14767050802041961

  • CrossRef
  • Google Scholar

• 711

  VastaGR. Roles of galectins in infection. Nat Rev Microbiol (2009) 7:424–38.10.1038/nrmicro2146

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 712

  PoltorakAHeXLSmirnovaILiuMYVan HuffelCDuXet alDefective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 282:2085–8.10.1126/science.282.5396.2085

  • CrossRef
  • Google Scholar

• 713

  HoshinoKTakeuchiOKawaiTSanjoHOgawaTTakedaYet alToll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 162:3749–52.

  • Google Scholar

• 714

  LienEMeansTKHeineHYoshimuraAKusumotoSFukaseKet alToll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest (2000) 105:497–504.10.1172/JCI8541

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 715

  SchwandnerRDziarskiRWescheHRotheMKirschningCJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem (1999) 274:17406–9.10.1074/jbc.274.25.17406

  • CrossRef
  • Google Scholar

• 716

  UnderhillDMOzinskyAHajjarAMStevensAWilsonCBBassettiMet alThe toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature (1999) 401:811–5.10.1038/44605

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 717

  IshiiKJAkiraS. Toll-like receptors and sepsis. Curr Infect Dis Rep (2004) 6:361–6.10.1007/s11908-004-0034-1

  • CrossRef
  • Google Scholar

• 718

  ZähringerULindnerBInamuraSHeineHAlexanderC. TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology (2008) 213:205–24.10.1016/j.imbio.2008.02.005

  • CrossRef
  • Google Scholar

• 719

  KawaiTAkiraS. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 34:637–50.10.1016/j.immuni.2011.05.006

  • CrossRef
  • Google Scholar

• 720

  KumarHKawaiTAkiraS. Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 30:16–34.10.3109/08830185.2010.529976

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 721

  Oliveira-NascimentoLMassariPWetzlerLM. The role of TLR2 in infection and immunity. Front Immunol (2012) 3:79.10.3389/fimmu.2012.00079

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 722

  AlexanderSPABensonHEFaccendaEPawsonAJSharmanJLSpeddingMet alThe concise guide to pharmacology 2013/14: catalytic receptors. Br J Pharmacol (2013) 170:1676–705.10.1111/bph.12449

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 723

  KumarSIngleHPrasadDVKumarH. Recognition of bacterial infection by innate immune sensors. Crit Rev Microbiol (2013) 39:229–46.10.3109/1040841X.2012.706249

  • CrossRef
  • Google Scholar

• 724

  LiuYYinHZhaoMLuQ. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol (2014) 47:136–47.10.1007/s12016-013-8402-y

  • CrossRef
  • Google Scholar

• 725

  Jiménez-DalmaroniMJGerswhinMEAdamopoulosIE. The critical role of toll-like receptors – from microbial recognition to autoimmunity: a comprehensive review. Autoimmun Rev (2016) 15:1–8.10.1016/j.autrev.2015.08.009

  • CrossRef
  • Google Scholar

• 726

  MukherjeeSKarmakarSBabuSP. TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review. Braz J Infect Dis (2016) 20:193–204.10.1016/j.bjid.2015.10.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 727

  TinsleyJHChiassonVLMahajanAYoungKJMitchellBM. Toll-like receptor 3 activation during pregnancy elicits preeclampsia-like symptoms in rats. Am J Hypertens (2009) 22:1314–9.10.1038/ajh.2009.185

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 728

  AkiraSUematsuSTakeuchiO. Pathogen recognition and innate immunity. Cell (2006) 124:783–801.10.1016/j.cell.2006.02.015

  • CrossRef
  • Google Scholar

• 729

  SchroderKMuruveDATschoppJ. Innate immunity: cytoplasmic DNA sensing by the AIM2 inflammasome. Curr Biol (2009) 19:R262–5.10.1016/j.cub.2009.02.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 730

  SauerJDWitteCEZemanskyJHansonBLauerPPortnoyDA. Listeria monocytogenes triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. Cell Host Microbe (2010) 7:412–9.10.1016/j.chom.2010.04.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 731

  BarberGN. Cytoplasmic DNA innate immune pathways. Immunol Rev (2011) 243:99–108.10.1111/j.1600-065X.2011.01051.x

  • CrossRef
  • Google Scholar

• 732

  KonnoHBarberGN. The STING controlled cytosolic-DNA activated innate immune pathway and microbial disease. Microbes Infect (2014) 16:998–1001.10.1016/j.micinf.2014.10.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 733

  PaludanSR. Activation and regulation of DNA-driven immune responses. Microbiol Mol Biol Rev (2015) 79:225–41.10.1128/MMBR.00061-14

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 734

  GirlingJEHedgerMP. Toll-like receptors in the gonads and reproductive tract: emerging roles in reproductive physiology and pathology. Immunol Cell Biol (2007) 85:481–9.10.1038/sj.icb.7100086

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 735

  van RijnBBFranxASteegersEAPDe GrootCJMBertinaRMPasterkampGet alMaternal TLR4 and NOD2 gene variants, pro-inflammatory phenotype and susceptibility to early-onset preeclampsia and HELLP syndrome. PLoS One (2008) 3:e1865.10.1371/journal.pone.0001865

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 736

  RileyJKNelsonDM. Toll-like receptors in pregnancy disorders and placental dysfunction. Clin Rev Allergy Immunol (2010) 39:185–93.10.1007/s12016-009-8178-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 737

  PinedaAVerdin-TeránSLCamachoAMoreno-FierrosL. Expression of toll-like receptor TLR-2, TLR-3, TLR-4 and TLR-9 is increased in placentas from patients with preeclampsia. Arch Med Res (2011) 42:382–91.10.1016/j.arcmed.2011.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 738

  PandaBPandaAUedaIAbrahamsVMNorwitzERStanicAKet alDendritic cells in the circulation of women with preeclampsia demonstrate a pro-inflammatory bias secondary to dysregulation of TLR receptors. J Reprod Immunol (2012) 94:210–5.10.1016/j.jri.2012.01.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 739

  ZhangLYangH. Expression and localization of TLR4 and its negative regulator tollip in the placenta of early-onset and late-onset preeclampsia. Hypertens Pregnancy (2012) 31:218–27.10.3109/10641955.2011.642434

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 740

  AmirchaghmaghiETaghaviSAShapouriFSaeidiSRezaeiAAflatoonianR. The role of toll like receptors in pregnancy. Int J Fertil Steril (2013) 7:147–54.

  • Google Scholar

• 741

  ZhuYWuMWuCYXiaGQ. Role of progesterone in TLR4-MyD88-dependent signaling pathway in pre-eclampsia. J Huazhong Univ Sci Technolog Med Sci (2013) 33:730–4.10.1007/s11596-013-1188-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 742

  KogaKIzumiGMorGFujiiTOsugaY. Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy complications. Am J Reprod Immunol (2014) 72:192–205.10.1111/aji.12258

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 743

  XuePPZhengMMGongPLinCMZhouJJLiYJet alSingle administration of ultra-low-dose lipopolysaccharide in rat early pregnancy induces TLR4 activation in the placenta contributing to preeclampsia. PLoS One (2015) 10:e0124001.10.1371/journal.pone.0124001

  • CrossRef
  • Google Scholar

• 744

  GongPLiuMHongGLiYXuePZhengMet alCurcumin improves LPS-induced preeclampsia-like phenotype in rat by inhibiting the TLR4 signaling pathway. Placenta (2016) 41:45–52.10.1016/j.placenta.2016.03.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 745

  KulikovaGVNizyaevaNVNagovitsinaMNLyapinVMLoginovaNSKanNEet alSpecific features of TLR4 expression in structural elements of placenta in patients with preeclampsia. Bull Exp Biol Med (2016) 160:718–21.10.1007/s10517-016-3259-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 746

  FaasMMSchuilingGABallerJFVisscherCABakkerWW. A new animal model for human preeclampsia: ultra-low-dose endotoxin infusion in pregnant rats. Am J Obstet Gynecol (1994) 171:158–64.10.1016/0002-9378(94)90463-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 747

  FujitaYMiharaTOkazakiTShitanakaMKushinoRIkedaCet alToll-like receptors (TLR) 2 and 4 on human sperm recognize bacterial endotoxins and mediate apoptosis. Hum Reprod (2011) 26:2799–806.10.1093/humrep/der234

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 748

  LiNWangTHanD. Structural, cellular and molecular aspects of immune privilege in the testis. Front Immunol (2012) 3:152.10.3389/fimmu.2012.00152

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 749

  SaeidiSShapouriFAmirchaghmaghiEHoseinifarHSabbaghianMSadighi GilaniMAet alSperm protection in the male reproductive tract by toll-like receptors. Andrologia (2014) 46:784–90.10.1111/and.12149

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 750

  HaganSKhuranaNChandraSAbdel-MageedABMondalDHellstromWJet alDifferential expression of novel biomarkers (TLR-2, TLR-4, COX-2, and Nrf-2) of inflammation and oxidative stress in semen of leukocytospermia patients. Andrology (2015) 3:848–55.10.1111/andr.12074

  • CrossRef
  • Google Scholar

• 751

  KunjaraSGreenbaumALWangDYCaroHNMcleanPRedmanCWGet alInositol phosphoglycans and signal transduction systems in pregnancy in preeclampsia and diabetes: evidence for a significant regulatory role in preeclampsia at placental and systemic levels. Mol Genet Metab (2000) 69:144–58.10.1006/mgme.2000.2964

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 752

  WilliamsPJGumaaKSciosciaMRedmanCWRademacherTW. Inositol phosphoglycan P-type in preeclampsia: a novel marker?Hypertension (2007) 49:84–9.10.1161/01.HYP.0000251301.12357.ba

  • CrossRef
  • Google Scholar

• 753

  SciosciaMPaineMAGumaaKRodeckCHRademacherTW. Release of inositol phosphoglycan P-type by the human placenta following insulin stimulus: a multiple comparison between preeclampsia, intrauterine growth restriction, and gestational hypertension. J Matern Fetal Neonatal Med (2008) 21:581–5.10.1080/14767050802199934

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 754

  SciosciaMGumaaKRademacherTW. The link between insulin resistance and preeclampsia: new perspectives. J Reprod Immunol (2009) 82:100–5.10.1016/j.jri.2009.04.009

  • CrossRef
  • Google Scholar

• 755

  SciosciaMGumaaKSelvaggiLERodeckCHRademacherTW. Increased inositol phosphoglycan P-type in the second trimester in pregnant women with type 2 and gestational diabetes mellitus. J Perinat Med (2009) 37:469–71.10.1515/JPM.2009.082

  • CrossRef
  • Google Scholar

• 756

  PaineMASciosciaMWilliamsPJGumaaKRodeckCHRademacherTW. Urinary inositol phosphoglycan P-type as a marker for prediction of preeclampsia and novel implications for the pathophysiology of this disorder. Hypertens Pregnancy (2010) 29:375–84.10.3109/10641950903242667

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 757

  SciosciaMWilliamsPJGumaaKFratelliNZorziCRademacherTW. Inositol phosphoglycans and preeclampsia: from bench to bedside. J Reprod Immunol (2011) 89:173–7.10.1016/j.jri.2011.03.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 758

  SciosciaMRobillardPYHallDRRademacherLHWilliamsPJRademacherTW. Inositol phosphoglycan P-type in infants of preeclamptic mothers. J Matern Fetal Neonatal Med (2012) 25:193–5.10.3109/14767058.2011.557789

  • CrossRef
  • Google Scholar

• 759

  SciosciaMSiwetzMFascillaFHuppertzB. Placental expression of D-chiro-inositol phosphoglycans in preeclampsia. Placenta (2012) 33:882–4.10.1016/j.placenta.2012.07.007

  • CrossRef
  • Google Scholar

• 760

  SciosciaMSiwetzMCampanaCHuppertzB. Differences in d-chiro-inositol-phosphoglycan expression between first and third trimester human placenta. Pregnancy Hypertens (2013) 3:1–2.10.1016/j.preghy.2012.10.001

  • CrossRef
  • Google Scholar

• 761

  SciosciaMNigroMMontagnaniM. The putative metabolic role of d-chiro inositol phosphoglycan in human pregnancy and preeclampsia. J Reprod Immunol (2014) 101-102:140–7.10.1016/j.jri.2013.05.006

  • CrossRef
  • Google Scholar

• 762

  KunjaraSMcleanPRademacherLRademacherTWFascillaFBettocchiSet alPutative key role of inositol messengers in endothelial cells in preeclampsia. Int J Endocrinol (2016) 2016:7695648.10.1155/2016/7695648

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 763

  PretoriusEBesterJKellDB. A bacterial component to Alzheimer-type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease. J Alzheimers Dis (2016) 53:1237–56.10.3233/JAD-160318

  • CrossRef
  • Google Scholar

• 764

  KellDBPretoriusE. To what extent are the terminal stages of sepsis, septic shock, SIRS, and multiple organ dysfunction syndrome actually driven by a toxic prion/amyloid form of fibrin?Semin Thromb Hemost (2017).10.1055/s-0037-1604108

  • CrossRef
  • Google Scholar

• 765

  PretoriusEMbotweSKellDB. Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular comorbidities. Sci Rep (2017) 7:9680.10.1038/s41598-017-09860-4

  • CrossRef
  • Google Scholar

• 766

  PretoriusEPageMJEngelbrechtLEllisGCKellDB. Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. Cardiovasc Diabetol (2017) 16:141.10.1186/s12933-017-0624-5

  • CrossRef
  • Google Scholar

• 767

  CerveraRBalaschJ. Bidirectional effects on autoimmunity and reproduction. Hum Reprod Update (2008) 14:359–66.10.1093/humupd/dmn013

  • CrossRef
  • Google Scholar

• 768

  HeilmannLSchorschMHahnTFareedJ. Antiphospholipid syndrome and pre-eclampsia. Semin Thromb Hemost (2011) 37:141–5.10.1055/s-0030-1270341

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 769

  ChenQGuoFHensby-BennettSStonePChamleyL. Antiphospholipid antibodies prolong the activation of endothelial cells induced by necrotic trophoblastic debris: implications for the pathogenesis of preeclampsia. Placenta (2012) 33:810–5.10.1016/j.placenta.2012.07.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 770

  LefkouEMamopoulosAFragakisNDagklisTVosnakisCNounopoulosEet alClinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension (2014) 63:e118–9.10.1161/HYPERTENSIONAHA.114.03115

  • CrossRef
  • Google Scholar

• 771

  van HoornMEHagueWMVan PampusMGBezemerDDe VriesJIPInvestigatorsF. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol (2016) 197:168–73.10.1016/j.ejogrb.2015.12.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 772

  AshersonRACerveraR. Antiphospholipid antibodies and infections. Ann Rheum Dis (2003) 62:388–93.10.1136/ard.62.5.388

  • CrossRef
  • Google Scholar

• 773

  ShoenfeldYBlankMCerveraRFontJRaschiEMeroniPL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis (2006) 65:2–6.10.1136/ard.2005.045443

  • CrossRef
  • Google Scholar

• 774

  AminNM. Antiphospholipid syndromes in infectious diseases. Hematol Oncol Clin North Am (2008) 22:131–143, vii–viii.10.1016/j.hoc.2007.10.001

  • CrossRef
  • Google Scholar

• 775

  SèneDPietteJCCacoubP. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev (2008) 7:272–7.10.1016/j.autrev.2007.10.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 776

  García-CarrascoMGalarza-MaldonadoCMendoza-PintoCEscarcegaROCerveraR. Infections and the antiphospholipid syndrome. Clin Rev Allergy Immunol (2009) 36:104–8.10.1007/s12016-008-8103-0

  • CrossRef
  • Google Scholar

• 777

  ZingerHShererYGoddardGBerkunYBarzilaiOAgmon-LevinNet alCommon infectious agents prevalence in antiphospholipid syndrome. Lupus (2009) 18:1149–53.10.1177/0961203309345738

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 778

  KroneKAAllenKLMccraeKR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep (2010) 12:53–7.10.1007/s11926-009-0075-4

  • CrossRef
  • Google Scholar

• 779

  Martínez-ZamoraMATassiesDCarmonaFEspinosaGCerveraRReverterJCet alClot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies. J Reprod Immunol (2010) 86:133–40.10.1016/j.jri.2010.05.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 780

  LockshinMD. Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy. Clin Lab Med (2013) 33:367–76.10.1016/j.cll.2013.01.001

  • CrossRef
  • Google Scholar

• 781

  LockshinMD. Pregnancy and antiphospholipid syndrome. Am J Reprod Immunol (2013) 69:585–7.10.1111/aji.12071

  • CrossRef
  • Google Scholar

• 782

  MeroniPLChighizolaCBRovelliFGerosaM. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther (2014) 16:209.10.1186/ar4549

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 783

  BuhimschiIANayeriUAZhaoGShookLLPensalfiniAFunaiEFet alProtein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci Transl Med (2014) 6:245ra292.10.1126/scitranslmed.3008808

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 784

  JonasSMDesernoTMBuhimschiCSMakinJChomaMABuhimschiIA. Smartphone-based diagnostic for preeclampsia: an mHealth solution for administering the Congo Red Dot (CRD) test in settings with limited resources. J Am Med Inform Assoc (2016) 23:166–73.10.1093/jamia/ocv015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 785

  KouzaMBanerjiAKolinskiABuhimschiIAKloczkowskiA. Oligomerization of FVFLM peptides and their ability to inhibit beta amyloid peptides aggregation: consideration as a possible model. Phys Chem Chem Phys (2017) 19:2990–9.10.1039/c6cp07145g

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 786

  ClarkEASSilverRMBranchDW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?Curr Rheumatol Rep (2007) 9:219–25.10.1007/s11926-007-0035-9

  • CrossRef
  • Google Scholar

• 787

  SacconeGBerghellaVMaruottiGMGhiTRizzoGSimonazziGet alAntiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol (2017) 216:525.e521–525.e512.10.1016/j.ajog.2017.01.026

  • CrossRef
  • Google Scholar

• 788

  HorvathSEDaumG. Lipids of mitochondria. Prog Lipid Res (2013) 52:590–614.10.1016/j.plipres.2013.07.002

  • CrossRef
  • Google Scholar

• 789

  MejiaEMNguyenHHatchGM. Mammalian cardiolipin biosynthesis. Chem Phys Lipids (2014) 179:11–6.10.1016/j.chemphyslip.2013.10.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 790

  RenMPhoonCKLSchlameM. Metabolism and function of mitochondrial cardiolipin. Prog Lipid Res (2014) 55:1–16.10.1016/j.plipres.2014.04.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 791

  HatchGM. Cardiolipin: biosynthesis, remodeling and trafficking in the heart and mammalian cells (review). Int J Mol Med (1998) 1:33–41.

  • Pubmed Abstract
  • Google Scholar

• 792

  Saini-ChohanHKHolmesMGChiccoAJTaylorWAMooreRLMccuneSAet alCardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure. J Lipid Res (2009) 50:1600–8.10.1194/jlr.M800561-JLR200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 793

  ChabanYBoekemaEJDudkinaNV. Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim Biophys Acta (2014) 1837:418–26.10.1016/j.bbabio.2013.10.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 794

  MileykovskayaEDowhanW. Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes. Chem Phys Lipids (2014) 179:42–8.10.1016/j.chemphyslip.2013.10.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 795

  ParadiesGParadiesVDe BenedictisVRuggieroFMPetrosilloG. Functional role of cardiolipin in mitochondrial bioenergetics. Biochim Biophys Acta (2014) 1837:408–17.10.1016/j.bbabio.2013.10.006

  • CrossRef
  • Google Scholar

• 796

  ParadiesGParadiesVRuggieroFMPetrosilloG. Cardiolipin and mitochondrial function in health and disease. Antioxid Redox Signal (2014) 20:1925–53.10.1089/ars.2013.5280

  • CrossRef
  • Google Scholar

• 797

  DolinskyVWColeLKSparagnaGCHatchGM. Cardiac mitochondrial energy metabolism in heart failure: role of cardiolipin and sirtuins. Biochim Biophys Acta (2016) 1861:1544–54.10.1016/j.bbalip.2016.03.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 798

  BlankMKrauseIFridkinMKellerNKopolovicJGoldbergIet alBacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest (2002) 109:797–804.10.1172/JCI12337

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 799

  HarelMAron-MaorAShererYBlankMShoenfeldY. The infectious etiology of the antiphospholipid syndrome: links between infection and autoimmunity. Immunobiology (2005) 210:743–7.10.1016/j.imbio.2005.10.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 800

  Cruz-TapiasPBlankMAnayaJMShoenfeldY. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol (2012) 24:389–93.10.1097/BOR.0b013e32835448b8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 801

  EbringerARashidT. Rheumatoid arthritis is caused by Proteus: the molecular mimicry theory and Karl Popper. Front Biosci (Elite Ed) (2009) 1:577–86.10.2741/e56

  • CrossRef
  • Google Scholar

• 802

  MargulisL. Origin of Eukaryotic Cells. New Haven: Yale University Press (1970).

  • Google Scholar

• 803

  BullerwellCEGrayMW. Evolution of the mitochondrial genome: protist connections to animals, fungi and plants. Curr Opin Microbiol (2004) 7:528–34.10.1016/j.mib.2004.08.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 804

  WilliamsKPSobralBWDickermanAW. A robust species tree for the alphaproteobacteria. J Bacteriol (2007) 189:4578–86.10.1128/JB.00269-07

  • CrossRef
  • Google Scholar

• 805

  GrayMW. Mitochondrial evolution. Cold Spring Harb Perspect Biol (2012) 4:a011403.10.1101/cshperspect.a011403

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 806

  BurgerGGrayMWForgetLLangBF. Strikingly bacteria-like and gene-rich mitochondrial genomes throughout jakobid protists. Genome Biol Evol (2013) 5:418–38.10.1093/gbe/evt008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 807

  WangZWuM. An integrated phylogenomic approach toward pinpointing the origin of mitochondria. Sci Rep (2015) 5:7949.10.1038/srep07949

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 808

  BallSGBhattacharyaDWeberAPM. Pathogen to powerhouse. Science (2016) 351:659–60.10.1126/science.aad8864

  • CrossRef
  • Google Scholar

• 809

  JohnPWhatleyFR. Paracoccus denitrificans and the evolutionary origin of the mitochondrion. Nature (1975) 254:495–8.10.1038/254495a0

  • CrossRef
  • Google Scholar

• 810

  MatsumotoKKusakaJNishiboriAHaraH. Lipid domains in bacterial membranes. Mol Microbiol (2006) 61:1110–7.10.1111/j.1365-2958.2006.05317.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 811

  EpandRMEpandRF. Domains in bacterial membranes and the action of antimicrobial agents. Mol Biosyst (2009) 5:580–7.10.1039/b900278m

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 812

  MileykovskayaEDowhanW. Cardiolipin membrane domains in prokaryotes and eukaryotes. Biochim Biophys Acta (2009) 1788:2084–91.10.1016/j.bbamem.2009.04.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 813

  RomantsovTGuanZWoodJM. Cardiolipin and the osmotic stress responses of bacteria. Biochim Biophys Acta (2009) 1788:2092–100.10.1016/j.bbamem.2009.06.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 814

  BarákIMuchováK. The role of lipid domains in bacterial cell processes. Int J Mol Sci (2013) 14:4050–65.10.3390/ijms14024050

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 815

  MukamolovaGVYanopolskayaNDVotyakovaTVPopovVIKaprelyantsASKellDB. Biochemical changes accompanying the long-term starvation of Micrococcus luteus cells in spent growth medium. Arch Microbiol (1995) 163:373–9.10.1007/BF00404211

  • CrossRef
  • Google Scholar

• 816

  KellDBPretoriusE. Serum ferritin is an important disease marker, and is mainly a leakage product from damaged cells. Metallomics (2014) 6:748–73.10.1039/C3MT00347G

  • CrossRef
  • Google Scholar

• 817

  Agmon-LevinNRosárioCKatzBSZandman-GoddardGMeroniPCerveraRet alFerritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus (2013) 22:1327–35.10.1177/0961203313504633

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 818

  RosárioCZandman-GoddardGMeyron-HoltzEGD’cruzDPShoenfeldY. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med (2013) 11:185.10.1186/1741-7015-11-185

  • CrossRef
  • Google Scholar

• 819

  AndradeSEGurwitzJHDavisRLChanKAFinkelsteinJAFortmanKet alPrescription drug use in pregnancy. Am J Obstet Gynecol (2004) 191:398–407.10.1016/j.ajog.2004.04.025

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 820

  Egen-LappeVHasfordJ. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol (2004) 60:659–66.10.1007/s00228-004-0817-1

  • CrossRef
  • Google Scholar

• 821

  RileyEHFuentes-AfflickEJacksonRAEscobarGJBrawarskyPSchreiberMet alCorrelates of prescription drug use during pregnancy. J Womens Health (Larchmt) (2005) 14:401–9.10.1089/jwh.2005.14.401

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 822

  DawJRHanleyGEGreysonDLMorganSG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf (2011) 20:895–902.10.1002/pds.2184

  • CrossRef
  • Google Scholar

• 823

  MitchellAAGilboaSMWerlerMMKelleyKELouikCHernández-DíazSet alMedication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol (2011) 205:51.e51–8.10.1016/j.ajog.2011.02.029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 824

  DawJRMintzesBLawMRHanleyGEMorganSG. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001–2006). Clin Ther (2012) 34(239–249):e232.10.1016/j.clinthera.2011.11.025

  • CrossRef
  • Google Scholar

• 825

  Cea-SorianoLGarcia RodríguezLAFernández CanteroOHernández-DíazS. Challenges of using primary care electronic medical records in the UK to study medications in pregnancy. Pharmacoepidemiol Drug Saf (2013) 22:977–85.10.1002/pds.3472

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 826

  PalmstenKHernández-DíazSChambersCDMogunHLaiSGilmerTPet alThe most commonly dispensed prescription medications among pregnant women enrolled in the U.S. Medicaid program. Obstet Gynecol (2015) 126:465–73.10.1097/AOG.0000000000000982

  • CrossRef
  • Google Scholar

• 827

  SmolinaKHanleyGEMintzesBOberlanderTFMorganS. Trends and determinants of prescription drug use during pregnancy and postpartum in British Columbia, 2002–2011: a population-based cohort study. PLoS One (2015) 10:e0128312.10.1371/journal.pone.0128312

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 828

  ValentFGongoloFDeromaLZanierL. Prescription of systemic antibiotics during pregnancy in primary care in Friuli Venezia Giulia, Northeastern Italy. J Matern Fetal Neonatal Med (2015) 28:210–5.10.3109/14767058.2014.906572

  • CrossRef
  • Google Scholar

• 829

  HeikkiläAM. Antibiotics in pregnancy – a prospective cohort study on the policy of antibiotic prescription. Ann Med (1993) 25:467–71.10.3109/07853899309147314

  • CrossRef
  • Google Scholar

• 830

  SantosFOraichiDBérardA. Prevalence and predictors of anti-infective use during pregnancy. Pharmacoepidemiol Drug Saf (2010) 19:418–27.10.1002/pds.1915

  • CrossRef
  • Google Scholar

• 831

  de JongeLBosHJVan LangenIMDe Jong-Van Den BergLTWBakkerMK. Antibiotics prescribed before, during and after pregnancy in the Netherlands: a drug utilization study. Pharmacoepidemiol Drug Saf (2014) 23:60–8.10.1002/pds.3492

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 832

  BookstaverPBBlandCMGriffinBStoverKREilandLSMclaughlinM. A review of antibiotic use in pregnancy. Pharmacotherapy (2015) 35:1052–62.10.1002/phar.1649

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 833

  CalogeroAECondorelliRARussoGIVigneraS. Conservative nonhormonal options for the treatment of male infertility: antibiotics, anti-inflammatory drugs, and antioxidants. Biomed Res Int (2017) 2017:4650182.10.1155/2017/4650182

  • CrossRef
  • Google Scholar

• 834

  KabirS. The current status of Helicobacter pylori vaccines: a review. Helicobacter (2007) 12:89–102.10.1111/j.1523-5378.2007.00478.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 835

  D’EliosMMCzinnSJ. Immunity, inflammation, and vaccines for Helicobacter pylori. Helicobacter (2014) 19(Suppl 1):19–26.10.1111/hel.12156

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 836

  SuttonPChionhYT. Why can’t we make an effective vaccine against Helicobacter pylori?Expert Rev Vaccines (2013) 12:433–41.10.1586/erv.13.20

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 837

  NgGZChionhYTSuttonP. Vaccine-mediated protection against Helicobacter pylori is not associated with increased salivary cytokine or mucin expression. Helicobacter (2014) 19:48–54.10.1111/hel.12099

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 838

  GrixtiJO’HaganSDayPJKellDB. Enhancing drug efficacy and therapeutic index through cheminformatics-based selection of small molecule binary weapons that improve transporter-mediated targeting: a cytotoxicity system based on gemcitabine. Front Pharmacol (2017) 8:155.10.3389/fphar.2017.00155

  • CrossRef
  • Google Scholar

• 839

  BorisyAAElliottPJHurstNWLeeMSLeharJPriceERet alSystematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A (2003) 100:7977–82.10.1073/pnas.1337088100

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 840

  LehárJKruegerASAveryWHeilbutAMJohansenLMPriceERet alSynergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol (2009) 27:659–66.10.1038/nbt.1549

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 841

  KellDB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genom (2009) 2:2.10.1186/1755-8794-2-2

  • CrossRef
  • Google Scholar

• 842

  KellDB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol (2010) 577:825–89.10.1007/s00204-010-0577-x

  • CrossRef
  • Google Scholar

• 843

  CareyN. The Epigenetics Revolution. London: Icon Books (2012).

  • Google Scholar

• 844

  DayJSavaniSKrempleyBDNguyenMKitlinskaJB. Influence of paternal preconception exposures on their offspring: through epigenetics to phenotype. Am J Stem Cells (2016) 5:11–8.

  • Pubmed Abstract
  • Google Scholar

• 845

  AbbasiJ. The paternal epigenome makes its mark. JAMA (2017) 317:2049–51.10.1001/jama.2017.1566

  • CrossRef
  • Google Scholar

• 846

  AgarwalASekhonLH. The role of antioxidant therapy in the treatment of male infertility. Hum Fertil (2010) 13:217–25.10.3109/14647273.2010.532279

  • CrossRef
  • Google Scholar

• 847

  NakataKYamashitaNNodaYOhsawaI. Stimulation of human damaged sperm motility with hydrogen molecule. Med Gas Res (2015) 5:2.10.1186/s13618-014-0023-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 848

  HalliwellBCheahIKDrumCL. Ergothioneine, an adaptive antioxidant for the protection of injured tissues? A hypothesis. Biochem Biophys Res Commun (2016) 470:245–50.10.1016/j.bbrc.2015.12.124

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 849

  AhmedASinghJKhanYSeshanSVGirardiG. A new mouse model to explore therapies for preeclampsia. PLoS One (2010) 5:e13663.10.1371/journal.pone.0013663

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 850

  BonneyEA. Demystifying animal models of adverse pregnancy outcomes: touching bench and bedside. Am J Reprod Immunol (2013) 69:567–84.10.1111/aji.12102

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 851

  LaMarcaBAmaralLMHarmonACCorneliusDCFaulknerJLCunninghamMWJr. Placental ischemia and resultant phenotype in animal models of preeclampsia. Curr Hypertens Rep (2016) 18:38.10.1007/s11906-016-0633-x

  • CrossRef
  • Google Scholar

• 852

  KennyLCBroadhurstDIDunnWBrownMFrancis-McintyreSNorthRAet alRobust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension (2010) 56:741–9.10.1161/HYPERTENSIONAHA.110.157297

  • CrossRef
  • Google Scholar

• 853

  KellDBOliverSG. The metabolome 18 years on: a concept comes of age. Metabolomics (2016) 12:148.10.1007/s11306-016-1108-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 854

  Infectious Diseases Society of AmericaSpellbergBBlaserMGuidosRJBoucherHWBradleyJSet alCombating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 52(Suppl 5):S397–428.10.1093/cid/cir153

  • CrossRef
  • Google Scholar

• 855

  GelbandHLaxminarayanR. Tackling antimicrobial resistance at global and local scales. Trends Microbiol (2015) 23:524–6.10.1016/j.tim.2015.06.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 856

  LaxminarayanRSridharDBlaserMWangMWoolhouseM. Achieving global targets for antimicrobial resistance. Science (2016) 353:874–5.10.1126/science.aaf9286

  • CrossRef
  • Google Scholar

• 857

  CoatesARMHuY. New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. Drugs R D (2006) 7:133–51.10.2165/00126839-200607030-00001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 858

  CoatesARHallsGHuY. Novel classes of antibiotics or more of the same?Br J Pharmacol (2011) 163:184–94.10.1111/j.1476-5381.2011.01250.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 859

  HuYLiuAOrtega-MuroFAlameda-MartinLMitchisonDCoatesA. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. Front Microbiol (2015) 6:641.10.3389/fmicb.2015.00641

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 860

  BroxmeyerL. Parkinson’s: another look. Med Hypotheses (2002) 59:373–7.10.1016/S0306-9877(02)00188-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 861

  ShenCHChouCHLiuFCLinTYHuangWYWangYCet alAssociation between tuberculosis and Parkinson disease: a nationwide, population-based cohort study. Medicine (Baltimore) (2016) 95:e2883.10.1097/MD.0000000000002883

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 862

  BerstadKBerstadJER. Parkinson’s disease; the hibernating spore hypothesis. Med Hypotheses (2017) 104:48–53.10.1016/j.mehy.2017.05.022

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 863

  RaymondDPetersonE. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv (2011) 66:497–506.10.1097/OGX.0b013e3182331028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 864

  ChaiworapongsaTRomeroRWhittenATarcaALBhattiGDraghiciSet alDifferences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaa. J Perinat Med (2013) 41:485–504.10.1515/jpm-2013-0082

  • CrossRef
  • Google Scholar

• 865

  LisonkovaSJosephKS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol (2013) 209:544.e541–544.e512.10.1016/j.ajog.2013.08.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 866

  LisonkovaSSabrYMayerCYoungCSkollAJosephKS. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol (2014) 124:771–81.10.1097/AOG.0000000000000472

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 867

  MadazliRYukselMAImamogluMTutenAOnculMAydinBet alComparison of clinical and perinatal outcomes in early- and late-onset preeclampsia. Arch Gynecol Obstet (2014) 290:53–7.10.1007/s00404-014-3176-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar